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ABSTRACT OF DISSERTATION 
 
 
EPIGENETIC MODIFICATIONS TO CYTOSINE AND ALZHEIMER’S DISEASE: A 
QUANTITATIVE ANALYSIS OF POST-MORTEM TISSUE 
 
Alzheimer’s disease (AD) is the most common form of dementia and the sixth 
leading cause of death in the United States, with no therapeutic option to slow or halt 
disease progression. Development of two characteristic pathologic lesions, amyloid beta 
plaques and neurofibrillary tangles, in the brain are associated with synaptic dysfunction 
and neuron loss leading to memory impairment and cognitive decline. Although mutations 
in genes involved in amyloid beta processing are linked to increased plaque formation in 
the inherited familial form of AD, the more common idiopathic form, termed sporadic AD, 
develops in the absence of gene mutations. In contrast, alterations in gene expression and 
transcription occur in plaque and tangle susceptible brain regions of sporadic AD subjects, 
even in the earliest stages of development of pathologic burden, and may give insight into 
the pathogenesis of AD. Epigenetic modifications to cytosine are known to alter 
transcriptional states and gene expression in embryonic development as well as in cancer 
studies. With the discovery of enzymatically oxidized derivatives of 5-methylcytosine (5-
mC), the most common epigenetic cytosine modification, a probable demethylation 
pathway has been suggested to alter transcriptional states of DNA. The most abundant 5-
mC derivative, 5-hydroxymethylcytosine (5-hmC), while expressed at low concentrations 
throughout the body, is expressed at high concentrations in brain cells.  
To determine the role cytosine modifications play in AD, this study was directed at 
the quantification of epigenetic modifications to cytosine in several stages of AD 
progression using global, genome-wide, and gene-specific studies. To determine global 
levels of each cytosine derivative in brain regions relevant to AD progression, a gas 
chromatography/mass spectrometry quantitative analysis was utilized to analyze cytosine, 
5-mC, and 5-hmC in tissue specimens from multiple brain regions of AD subjects, 
including early and late stages of AD progression. To determine the genome-wide impact 
of 5-hmC on biologically relevant pathways in AD, a single-base resolution sequencing 
analysis was used to map hydroxymethylation throughout the hippocampus of late stage 
AD subjects. Finally, to determine gene-specific levels of cytosine, 5-mC, and 5-hmC, a 
quantitative polymerase chain reaction (qPCR) protocol was paired with specific restriction 
enzyme digestion to analyze target sequences within exons of genes related to sporadic 
AD. Results from these studies show epigenetic modifications to cytosine are altered on 
the global, genome-wide, and gene-specific levels in AD subjects compared to normal 
aging, particularly in early stages of AD progression, suggesting alterations to the 
epigenetic landscape may play a role in the dysregulation of transcription and the 
pathogenesis of AD.  
 
KEYWORDS: cytosine, 5-hydroxymethylcytosine, 5-methylcytosine, Alzheimer’s 
disease, epigenetic modifications 
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CHAPTER 1: INTRODUCTION AND BACKGROUND 
1.1 Alzheimer’s disease 
1.1.1 History of Alzheimer’s disease 
Dr. Alois Alzheimer, a psychiatrist and neuropathologist in Germany in the early 
1900s, was the first to describe plaque and tangle pathology in post-mortem brain tissue 
of his former patient, Mrs. Auguste Deter, who exhibited memory loss, deficits in 
cognition, and psychoses at the age of 51 [1, 2]. While dementia, referred to as senile 
dementia at the time, was a common ailment in the early 1900s for elderly patients near 
70 years old, the young age of symptom onset and the severity of memory loss in Mrs. 
Deter’s case was unprecedented. However, little research effort was put forth to 
understand Dr. Alzheimer’s discovery for the next half century, and was generally 
referred to as a rare form of senile dementia for the next 50 years. Research interest in 
Alzheimer’s disease (AD) was reignited in the late 1960s, when two groups published 
images of strange neuropathological lesions in AD brain tissue [3-5] and again in the 
1970s, when an editorial was published that pointed out the potential public health crisis 
Alzheimer’s disease would likely inflict [6]. However, it wasn’t until the late 1980s when 
the identities of aggregated proteins comprising plaques and tangles were discovered that 
the stage was set for current Alzheimer’s disease research [7-12].  
Today, Alzheimer’s disease ranks as the sixth leading cause of death in the United 
States, accounts for 60-80% of all dementia cases, and is the only disease on the list of 
the top ten causes of death with no therapeutic option to slow or halt progression [13]. 
Over 5 million patients currently suffer from Alzheimer’s dementia in the US, and that 
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number is projected to grow to more than 13 million by 2050. The anticipated annual cost 
for caring for AD and dementia patients in 2017 is more than $250 billion [13], and in the 
wake of the baby-boom generation approaching the age of onset of AD, the future impact 
on the healthcare system in the US alone will be astronomical with no therapeutic option 
to slow or halt degeneration.  
1.1.2 Familial and Sporadic AD 
The majority of information and breakthroughs in understanding the pathogenesis 
of AD has largely come from studies of mutations in genes inherited in family groups. 
These deterministic genes are involved in the production of one of the key pathologic 
features of AD, senile plaques. Mutations in presenilin-1 (PS1) [14, 15], presenilin-2 
(PS2) [16, 17], and the amyloid precursor protein (APP) [9, 18] increase plaque 
formation and are thought to lead to the inherited form of AD, known as familial AD 
[19]. In Down’s syndrome, a trisomy disease where an extra copy of chromosome 21 
leads to neurological dysfunction, similar neuropathologic lesions occur as in AD. It is 
believed that the extra copy of chromosome 21, where APP is encoded, causes plaque 
formation to be evident in brain regions as early as teen years, with eventual AD 
diagnosis in Down’s syndrome patients in their fifties [20-23]. The manipulation of genes 
involved in plaque formation, both by mutations and increased copy number of APP, are 
likely causal to the early-onset form of AD, however more research into the how these 
mechanisms lead to neurodegeneration is needed.   
While familial AD occurs before age 65 and is responsible for less than 5% of all 
AD cases [13], the remaining 95% of diagnoses are idiopathic, often termed late onset 
AD (LOAD) or sporadic AD. The sporadic form of AD lacks causal gene mutations and 
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yet shows the same clinical symptoms and neuropathological features, with the exception 
of symptom onset occurring after age 65 [24]. However, despite the discovery of gene 
mutations indicating eventual development of familial AD, current pharmaceutical 
options only produce symptom relief and have no measureable effect on disease 
progression in the familial or sporadic form.  
1.1.3 Clinical symptoms 
While Alzheimer’s disease is the most common form of dementia, some of the 
clinical symptoms overlap with other types of neurodegeneration. Symptoms of possible 
AD can be detected in clinical examinations of cognitive performance and memory 
evaluations, although definitive diagnosis of AD is only confirmed at autopsy upon 
analysis of neuropathological features in post-mortem brain tissue. Typically, the first 
clinical indication of AD is a memory complaint by a family member, specifically related 
to the development of new memories [25]. Early symptoms of AD include difficulty 
remembering recent interactions, i.e. conversations, events, and names, as well as 
behavioral changes such as depression and apathy [13]. While some symptoms can be 
explained by age-related changes in memory, most early AD symptoms cause disruptions 
and difficulties in activities of daily living. These include difficulty following a 
conversation or problem solving, the inability to retrace ones steps, confusion in normally 
familiar locations, as well as struggling with vocabulary and remembering the correct 
term for an object [13].  
As the patient ages and the disease progresses, symptoms include increasing 
memory loss, progressive deficits in cognitive performance, and neurobehavioral 
changes, for example alterations to sleep patterns, enhanced agitation, and delusions [13]. 
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Upon clinical diagnosis of either mild cognitive impairment (MCI) or dementia, the 
average duration of disease is 4-8 years, with much of this time spent in the final stage of 
progression where cognitive decline and advanced memory loss result in constant care 
[13]. While AD is the underlying cause of death, the primary cause is typically 
pneumonia which is prevalent in bed-ridden patients where immobility and malnutrition 
cause rapid decline.  
1.1.4 Disease Progression 
The extent of AD pathology is generally determined histochemically, where 
tangles and plaques are stained and counted in AD-pathology susceptible brain regions. 
Senile plaques fall into two categories, diffuse plaques and neuritic plaques. While 
diffuse plaques are common in the brains of elderly individuals with no indication of 
cognitive impairment, neuritic plaques containing dystrophic neurites are associated with 
cognitive decline [26, 27]. For tangle burden counts, pathologic progression is 
determined by guidelines described by Braak et al., where severity is depicted based on 
the Braak staging scale of 0-VI, with 0 being little to no tangles near the hippocampus 
and VI being heavy tangle counts present in all susceptible brain regions [28]. A diagram 
demonstrating the progression of pathologic lesions throughout the brain is shown in 
Figure 1.1, where increasing color density depicts pathologic burden severity at each 
stage of progression.  
One of the earliest brain regions affected by AD pathology is the hippocampus, 
the center for memory formation, and as such, is thought to be the reason why a memory 
complaint is the first clinical indication of AD. As pathology progresses from the  
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Figure 1.1 Braak Staging Scores. As a measure of pathologic burden in AD, Braak et 
al. [28] developed a scale to rate neurofibrillary tangle burden progression in AD. 
Tangles begin to form in the transentorhinal cortex (I-II), spreading to limbic regions (III-
IV), with eventually development of NFTs throughout the neocortex (V-VI). Increasing 
color density denotes severity of NFT burden.  
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entorhinal cortex (Braak Stage I-II) to limbic regions (Braak Stage III-IV), decreasing 
cognitive performance is likely evident in clinical medical exams, eventually leading to a 
clinical diagnosis of probable AD. As the severity of the pathologic burden increases and 
spreads to isocortical regions (Braak Stage V-VI), this stage of progression likely leads to 
memory loss and cognitive decline (Figure 1.1). While increasing Braak Stage scores are 
correlated with decreasing performance on memory and cognition exams [27-30], it 
should be noted that pathologic burden and cognitive performance do not always 
correlate, but can be variable for individual subjects. Some subjects with significant 
pathologic burden at autopsy (Braak Stage IV-V) showed no indication of memory 
impairment upon clinical examinations [31]. This is one of the reasons why confirmation 
of AD occurs post-mortem, using clinical and neuropathological patient data.  
The progression of AD is characterized into three stages: preclinical AD (PCAD), 
mild cognitive impairment due to AD (MCI), and dementia due to AD (NIA guidelines 
2012). Upon post-mortem analysis, PCAD subjects exhibit heavy pathologic burden yet 
show no clinical indication of memory loss or cognitive impairment [31]. Some 
researchers and clinicians have attributed this to increased “cognitive reserve” where 
advanced education and life-long learning may build a tolerance to memory impairment 
caused by increased pathologic burden in susceptible brain regions [30, 32, 33]. While 
the preclinical stage often goes undetected as pathologic burden increases, likely 15-20 
years before symptom onset [34], clinical diagnosis typically occurs later in the MCI 
stage. In MCI, increased plaque and tangle burden coincide with neuronal injury and cell 
loss, producing symptoms of memory loss and decreased cognitive performance, but not 
to an extent that warrants a clinical diagnosis of dementia. MCI subjects begin to show 
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memory loss symptoms, specifically the inability to form new memories, as well as 
alterations in established sleep patterns and some behavioral changes [35, 36]. As cell 
loss and neuronal injury spread throughout the brain, memory and cognition continue to 
decline until the patient is diagnosed with dementia with probable AD to be confirmed at 
autopsy.  
1.1.5 Pathologic features 
The two main pathologic markers of AD include neurofibrillary tangles (NFTs) 
composed of hyperphosphorylated tau fibrils and senile plaques (SPs) comprised of 
amyloid beta (Aβ) peptide. The accumulation of these neuropathologic lesions likely 
occurs in brain regions decades before deficits in cognition, alterations in reasoning, and 
memory loss present as clinical symptoms of dementia [34]. Formation of senile plaques 
begins with the cleavage of Aβ from APP (amyloid precursor protein) by a family of 
secretase enzymes (Figure 1.2). While APP is likely involved in central nervous system 
(CNS) development, synaptic plasticity, and neuroprotection [37], the exact physiological 
function is uncertain. The cleavage site of α-secretase lies within the Aβ domain of APP 
and sequential cleavage by α-secretase and the γ-secretase complex produce non-amyloid 
fragments, termed the nonamyloidogenic pathway. In contrast, initial cleavage by β-
secretase followed by γ-secretase produces Aβ fragments between 38-43 amino acids in 
length that are released extracellularly. In AD, β-secretase activity is increased, pushing 
the amyloidogenic pathway and increasing cleavage of Aβ. Mutations in proteins that 
comprise the γ-secretase complex, including PS1 and PS2, are prevalent in familial AD 
and increase the production of longer Aβ fragments, mainly Aβ1-42. In familial and 
sporadic AD, there is an increase in the production of Aβ1-42, which is prone to  
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Figure 1.2 Secretase cleavage of APP. A family of secretase enzymes cleave APP at 
specific locations along extracellular and membrane bound regions. Sequential cleavage 
of β-Secretase followed by γ-Secretase produces Aβ fragments of 38-43 amino acids in 
length released extracellularly. AICD: APP intracellular domain.  
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aggregation and thought to be a major player in plaque formation [38-40]. The most 
common theory of how these pathological features cause neurodegeneration is termed the 
amyloid hypothesis [41-43].  
The amyloid hypothesis theorizes that Aβ fragments aggregate to form 
protofibrils or oligomeric Aβ, shown to be toxic in cell culture models [41, 44]. 
Oligomeric Aβ then aligns into β-sheet fibrils and finally aggregates into plaques in 
extracellular spaces between neurons (Figure 1.3a). Similar to senile plaque formation, 
the aggregation of tau is theorized to be the beginning of tangle pathology. The tau 
protein, typically between 350-440 amino acids in length, stabilizes microtubules within 
neurons. However, in AD, tau becomes hyperphosphorylated and dissociates from 
microtubules to form soluble aggregates or oligomers. These aggregates bind together to 
form paired helical filaments that eventually produce intracellular NFTs [41, 45, 46] 
(Figure 1.3b). This combination of intracellular and extracellular protein aggregation is 
hypothesized to lead to cell death and neuron loss within affected brain regions. While 
the amyloid hypothesis is the reigning theory in AD, some studies have suggested a 
cholinergic pathway where initial dysfunction and loss of cholinergic neurons, prior to 
amyloid deposition, contributes to cognitive decline and AD [47]. 
While the mechanism of action is still not fully understood that leads to plaque 
and tangle pathology, downstream effects of these markers have been demonstrated in 
cell culture and animal models as well as in post-mortem tissue of AD subjects [48]. 
Other pathologic features include brain atrophy [49], severe neuron loss [50], chronic 
inflammatory response [51], increased levels of reactive oxygen species [52-55], 
deregulation of calcium signaling [56, 57], as well as alterations in gene expression and   
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Figure 1.3 Plaque and tangle formation. The amyloid hypothesis suggests aggregation 
of amyloid beta fragments (a) and hyperphosphorylated tau (b) lead to development of 
characteristic pathologic lesions in susceptible brain regions of AD subjects. Adapted 
from Graham et al.  
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transcription mechanisms [58, 59]. The combination of dysfunction in numerous 
biological mechanisms likely causes the rapid decline associated with late stage AD, 
however, more research is essential to understanding how these mechanisms are 
deregulated in AD progression.  
1.1.6 AD and Gene Expression 
Several studies show biological pathways relevant to sporadic AD have altered 
transcription throughout progression of the disease [59-67]. In a genome-wide expression 
study of AD and NC subjects with Braak staging scores between 0-VI, Bossers et al. 
showed altered expression of genes essential to synaptic plasticity and activity, 
transcriptional regulation, cell differentiation/ proliferation, and inflammation pathways 
throughout the advancement of tangle pathology burden (increasing Braak staging scores) 
in the medial frontal gyrus [58]. In a microarray study of hippocampal mRNA 
(messenger ribonucleic acid) in sporadic AD subjects, Blalock et al. found genes 
involved in cell growth, differentiation, and tumor suppression were activated, while 
genes involved in protein transport, energy metabolism, and signaling were repressed 
[59].  
The heterogeneity of cell types within the brain, including neuronal and non-
neuronal cells like glia and astrocytes, complicate gene expression data where alterations 
in gene expression likely vary between cell types. However, some cell specific studies 
have clarified this complication. A cell specific study of astrocytes showed altered 
expression of immune response and mitochondrial genes in the cortex of AD subjects 
[60], while neurons in multiple brain regions of AD subjects showed altered expression in 
transport, metabolism, neurotransmitter secretion, and synaptic transmission in another 
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study [62, 68]. It is clear that the deregulation of transcription plays a role throughout the 
progression of AD, in multiple brain regions, and across cell types. The extent of this role 
and the implications for the disease mechanism, however, remain unclear.  
1.1.7 Risk factors 
Advanced age remains the most significant risk factor for developing AD [69]. A 
family history of AD increases the risk, as well as several genetic components, including 
deterministic genes and risk genes. Deterministic genes lead to a small portion of AD 
cases known as familial AD, where mutations in APP, PS1, and PS2 lead to eventual 
development of the disease, while sporadic AD has no known genetic mutation 
component to lead to plaque formation.  
Several risk genes have been identified that increase the likelihood of developing 
AD, but do not guarantee eventual diagnosis. One of these genes, a cholesterol 
transporter protein, apolipoprotein E allele Ԑ4 (APOE-Ԑ4), is thought to contribute to 25% 
of sporadic AD cases [13, 70]. Recently, several other genes were implicated through 
meta-analysis of single nucleotide polymorphism (SNP) data of sporadic AD subjects. 
SNPs are single nucleotide variations in DNA sequences common among a significant 
portion of the population. The genes identified by the meta-analysis may play a role in 
the progression of pathology in AD, where dysfunction in these genes increase the risk of 
developing AD [71, 72]. Most of these risk genes fall into four biological pathways: 
endocytosis, immune function, lipid processing, and clearance mechanisms [73]. 
However, the percent of the population with identified SNPs in risk genes accounts for on 
average only 12% (excluding APOE-Ԑ4) of sporadic AD cases [73, 74], indicating that 
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AD is more complicated than gene variations alone and more study into the biological 
mechanism of AD is needed. 
While age and some genetic factors increase the risk of developing sporadic AD, 
several factors have been shown to be protective, including advanced education and 
continued learning throughout one’s life, sometimes termed “cognitive reserve” [32, 33]. 
Healthy diet and exercise, as well as factors that are recommended for cardiovascular 
health [75] may also reduce one’s risk of developing dementia. Some studies indicate a 
benefit of resveratrol, a compound found in red grapes, as well as a Mediterranean diet, 
where fish is the main source of protein, help to reduce the risk of developing AD [76-
78]. Like many idiopathic diseases, where the biological mechanisms of dysfunction are 
elusive, preventative methods are typically associated with general well-being and 
maintaining healthy habits.  
1.1.8 Other neurodegenerative diseases 
 While AD is the most common type of dementia, several neurodegenerative 
diseases lead to nerve cell damage and cell death. Some neurological disorders classically 
affect motor neurons, including Parkinson’s disease (PD), Huntington’s disease, and 
amyotrophic lateral sclerosis, while others may affect motor functions, speech and 
language, memory and/or cognition, including progressive supranuclear palsy, 
corticobasal degeneration, Creutzfeldt-Jakob disease, vascular dementia, dementia with 
Lewy bodies (DLB), and frontotemporal lobar degeneration (FTLD) [13, 79-82]. 
Although each disease exhibits unique features in the clinical setting as well as upon 
analysis of neuropathologic features, some share similarities with AD, including DLB 
and FTLD.  Although considered separate diseases, nearly half of AD cases show 
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coexisting pathologic features across different dementias, usually DLB, and can be 
diagnosed as mixed dementia in clinical settings and confirmed post-mortem [13].  
 Aggregation of the misfolded protein alpha-synuclein leads to pathologic lesions 
termed Lewy bodies in the cortex of DLB subjects [83-85]. Although several clinical 
symptoms are similar to AD, DLB patients initially show increased sleep disturbances, 
motor function impairments, and visual hallucinations sometimes prior to memory 
impairment [86, 87]. Lewy bodies also form in PD, although clinical symptom onset 
differs in PD compared to DLB. Motor function impairment is usually the first clinical 
symptom in PD, while decreased cognitive performance is typically associated with 
DLB.  
 For FTLD subjects, memory impairment typically occurs later in disease 
progression, where initial clinical symptoms include personality and behavior changes 
accompanied by difficulties with language comprehension [13]. Degeneration of nerve 
cells in the frontal and temporal lobes of the brain lead to atrophy, and similar to AD, tau 
protein aggregates form in the cortex [88, 89]. Unlike AD, most FTLD patients display 
clinical symptoms between age 45-60 and accounts for only 10% of dementia cases [13].  
 Although many neurological disorders, including DLB and FTLD, contribute to 
the overall global pool of dementia patients, AD diagnoses far outweigh other forms of 
neurodegeneration. Some pathologic features and clinical symptoms, as well deregulated 
biological systems such as inflammation, oxidative damage, and transcription, overlap 
between neurodegenerative diseases [13]. Recently, it was shown that several SNPs 
overlap between dementia types and may share common genes in altered pathways 
leading to degeneration [90]. Thus, research into the pathological mechanism of 
 
15 
 
dysfunction in AD could lead to breakthroughs in other types of dementia as well, but 
only time will tell.  
1.1.9 AD therapeutic options 
After the discovery of genetic mutations in APP, PS1, and PS2 in familial AD, the 
development of cell culture and animal models to mimic AD progression has led to the 
production of over 244 unique pharmaceutical compounds tested in more than 400 
clinical trials to aid AD patients [91]. The majority of these pharmaceuticals aim to 
improve cognitive performance or use small molecules to modify the disease (typically 
targeting Aβ), while a minority of clinical trials use immunotherapies to modify the 
disease [91]. Between the years of 2002-2012, the success rate of a drug advancing 
through FDA (Federal Drug Administration) approval was 0.4% with memantine, an 
NMDA receptor agonist regulating glutaminergic pathways, gaining approval in 2004 
[91]. Currently, only five FDA approved therapeutics including memantine (the other 
four are tacrine, donepezil, rivastigimine, and galantamine which target cholinergic 
systems to provide symptom relief) are available for patients, while more than 100 drugs 
are currently in Phase 0-4 trials [46].  
The failure of so many clinical trials was suggested to be attributed to a lack of 
mechanistic understanding of the progression of sporadic AD [92], an over reliance on 
the gene mutation model attributed to familial AD rather than upstream gene mechanisms 
that play a role in Aβ processing, over simplified animal and cell models that do not 
account for the multifaceted nature of AD, as well as treatments that attempt to intervene 
late in disease progression where ample synapse loss and cell death likely prevent 
recovery [46, 91, 92]. Moving forward, a better understanding of the biological pathways 
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involved early in disease progression, as well as mechanisms that deregulate genes within 
these pathways, will be key to developing therapeutic options to combat AD. One such 
mechanism of interest includes epigenetic modifications to cytosine, known to alter 
transcription of genes involved in cancer pathways, but may also play a role in the 
deregulation of genes in neurological disorders like AD.  
 
1.2 Epigenetic Modifications 
1.2.1 Categories of Epigenetic Modification 
While the definition of epigenetic modifications has evolved since its inception in 
1942 [93], it currently refers to potentially heritable changes in gene expression without 
mutations to the DNA sequence [94]. Epigenetic modifications can be classified into 
three categories: histone modifications, non-coding RNAs, and DNA methylation. These 
epigenetic mechanisms play a role in gene expression and regulation, although how this 
occurs and the extent to which each form of epigenetic regulation works cohesively 
remains elusive [95, 96]. Each category of epigenetic regulation is discussed briefly 
below.  
The methylation and acetylation of histones regulates the compaction and release 
of chromatin structures from DNA. Histone proteins associate together in groups of eight 
to form chromatin structures, where DNA wraps around the histone complex to compact 
the DNA with the nucleus. While the release of chromatin leads to an open conformation 
allowing transcription of DNA to occur, the compaction of chromatin hides the DNA 
structure, resulting in gene silencing [97]. Acetylation of histone tails is generally 
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correlated with increased gene expression, while the regulation provided by the 
methylation of histone tails is more complicated. The singular methylation of one 
particular site at histone 3 lysine 27 (H3K27me1) correlates with actively transcribed 
promoter regions [98], however, triple methylation of the same site (H3K27me3) leads to 
repressed gene expression [99].  
Regulatory non-coding RNAs (ncRNA), not related to translation, participate in 
epigenetic mechanisms and are classified into two categories, long ncRNA and short 
ncRNA. Long ncRNAs form complexes with proteins to modify chromatin states, trigger 
histone methylation, and regulate transcription [100]. Short ncRNAs, including short 
interfering RNAs (siRNAs) and micro RNAs (miRNAs), bind to messenger RNA 
(mRNA) targets to either degrade mRNA or regulate protein translation [101]. While 
siRNAs are used extensively in cell culture experiments to knockdown gene expression, 
miRNAs were shown to regulate gene expression in tumor suppression and activation 
pathways in cancer models [102-104].  
The third category of epigenetic modification is methylation of the fifth position 
of the ring structure of cytosine. A family of DNA methyltransferase (DNMT) enzymes 
modify cytosine to 5-methylcytosine (5-mC) by the donation of a methyl group from S-
adenosyl methionine (SAM) as it is converted to S-adenosyl homocysteine (SAH) within 
the methionine cycle (Figure 1.4). While DNMT3a and DNMT3b generate new 
methylation patterns in DNA, DNMT1 is responsible for maintaining the existing 
methylation pattern throughout DNA replication [105]. Using dnmt1 knockout mice, Li et 
al. showed loss of methylation caused reactivation of innately inactive genes, suggesting 
DNA methylation works to silence genes in biological systems [106].  
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Figure 1.4 Simplified methionine cycle. The loss of a methyl group results in 
conversion of S-adenosyl methionine (SAM) to S-adenosyl homocysteine by several 
methyltransferase enzymes. Initiating DNA methylation, transfer of the methyl group 
from SAM to cytosine produces 5-methylcytosine. A methyl group is reintroduced into 
the methionine cycle by removal of a methyl group from 5-methyltetrahydrofolate to 
produce tetrahydrofolate by several enzymes from the folic acid cycle. Transfer of this 
methyl group to homocysteine produced methionine to continue the cycle.  
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While all three epigenetic mechanisms likely work cohesively to regulate gene 
expression, the etiology of how this process occurs is unknown. This dissertation focuses 
on cytosine modifications and the likely role this category of epigenetic modifications 
play in neurodegeneration, specifically AD. Detail into the proposed mechanisms of 
DNA methylation and the role cytosine modifications play in regulating transcription is 
described below.  
1.2.2 Methylation and Demethylation of Cytosine 
5-mC was discovered in genomic DNA in 1950 [107, 108] and was studied 
extensively in mammalian, bacterial, and plant DNA [109-111]. The removal of the 5-
mC mark was suggested to occur through passive demethylation mechanisms, where 
DNA replication would eventually dilute 5-mC to unmodified cytosine. While the first 
indication of an oxidized derivative of 5-mC in mammals was introduced in 1972 [112], 
it wasn’t until the rediscovery of oxidized 5-mC compounds in 2009 that an active 
demethylation mechanism was suggested [113-115].  
The enzymatic oxidation of 5-mC by the ten-eleven translocase (TET) family of 
enzymes leads to several derivatives: 5-hydroxymethylcytosine (5-hmC), 5-
formylcytosine (5-fC), and 5-carboxylcytosine (5-caC). These TET enzymes (TET1, 
TET2, and TET3) are activated by alpha keto-glutarate (αKG) and iron (II) cofactors and 
participate in an active cytosine demethylation pathway (Figure 1.5). Recently, it was 
shown that 5-mC is oxidized by TET1 to produce 5-hmC, while TET2 and TET3 
convert5-hmC to 5-fC and 5-fC to 5-caC in a cancer cell model [116]. However, other 
studies have shown that all three TET enzymes can oxidize 5-mC to 5-hmC [114, 117], 
thus the exact mechanism of TET demethylation remains unclear.  
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Figure 1.5 TET demethylation cycle. As a methyl group is transferred from the 
methionine cycle to DNA, the methylation of cytosine by a family of DNA 
methyltransferase (DNMT) enzymes produces 5-mC. Oxidation of 5-mC by a family of 
ten-eleven translocase (TET) enzymes yields 5-hydroxymethylcytosine (5-hmC), 5-
formylcytosine (5-fC) and 5-carboxylcytosine (5-caC). Along with TET demethylation, 
enzymes within base excision repair mechanisms, namely TDG (thyamine DNA-
glycosylase), can demethylate cytosine from 5-fC or 5-caC.  
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Additionally, several other enzymes have been identified to play a possible role in 
the demethylation of cytosine. 5-hmC can be deaminated by base-excision repair (BER) 
enzymes to 5-hydroxymethyluracil, followed by thyamine DNA glycosylase (TDG) to 
produce an abasic site, replaced by unmodified cytosine. TDG also plays a role in the 
TET pathway, where 5-fC and 5-caC were shown to be susceptible to TDG abasic site 
production, eventually producing unmodified cytosine (Figure 1.5) [118]. A less 
supported theory involves an unknown decarboxylase enzyme to convert 5-caC to 
cytosine directly, similar to the removal of a carboxyl group in the thymidine salvage 
pathway via iso-orotate decarboxylase in fungi [119, 120]. While the exact mechanism is 
unknown, the active demethylation of cytosine by oxidized derivatives of 5-mC likely 
plays a role in the pliability of regulating transcription mechanisms within cells [121, 
122].  
1.2.3 Detection methods of 5-mC  
Current detection methods for 5-mC modifications can be separated into two 
groups, global and sequencing studies. While global studies typically utilize 
immunohistochemical/immunofluorescent techniques to label analytes in mammalian 
tissue, some studies have used chromatography and mass spectrometry to quantify levels 
of the epigenetic mark. For sequencing studies, the gold standard technique for 
quantifying 5-mC uses bisulfite conversion. Sodium sulfite converts unmodified cytosine 
to uracil via sulphonation and deamination mechanisms, while 5-mC bases are not 
converted and read as cytosine during sequencing. The treated and the control libraries 
can then be compared to determine locations of cytosine methylation throughout the 
genome [123, 124]. 
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Disadvantages of immunochemical techniques include the potential for non-
specific binding, variation in antigen retrieval techniques in tissue mounted slides, 
disparity in processing and quantification of analyte signals, and the inherent semi-
quantitative nature of immunochemical studies. In addition, bisulfite sequencing does not 
distinguish between 5-mC and 5-hmC, and is better described as a detection method for 
modified cytosine rather than solely cytosine methylation [125]. To decipher the exact 
role 5-mC plays in regulating gene expression, improvements in detection techniques for 
5-mC need to be expanded upon, both in global and sequencing studies.  
1.2.4 Cytosine modifications and gene regulation 
Generally thought of as a mark of gene repression and silencing, 5-mC is 
associated with a compacted confirmation of chromatin and the methylation of histone 
protein tails. Several theories as to how this cytosine modification regulates transcription 
include interference in transcription factor binding, aiding mechanisms of chromatin 
remodeling, and playing a role in gene splicing pathways [126]. Specific genomic regions 
with cytosine modifications were also associated with gene expression regulation. 
Several of these studies are described below.  
Several studies showed variations in methylation of CpG (cytosine–phosphate–
guanine) sequences within the major and minor grooves of DNA altered chromatin and 
histone positioning. Structurally, 5-mC modifications were suggested to increase rigidity 
of the DNA backbone, to increase base pair stacking, and to alter water-mediated 
hydrogen bonding interactions within the major groove [127-130]. Collings et al. showed  
methylation of CpGs within the minor groove stabilized the nucleosome [131], while 
unmodified minor groove CpGs were not associated with histone binding sites [131, 
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132]. Methylation of CpGs in the major groove near the histone complex, however, were 
associated with an open chromatin structure [133] and projection of the 5-mC group from 
the major groove likely promoted interactions with methyl binding proteins [134]. The 
role 5-mC plays in remodeling chromatin structures will become clearer as this field of 
research develops.  
Transcription factor (TF) binding appears to be regulated by cytosine 
modifications depending on the location of 5-mC and the TF binding site. Fujimoto et al. 
showed 5-mC modifications adjacent to the core binding motif of activator protein-1 
blocked the TF complex from binding in a cancer cell line [135], while Zhu et al. showed 
similar results in methylated regions near the specificity protein 1/ specificity protein 3 
binding region in lung cancer cells [136]. However, in more than 150 DNA/TF binding 
sites, 5-mC either enhanced the interaction or prevented binding of TFs to DNA target 
sites in human embryonic H1 cells [137]. While DNA methylation clearly plays a role in 
TF binding, it may depend on individual genes rather than a “one size fits all” model, but 
more research is needed to address the relationship between 5-mC modifications and 
TF/DNA interactions.  
While the field of splice variant research has made strides in the last 40 years, 
many questions remain unanswered. One new area of interest is the role cytosine 
modifications play in DNA splicing and gene expression. Enrichment of 5-mC within 
gene bodies was associated with gene splicing [138], particularly enrichment of 5-mC 
near known splice sites [139, 140]. Wan et al. showed differentially methylated cytosine 
modifications preferred protein-coding genes with splice variants in mouse brain and eye 
DNA [141]. In studies of 5-mC modifications and protein-DNA interactions as they 
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relate to splice variant production, an increase in 5-mC blocked CTCF binding, increased 
the activity of RNA Polymerase II to ultimately cause exon exclusion in various cell lines 
[142]. In contrast, increased levels of 5-mC in several cell lines increased MeCP2 
(methyl CpG binding protein-2) binding, recruitment of histone acetylation enzymes, 
decreased RNA Polymerase II binding, thereby increasing exon inclusion [143]. While 
more research is needed to understand the role epigenetic modifications to cytosine play 
in DNA splicing mechanisms, these initial studies, while contradictory, suggest a major 
role.  
Placement of 5-mC in specific genomic regions seems to regulate gene expression 
as well.  Enrichment of 5-mC upstream of transcription start sites within coding genes led 
to gene repression [134, 144]. In a genome-wide study of 5-mC levels in human blood 
cells, highly methylated genes showed very low expression levels while highly expressed 
genes showed low methylation levels, confirming previous studies correlating 5-mC with 
gene silencing [145]. However, in the same study, gene body methylation was a better 
indicator of expression rather than promoter levels, even in the extreme highly 
methylated/rarely methylated distributions [145]. With the advancement of sequencing 
technologies in mapping 5-mC across the genome at single-base resolution, the role 5-
mC locations play in regulating transcription will become clear, particularly within gene 
bodies.  
It should also be noted that the majority of sequencing studies analyzing 
methylation levels and correlating gene expression mechanisms used bisulfite sequencing 
to map 5-mC throughout the genome. As stated previously, this technique is unable to 
distinguish 5-mC from 5-hmC. This is an issue due to the seemingly opposing roles 5-mC 
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and 5-hmC play in regulating transcription. Where increased levels of 5-hmC within the 
gene body of highly expressed genes correlated with open chromatin confirmations and 
histone acetylation, minimal levels of 5-hmC were found in genes with low transcription 
levels [96]. However, the hydroxymethylation of promoter regions was shown to 
correlate with increased expression as well as decreased expression in cell culture models 
[144, 146, 147]. 5-hmC marks were also more related to exon-intron boundaries in recent 
studies [146-148], possibly playing a role in splicing events.  
While the exact mechanism of deregulating transcription by cytosine 
modifications is not well understood, it is clear that 5-mC and 5-hmC likely play a role in 
altering gene expression. While many of the previously mentioned studies have begun to 
unravel how gene expression is regulated by epigenetic modifications, going forward, it 
is essential to utilize techniques capable of distinguishing between various cytosine 
derivatives to elucidate the mechanism of interaction of 5-mC and 5-hmC and gene 
expression. Given that gene expression alterations are a common pathologic feature of 
each stage of AD progression, examination of the role epigenetic modifications to 
cytosine may play in deregulating transcription in neurodegenerative diseases is worth 
exploring.  
 
1.3 Epigenetics and Neurodegeneration 
1.3.1 Cytosine modifications and neurological disorders 
Epigenetic modifications were studied extensively in cancer research and in 
embryonic development, but only recently in neurodegeneration. While cytosine 
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methylation levels are relatively stable across most tissues, levels of 5-hmC were 10 fold 
higher in brain than in other mammalian organs [149-151]. Where 5-hmC accounts for 
less than 10% of total DNA in heart and breast cells [121, 122, 152], in the brain, some 
report 40% of total 5-mC was actually hydroxymethylated [149, 153]. Increased levels of 
5-hmC were shown in neurons, as well as non-neuronal cells like microglia and 
astrocytes, compared to other cell types, including muscle and adipose cells [122, 149, 
153]. Since neurons do not replicate, it is plausible that mechanisms that regulate 
transcription and methods to adapt to the microenvironment are enhanced in the brain.  
Alterations in genes that regulate epigenetic mechanisms contribute to mental 
retardation in neurological disorders such as X-linked and Rett syndromes [97, 154, 155]. 
Furthermore, genes that play a role in neuropsychological disorders including 
schizophrenia and depression [156] and deregulate neuronal activity in learning and 
memory [154, 157, 158] also regulate epigenetic mechanisms. Several of these genes 
play key roles in the epigenetic modification machinery, including an αKG regulator 
isocitrate dehydrogenase (IDH), the DNMT family of cytosine methylation enzymes, the 
TET family of 5-mC oxidation enzymes, and MeCP2 which contributes to gene silencing 
by binding to 5-mC modifications [96, 97].  
In addition to specific genes that regulate epigenetic mechanisms in neurological 
disorders and processes, metabolites that feed relevant biological pathways in 
neurodegeneration are also linked to epigenetic regulation. In mouse models, as well as in 
post-mortem brain tissue of AD subjects, levels of homocysteine, a key metabolite 
compound in the methionine cycle (refer to Figure 1.4) were elevated [159, 160]. Along 
with homocysteine, levels of SAM and SAH were deregulated in sporadic AD patients 
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[161-163] as well as in numerous cell culture and animal models of AD [164]. Due to the 
involvement of the methionine cycle in the methylation of cytosine, ultimately affecting 
the levels of oxidized derivatives of 5-mC (e.g. 5-hmC, 5-fC, and 5-caC), it is probable 
that epigenetic modifications to cytosine are altered in AD.  
1.3.2 Aging and Epigenetic Drift 
For most idiopathic neurodegenerative diseases, age is a common risk factor 
[165]. Several studies confirmed that age corresponds to altered levels of epigenetic 
modifications and likely plays a role in natural aging mechanisms [166, 167]. Termed 
“epigenetic drift”, several studies suggest that as one ages naturally, the distribution of 
epigenetic modifications shifts to regulate transcription of biological pathways relevant to 
aging and healthy cellular maintenance [166, 167]. Because advanced age is the most 
important risk factor for developing AD, it has been suggested that alterations in levels of 
epigenetic marks merely reflect the advanced age of AD patients rather than playing a 
direct role in the disease, however more research is needed to determine if alterations in 
epigenetic marks are relevant to AD or are merely a consequence of aging.  
1.3.3 TET dependent oxidation of 5-mC 
Since oxidative damage is a key feature of AD, it was suggested that oxidation of 
5-mC may be a consequence of these pathways. Whether or not oxidation of cytosine 
occurs enzymatically or is a result of external oxidative sources, e.g. increased reactive 
oxygen species, is of interest, particularly in neurodegenerative disorders where reactive 
oxygen species are elevated.  In cell culture models, compounds known to increase ROS 
activity, including ascorbate [168], hydroquinones [169, 170], benzoquinones [170], and 
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5-fluorouracil [171], also increased global levels of 5-hmC, but only in the presence of 
active TET enzymes. In an in vitro study, oxidized derivatives of 5-mC were increased 
with extreme radiation levels without TET enzymes [172]. However, these conditions do 
not reflect or mimic a biological system suggesting it is unlikely that oxidation of 5-mC 
occurs without TET in physiological conditions. Thus, while oxidative damage 
mechanisms may increase the activity of TET, the formation of oxidized derivatives of 5-
mC is the result of enzymatic oxidation mechanisms.   
1.3.4 Global 5-mC and 5-hmC studies in AD 
Recent interest in quantifying global levels of 5-mC and 5-hmC modification in 
post-mortem AD brain tissues was sparked in the early 2010s, with preliminary findings 
suggesting alterations in 5-mC in sporadic AD brain tissue [173-175]. However, after 
multiple contradicting studies from different research groups, the results were 
inconclusive and conflicting. While some studies reported increased levels of 5-mC 
and/or 5-hmC in brain regions susceptible to plaque and tangle pathology, others reported 
a global decrease in 5-mC and/or 5-hmC, while one study showed no difference between 
AD and NC subjects. These studies are briefly discussed below.  
Increased methylation and hydroxymethylation were reported in the hippocampus 
of PCAD and LOAD subjects compared to NC using immunohistochemical techniques 
by Bradley-Whitman et al. [176], as well as in the middle temporal gyrus and middle 
frontal gyrus of early onset and late onset AD subjects using immunofluorescent 
antibodies by Coppieters et al. [177]. Coppieters et al. found low levels of 5-mC and 5-
hmC in astrocytes and microglial cells, but enrichment in both markers in neurons. In 
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addition to these, Bakulski et al. reported increased 5-mC in the frontal cortex of LOAD 
subjects compared to NC using a bisulfite conversion technique [175].  
In contrast, several studies report decreased levels of epigenetic marks in AD 
brain. In glial cells and neurons of the hippocampus of LOAD subjects, Chouliares et al. 
found decreased levels of 5-mC and 5-hmC using fluorescently labeled antibodies [173]. 
Using fluorescently labeled antibodies to tag 5-mC and 5-hmC in the entorhinal cortex 
(EC) and the cerebellum (CER) of LOAD subjects, two studies reported various results. 
Condliffe et al. found decreased levels of 5-hmC in the EC and CER of LOAD subjects 
with no change in 5-mC in either region [178], while Mastroeni et al. found decreased 
levels of 5-mC in the EC with no change in the CER [174]. Contrary to all of these 
studies, Lashley et al. found no significant difference of 5-mC and 5-hmC levels in CER 
or EC of LOAD compared to NC subjects using an ELISA [179].  
The majority of these studies used antibody techniques to label 5-mC or 5-hmC in 
fixed tissue or use an ELISA platform to semi-quantify epigenetic marks. Differences in 
tissue processing procedures, including antigen retrieval techniques, analysis of 
fluorescence or staining procedures, as well as non-specific binding of antibodies must be 
considered as a possible source for the conflicting results. Apart from antibody 
techniques, these studies also cover multiple brain regions including the prefrontal cortex, 
cerebellum, entorhinal cortex, hippocampus, and temporal lobe. Levels of 5-mC and 5-
hmC vary across brain regions [180, 181], therefore caution should be taken when 
extrapolating trends to AD of semi-quantitative results from one brain region. It is clear 
that a specific and quantitative technique to analyze global levels of 5-mC and 5-hmC in 
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multiple brain regions of AD subjects is needed to shed light on the role epigenetic 
modifications likely play in the various stages of AD progression.   
1.3.5 Genome-wide methylation studies in AD 
 While some studies analyzed global levels of epigenetic marks in AD, very few 
sequencing studies have occurred. Two methylation studies in cortical regions of the AD 
genome produced target genes that may be relevant to the mechanism of 
neurodegeneration in sporadic AD [182, 183]. Many of these genes overlapped with 
targets in a genome-wide associate study of SNPs related to AD [71]. In a methylation 
sequencing study of three regions of the cortex (entorhinal cortex, superior temporal 
gyrus, and prefrontal corex), Lunnon et al. found two differentially methylated regions in 
ankryin 1, a cytoskeleton regulation protein, associated with Braak staging scores in three 
independent cohorts of AD subjects using bisulfite sequencing techniques [182]. In a 
similar study of prefrontal cortex methylation, De Jager et al. found seven genes 
associated with NP burden, AD diagnosis, as well as altered mRNA expression in two 
independent cohorts of subjects using bisulfite conversion of 5-mC. The seven genes 
(ankryin 1, cadherin related 23, disco interacting protein 2 homolog A, rhomboid family 
member 2, ribosomal protein L13, serpin family F member 1, and serpin family F 
member 2) identified by De Jager et al. are suggested to be involved in signaling, 
amyloid processing, and trafficking pathways in AD [183].  
While both studies highlight specific gene targets that were epigenetically 
regulated in cortical regions of AD compared to NC subjects, defining these results as 
“methylation” is erroneous due to the lack of specificity in bisulfite conversion and is 
better described as cytosine modifications. Additionally, each study used the Illumina 
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450k sequencing platform, limiting the analyses to a fraction of the genome (485,577 
CpG sites) and may be overlooking differentially modified regions relevant to AD. 
Despite the limitations, these studies do highlight the probable role epigenetic 
modifications play in AD progression. Moving forward, due to the seemingly opposing 
roles epigenetic modifications play in regulating gene expression, techniques capable of 
distinguishing methylation from hydroxymethylation are essential to defining biological 
pathways and target genes epigenetically regulated in sporadic AD.   
1.4 Dissertation Overview/ Hypothesis Statements 
To better understand the role cytosine modifications likely play in the 
deregulation of transcription in sporadic AD, the aim of this dissertation was to analyze 
levels of epigenetic marks in DNA of post-mortem sporadic AD tissues (i) globally, (ii) 
across the genome, and (iii) at loci-specific levels in target genes relevant to AD. 
Technical descriptions of each analytical method for global, genome-wide, and gene 
specific studies are detailed in the following chapter. Specific aims of each study and 
detailed descriptions of brain regions analyzed and patient groups included in the 
analyses are discussed in the following chapter as well.  
 For global analysis of epigenetic modifications, levels of cytosine, 5-mC, and 5-
hmC were quantified in DNA extracted from multiple brain regions susceptible to AD 
pathologic features in different stages of AD progression. While alterations in global 
levels would not give gene specific information, this study would determine brain regions 
with altered epigenomes in stages of AD progression for future intensive gene specific 
studies. To determine the role hydroxymethylation of cytosine plays in AD, 5-hmC 
modifications were sequenced across the genome of hippocampal DNA in LOAD 
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subjects compared to NC. Unlike previous AD methylation studies using bisulfite 
conversion, a new sequencing technique specific to 5-hmC sites will determine genes 
with differentially hydroxymethylated regions to identify biological pathways 
epigenetically modified in AD. Finally, to analyze loci-specific levels of cytosine, 5-mC, 
and 5-hmC at different stages of AD progression, DNA was extracted from SMTG 
specimens of AD and NC subjects. Sites of potential epigenetic modifications in two 
genes relevant to sporadic AD were analyzed to determine how site-specific changes in 
epigenetic marks may correlate to alterations in protein levels.  
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CHAPTER 2: PROJECTS 
2.1 Overview of Projects 
Rampant deregulation of key genes involved in biological pathways related to 
sporadic AD is a common symptom throughout all stages of disease progression [58, 59]. 
While the exact function of each epigenetic modification to cytosine in regulating normal 
transcription mechanisms is not well understood, 5-mC and 5-hmC play a role in altering 
gene expression in healthy cellular function as well as in disease [144]. Global 
distributions and correlations to gene expression of 5-mC and 5-hmC marks were studied 
extensively in cancer and embryonic development, and as technological advancements 
and technique specificity increase, the role these epigenetic marks play will become clear.  
Levels of 5-hmC were enriched in the CNS compared to other tissues [149, 151], 
sparking interest in the possibility of linking epigenetic modifications to the deregulation 
of genes in neurological disorders. Since neuronal cells do not replicate, a mechanism to 
adapt to a changing microenvironment by internally regulating transcription processes 
seems likely, particularly in diseases like AD where pathologic features occur in the 
intracellular and extracellular spaces of neurons. Preliminary studies of semi-quantitative 
levels of 5-mC and 5-hmC in AD brain regions and bisulfite sequencing studies of the 
AD genome have produced conflicting results, leading to the need of a specific and 
quantitative method to decipher the role cytosine modifications likely play in AD. 
To better understand the role epigenetic modifications to cytosine play in sporadic 
AD, levels of cytosine modifications were analyzed globally (Project I), across the 
genome (Project II), and at loci-specific levels in specific target genes relevant to AD 
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(Project III). While global levels would highlight brain regions with an altered epigenetic 
landscape, genome-wide alterations and loci-specific levels would give gene targets and 
biological pathways deregulated by epigenetic mechanisms in sporadic AD, potentially 
leading to possible therapeutic options. An introduction and technical overview of each 
project is discussed in detail below.  
 
2.2 Project I: Quantification of global levels of cytosine, 5-mC, and 5-hmC in multiple 
brain regions at different stages of AD progression and other types of neurodegeneration 
Several immunochemical studies of AD brain tissue reported levels of 5-mC and 
5-hmC, however results were conflicting. Studies reported elevated levels [175-177], 
decreased levels [173, 174, 178], or no significant difference in either mark in AD [179]. 
One reason may be the non-specificity of the techniques applied, mainly the use of 
antibodies to tag 5-mC or 5-hmC for immunohistochemical or immunofluorescent 
studies. These techniques, which are inherently semi-quantitative, are dependent on 
antigen retrieval processes and results can vary depending on signal quantification 
analysis and processing procedures. A second reason could be the differences in brain 
regions analyzed in the various studies, where alteration of cytosine modification levels 
may be brain region dependent, possibly related to region susceptible to AD pathology.  
To clarify the possible role global levels of 5-mC and 5-hmC play in AD, it was 
the goal of this study to determine levels of each cytosine modification using a specific 
and quantitative technique, gas chromatography mass spectrometry (GC/MS), in multiple 
brain regions of various stages of sporadic AD progression. To determine if global levels 
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of 5-mC and 5-hmC were representative of disease stage or merely reflected age related 
epigenetic alterations, tissue specimens from age-matched normal control subjects were 
obtained and analyzed in parallel with subjects of AD progression. To determine if 
alterations in global levels of cytosine modifications were specific to AD or common to 
neurodegenerative diseases, tissue specimens from two other forms of dementia, Frontal 
temporal lobar degeneration (FTLD) and Dementia with Lewy Bodies (DLB), were 
obtained and analyzed with AD and NC tissue.  
2.2.1 Gas Chromatography Mass Spectrometry 
GC/MS is a combination of a separation technique (gas chromatography) paired 
with a mass detection system (mass spectrometry) to quantify organic compounds in a 
complex mixture (Figure 2.1). In the analysis, a small volume of a liquid sample is 
injected through a heated septum, vaporized, and carried into a column by an inert carrier 
gas, typically high purity helium (99.999%). Chromatographic separation of analytes in a 
solution is achieved by chemical interactions of the compounds with the stationary phase 
of a capillary column and temperature gradients designed to separate compounds by 
boiling point. The stationary phase of the column, comprised of a ratio of solid packed 
5% phenyl and 95% dimethylpolysiloxane, provides a surface for non-covalent chemical 
interactions with analytes. Throughout the column, analytes are in equilibrium with the 
stationary phase of the column and the mobile phase (helium carrier gas) depending on 
chemical composition and similarity to the chemical properties of the stationary phase. 
Increased interactions with the stationary phase causes analytes to remain in the column, 
producing longer retention times and separation of the analytes in the mixture.  
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Figure 2.1 GC/MS Instrument Schematic. Samples are carried into the column by a 
carrier gas (ultra-high purity (UHP) helium) and are separated based on chemical 
interactions with the stationary phase and eluted into the mass spectrometer. Electron 
ionization of the analytes allowes for mass selection by a quadrupole mass analyzer and 
detection using an electron multiplier.  
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Since analyte boiling point is a key component of separation, volatilization is 
essential to gas chromatography. Polar compounds can be chemically altered to increase 
nonpolar properties, allowing gas separation within the column. This technique, termed 
derivatization, replaces labile hydrogen atoms of the analyte with a nonpolar group, e.g. 
trimethylsilyl (–Si(CH3)3), to increase compound volatility and thermal stability [184] 
(Figure 2.2). This technique was particularly helpful in analyzing individual bases of 
DNA, including DNA oxidation markers [185, 186].  
Once separated by chemical composition in the column, analytes enter the 
ionization chamber of the mass spectrometer. Electrons are ejected from a metal filament 
to produce an ion beam where interactions of an analyte electron cloud with the ion beam 
results in electrostatic repulsion of an outer shell electron from the analyte to produce a 
molecular ion. The highly excited molecular ion can then relax and fragment to produce 
daughter ions. The most statistically probable fragmentation pattern will result in the 
most abundant ion detected for the analysis. After ionization of analyte, mass selection is 
performed using two sets of hyperbolic rods, termed a quadrupole, with adjustable radio 
frequency (RF) and direct current (DC) voltages. By adjusting the RF/DC voltage 
applied, designated ions with stable trajectories within the quadrupole pass through the 
center of the rods, while ions outside of the desired m/z window are unstable and 
annihilated on the surface of the quadrupole. An electron multiplier behind the 
quadrupole mass analyzer detects stable ions, i.e. desired m/z ratios, and abundance and 
signal intensities are recorded and displayed as lines in a mass spectrum. Detection of 
separated compounds eluting from the column, measured chronologically, ultimately  
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Figure 2.2 Derivatization of cytosine bases. To increase volatility of cytosine bases for 
GC/MS analyses, labile hydrogens were replaced with trimethylsilyl groups using 
BSTFA:TMCS derivatization protocol.  
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results in a chromatogram of individual signal peaks at specific retention times (Figure 
2.3). 
Identification of analytes occurs by pairing the separation efficiency of gas 
chromatography with the specificity in mass analysis of the mass spectrometer, while 
quantification is achieved by comparing signal intensity to isotopically labeled standards 
of known concentration and response (i.e. standard response curves). The advantage of 
incorporating isotopically labeled standards includes identical chemical separation within 
the GC column, but a slightly altered m/z ratio directly related to the change in mass of 
the isotope. Thus, known concentrations of stable labeled standards can be characterized 
and standard response curves produced to develop a quantitative method to analyze 
specific compounds.  
2.2.2 Summary of Project I 
To quantify global levels of 5-mC and 5-hmC in AD, tissue specimens from four 
brain regions (hippocampus/parahippocampal gyrus (HPG), superior and middle 
temporal gyrus (SMTG), inferior parietal lobe (IPL), and cerebellum (CER)) (Figure 2.4) 
were obtained from three stages of AD (preclinical AD (PCAD), mild cognitive 
impairment due to AD (MCI), and dementia due to AD or late onset AD (LOAD)). 
Because epigenetic modifications to cytosine are altered in aged brain, tissue specimens 
from age-matched normal control (NC) subjects were obtained to determine whether 
changes in global levels merely reflect aging epigenetic drift or are relevant to disease 
progression. To determine if alterations in 5-mC and 5-hmC levels were AD specific, 
tissue specimens from two other forms of dementia, FTLD and DLB, were obtained. 
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Figure 2.3 Total Ion Chromatogram. Well separated chromatographic peaks of (a) 
cytosine (~17 min), (b) 5-mC (~19 min), and (c) 5-hmC (~37 min) were analyzed using 
single ion monitoring (SIM) mode in GC/MS analyses.  
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Figure 2.4 Schematic of brain regions analyzed. Tissue specimens from subjects were 
analyzed from four brain regions, including hippocampus/parahippocampal gyrus (HPG, 
purple), superior and middle temporal gyrus (SMTG, green), inferior parietal lobe (IPL, 
blue) and cerebellum (CER, orange).  
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Using GC/MS and stable isotopically labeled commercially available standards for 
cytosine, 5-mC, and 5-hmC (Figure 2.5), global levels of epigenetic marks were 
quantified throughout the stages of AD across multiple brain regions susceptible to AD 
pathologic features.  
 
2.3 Project II: Single-base resolution mapping of 5-hmC in hippocampus of LOAD 
subjects 
While global levels of epigenetic modifications give insight into regions of the 
brain affected by alterations in 5-mC and 5-hmC, bulk analysis provides no information 
on specific genes with altered epigenetic marks and possible contribution to the 
progression of AD. Thus, sequencing of epigenetic modifications throughout the AD 
genome is an important area of interest to decipher gene specific roles in the deregulation 
of transcription in sporadic AD. With the discovery that bisulfite conversion alone does 
not distinguish between 5-mC and 5-hmC modifications [125], several sequencing 
techniques were developed to analyze 5-hmC throughout the genome. Three of these 
techniques include oxBS-Seq (oxidative bisulfite sequencing), TAB-Seq (TET-assisted 
bisulfite sequencing), and RRHP (reduced representation hydroxymethyaltion profiling). 
While oxBS-Seq and TAB-Seq use harsh chemical labeling to quantify levels of 5-hmC 
modification [187], RRHP utilizes glucose protection of hydroxymethylation sites paired 
with specific restriction enzyme digestion to analyze counts of 5-hmC throughout the 
genome, and is suggested to be the most sensitive and reproducible single-base resolution 
hydroxymethylation sequencing technique to date [188].  
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Figure 2.5 Stable labeled cytosine bases. Commercially available stable labeled 
cytosine, 5-mC, and 5-hmC were used for GC/MS analyses. Cytosine and 5-hmC were 
labeled with 13C and 15N atoms, while 5-mC was labeled with deuterium (2H) atoms.  
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To better understand the role 5-hmC modifications play in regulating transcription 
in the hippocampus of LOAD subjects compared to NC, we sought to map 5-hmC across 
the AD genome using Zymo Research Corporation’s in-house RRHP technique. From the 
list of genes with altered hydroxymethylomes, we hypothesized that a list of biologically 
relevant pathways related to sporadic AD would be produced to provide possible gene 
targets for further study and possible development of therapeutic options in the future.  
2.3.1 RRHP and the Illumina platform 
The RRHP genome-wide mapping approach uses the specificity of restriction 
enzyme digestion paired with the deep sequencing capability of the Illumina platform to 
count sites of 5-hmC modifications at CCGG sequences throughout the genome [188]. 
Originally found in bacteria to provide a defensive mechanism against viral infection 
[189, 190], restriction endonuclease enzymes recognize specific DNA sequences and 
cleave at the sugar-phosphate bond of the DNA backbone. The methylation of cytosine 
typically occurs at CpG sequences within mammalian genomes. MspI, a type II 
restriction endonuclease, recognizes CCGG sequences within DNA and cleaves between 
the cytosine bases, regardless of whether the internal cytosine is modified by a methyl 
group or a hydroxymethyl group [188, 191]. In 2011, Davis et al found that glucosylation 
of the hydroxyl group of 5-hmC in DNA by another enzyme (beta glucose transerfase, 
T4-βGT) would prevent digestion by MspI, therefore creating a technique to study 5-
hmC within DNA genomes [192].  
While most Illumina workflows use a random DNA fragmentation process 
(Bentley 2008), the RRHP technique uses enzymatic fragmentation to allow for 
sequencing of cytosine bases modified with hydroxymethyl groups [188]. Using an initial 
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digestion of DNA by MspI, cleavage at the phosphate backbone bond of all CCGG 
sequences regardless of 5-mC or 5-hmC (blue circles) modification occurs (Figure 2.6). 
After MspI fragmentation, adapters (shown in red and orange) are added to both ends of 
the DNA fragments, followed by glucosylation of 5-hmC by T4-βGT. Now protected by 
the glucosyl group, the second round of MspI digestion is inhibited at glucose modified 
5-hmC (green circles) sites. Nonhydroxymethylated sequences with adapters are cleaved 
during the second round of MspI digestions and will not undergo amplification during 
Illumina workflow and further downstream analysis. 
As the most widely used next generation sequencing technique, the Illumina 
platform for deep sequencing is responsible for large advancements in mapping the 
human genome, specifically in the identification of risk SNPs of complex diseases [193]. 
DNA sequences are fragmented and ligated with specific adapters at each end of the 
fragment sequence. Ligated fragments are then bound to an Illumina flow cell where 
complimentary adapter sequences were previously attached (Figure 2.7a). Utilizing a 
bridge amplification technique (Figure 2.7b), template strands are formed on the flow 
cell. Several rounds of bridge amplification form clusters of complimentary sequences 
(Figure 2.7c). Once tens of thousands of clusters form on the flow cell (Figure 2.7d), 
fluorescently labeled nucleotides with reversible termination sites on the sugar of each 
nucleotide are added. In order to achieve high throughout sequencing, nucleotides are 
elongated one at a time and measured using fluorescent imaging. An example of the 
chemical structure of a reversible terminator nucleotide is shown in Figure 2.8, provided 
in the Illumina product information. 
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Figure 2.6 RRHP DNA fragmentation. Target DNA undergoes restriction enzyme 
digestion using MspI to cleave all CCGG sequences, regardless of whether the internal 
cytosine is hydroxymethylated (blue) or not. Fragmented DNA is ligated using Illumina 
adapter sequences at 5’ and 3’ ends of the fragments. To protect 5-hmC sites, 
glucosylation of hydroxyl groups (green) by T4-βGT prevents loss of ligated adapter 
sequences from DNA fragments during second MspI digestion.  
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Figure 2.7 Illumina Platform Workflow. Adapter ligated DNA fragments bound to an 
Illumina flow cell (a) undergo bridge amplification (b) to form new template strands (c). 
Many cycles of amplification produce clusters (d) of replicated DNA fragments. Addition 
of primers, Polymerase, and reversible terminator fluorescent nucleotides are added to the 
flow cell to initiate primer elongation and addition of a single nucleotide to template 
strands. Excitation of fluorophores (e) followed by imaging of the flow cell (f) results in 
base-by-base sequencing of DNA.  
 
 
 
 
48 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8 Fluorescent Nucleotide with Reversible Terminator. Illumina sequencing 
at single-base resolution occurs via the addition of a reversible terminator (-OCH2N3) to 
the sugar molecule of a fluorescently labeled nucleotide, shown here with cytosine.  
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Nucleotides, along with universal primers and specific polymerase enzymes, are 
added to the flow cell to induce primer elongation. Upon laser excitation (using lasers 
with 532 nm, 660 nm, and 700-840 nm wavelengths), each nucleotide emits a different 
wavelength (Figure 2.7e) and images of the fluorescence are captured at each addition of 
a nucleotide (Figure 2.7f). Enzymatic cleavage of the flurophore and loss of the 
termination site allows for primer elongation and the next nucleotide is excited and the 
flow cell imaged. Repeated cycles of nucleotide “extension – termination – fluorescence 
– cleavage – extension” result in base-by-base recognition and genome-wide sequencing 
of the DNA sample.  
2.3.2 Summary of Project II 
To quantify genome-wide levels of 5-hmC in HPG DNA of LOAD subjects 
compared to NC, isolated nuclear DNA was sent to Zymo Research Corporation (CA, 
USA) for their in-house hydroxymethylation sequencing technique (RRHP). Data files 
were downloaded from Zymo and analyzed using a freely available PERL script termed 
diffReps, initially coded for genome-wide analysis of chromatin immunoprecipitation 
sequencing (ChIP-seq) data [194]. To determine regions of differential 
hydroxymethylation in the hippocampus of LOAD subjects compared to NC, a negative 
binomial distribution analysis was applied to our RRHP data in diffReps to determine 200 
base pair regions of altered 5-hmC in the LOAD genome. Genes with significantly 
altered levels of 5-hmC in LOAD compared to NC subjects were sorted based on 
expression data in a previously published microarray [59], and the overlapping gene list 
was analyzed using the Reactome Functional Interaction Network tool in CytoScape®. 
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This tool determines significant relationships between the target gene list and known 
interactions of genes within biologically relevant pathways. 
 
2.4 Project III: Quantification of loci-specific 5-mC and 5-hmC levels in exons of PS1 
and ABCA7 in SMTG throughout stages of AD progression 
While genome-wide sequencing technologies have advanced greatly in the past 
several years, the financial cost of analyzing multiple biological replicates is high. Until 
the cost of novel sequencing techniques decrease, alternative methods applicable to 
multiple samples to analyze specific genomic regions rather than genome-wide analyses 
were developed. One such method pairs the specificity of target recognition by restriction 
endonuclease mechanisms with the quantification ability of quantitative polymerase 
chain reaction (qPCR) instrumentation. While the breadth of analysis is far smaller 
compared to genome-wide studies such as RRHP, the benefit of analyzing multiple 
biological replicates in various stages of AD progression at moderate cost could shed 
light on the role cytosine modifications play in regulating protein levels in target genes 
relevant to sporadic AD.  
To analyze specific target sequences within exon of genes relevant to sporadic 
AD, a quantification kit from New England Biolabs was used in which manipulation of 
two specific restriction endonucleases target particular genomic sequences to quantify 
levels of cytosine, 5-mC, and 5-hmC. Synthetic primers were designed flanking target 
sequences within exons of genes relevant to sporadic AD, including PS1 and ABCA7. 
These genes were implicated to play a possible role in the pathogenesis of AD, as well as 
showed altered expression in sporadic AD subjects as discussed below.   
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While mutations in PS1 were linked to the familial form of AD, deregulation of 
PS1 was shown in post-mortem sporadic AD tissues and wild type PS1 was implicated in 
leading to increased amyloid production with age in a mouse model of amyloid 
depositions [195, 196]. ABCA7 (ATP Binding Cassette Subfamily A Member 7) is likely 
a cholesterol transport protein and has been implicated as a possible risk gene in sporadic 
AD SNP studies [71]. Loss of function in ABCA7 activity was shown in the AD variant 
form [197], as well as a target in several AD methylation studies [183, 198]. These 
alterations in expression in sporadic AD may be related to changes to the epigenetic 
landscape of gene bodies, namely exons, within PS1 and ABCA7. To determine if 
epigenetic alterations may play a role in these changes to transcription, DNA from SMTG 
tissue specimens in various stages of AD progression was used to map epigenetic 
landscapes within the exons of these two genes, and correlated to expression by analyzing 
protein levels in the same tissue specimens.   
2.4.1 qPCR and Specific Restriction Enzyme Digestion 
The polymerase chain reaction (PCR) utilizes the biochemistry of DNA 
replication mechanisms to amplify specific regions of genes of interest in vitro. The three 
stages of PCR are denaturation, annealing, and elongation (Figure 2.9). Synthetic primers 
designed to be identical to target gene DNA sequences bind to single stranded DNA after 
denaturation. Primers anneal to the single stranded DNA and polymerase elongates the 
primers by incorporating nucleotides, eventually replicating the DNA sequences of the 
designed amplicon. The amplicon concentration doubles with each round of PCR during 
the amplification phase, then as reagent concentrations diminish, the reaction plateaus 
and amplicon production ceases. Analysis of product amplicons at the plateau phase, or  
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Figure 2.9 Polymerase Chain Reaction. Double stranded DNA is denatured to allow for 
synthetic primers to bind to single strands, termed annealing. Polymerase elongates the 
primers to form template strands, recreating double stranded DNA. Each denature-
anneal-elongate cycle results in doubling the amount of DNA from the previous cycle, 
thus amplifying the target DNA sequence.  
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the endpoint, typically occurs by separating DNA fragments on an agarose gel by 
electrophoresis, and fluorescent intercalating dyes and UV excitation are used for 
amplicon detection.   
The use of PCR to amplify DNA fragments was used for decades in microbiology 
and biochemistry, although, as an endpoint technique, it is inherently qualitative. The 
development of real time quantitative PCR (qPCR), where fluorescent measurements are 
obtained during product amplification rather than at the plateau phase, provides an 
extremely accurate and quantitative technique [199]. Using qPCR, amplification of 
products is measured in real time during the exponential phase of amplification where 
accurate measurements are used to extrapolate initial starting amounts of target DNA 
(Figure 2.10). SYBR Green, an intercalating fluorescent dye, binds to the minor groove 
of double stranded DNA and fluoresces [200-202]. During the amplification phase of the 
PCR mechanism, as amplicons are produced, bound SYBR green molecules increase 
fluorescent intensity as more product amplicons are formed (Figure 2.11).  Once this 
fluorescence passes a threshold, typically 10x the standard deviation of the background 
signal during early cycles, the cycle threshold number (Ct) value directly correlates to the 
starting amount of DNA and accurate quantification of the target can be analyzed using 
standard response curves.  
MspI restriction enzyme digestion was described previously (Projects 2.3.2), 
however pairing MspI with a second enzyme, the type II restriction endonuclease HpaII, 
allows for one to distinguish between 5-mC and 5-hmC at the same CCGG sequence. 
While MspI will cleave 5-hmC and 5-mC modifications, HpaII will only cleave 
unmodified cytosine in the same CCGG sequences. Protection of the 5-hmC group by 
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Figure 2.10 Real time qPCR Amplification Plot. While endpoint PCR utilizes the 
plateau phase of the amplification curve, real time qPCR measures fluorescence 
continuously, allowing for accurate measurement of initial starting amounts over a large 
concentration range of input DNA. At a critical threshold, shown as ΔRn = 0.183036, 
where fluorescence measures 10x above background signal, cycle threshold (Ct) values 
correlate to initial starting amounts of DNA, measured during exponential phase of 
amplification.  
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Figure 2.11 SYBR Green reaction. As an intercalating dye, SYBR green (circle) binds 
to double stranded DNA and fluoresces (sun). As the polymerase reaction forms new 
double stranded template strands, the fluorescent signal increases relative to the amount 
of product DNA amplified. 
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glucosylation and treatment with MspI allows for quantification of 5-hmC, while 
treatment of HpaII will allow for quantification of 5-mC and 5-hmC. Thus, the difference 
between the two treatments will allow for calculation of 5-mC levels (Figure 2.12). 
Optimizing the interaction of restriction endonuclease enzymes with DNA also allows the 
quantification of epigenetic modifications to cytosine at the single base level at sites 
within genes of interest, but only at a fraction of the cost of global sequencing studies. 
2.4.2 Summary of Project III 
To quantify levels of cytosine, 5-mC, and 5-hmC in CCGG sequences within 
exons of ABCA7 and PS1, glucosylation of 5-hmC by T4-βGT was paired with specific 
restriction endonuclease digestion by MspI and HpaII, analyzed by real time qPCR. 
Primers designed around specific CCGG sequences within the exons of each gene were 
optimized and tested for specificity using endpoint PCR for single amplicon verification 
as well as qPCR melt curves to ensure single product amplification. Levels of cytosine 
modifications within the temporal lobe (SMTG) were analyzed at several stages of AD 
progression, including PCAD, MCI, and LOAD, compared to NC subjects. To correlate 
epigenetic modifications with protein expression, levels of protein were analyzed using 
Western blot analysis. 
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Figure 2.12 EpiMark kit reactions diagram. Glucosylation of the hydroxyl group of 5-
hmC (ghmC) protects the site from MspI cleavage, whereas HpaII cleaves unmodified 
cytosine within CCGG sequences. By comparing the amount of undigested DNA (5-hmC 
and 5-mC+5-hmC) with the total amount of DNA where no enzyme was added, levels of 
5-hmC, 5-mC, and cytosine can be determined at loci-specific levels within genes. 
Unprotected digestion by MspI (no reaction) is used to control for enzyme cleavage 
efficiency.  
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CHAPTER 3: MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Reagents 
Proteinase K, BioUltra Phenol, cholorform, 3-methyl-1-butanol, formic acid, 
anhydrous pyridine, agarose gel, ethidium bromide, goTaq PCR colorless kit, beta-
mercaptoethanol, Novex protein standards, and Teflon seals were purchased from Sigma 
Aldrich, while BSTFA:TMCS, 99:1 was purchased from a Sigma Aldrich supplier 
company, Supelco Inc. GC/MS auto-sampler vials, microvolume inserts, vial caps were 
purchased from Agilent Technologies.  
Synthetic primer pairs were designed and purchased from IDT, while the EpiMark 
5-mC and 5-hmC quantification kit, as well as CutSmart buffer, were purchased from 
New England Biolabs. From Invitrogen Life Technologies, the Fast SYBR Green Master 
Mix, qPCR 96 well plates, adhesive film, and ultrapure DNAase free water were 
purchased.  
Polyclonal rabbit PS1 antibody and mouse GAPDH antibody were purchased 
from Santa Cruz Biotechnology, while polyclonal rabbit ABCA7 antibody was purchased 
from LifeSpan Bioscience. Fluorescently labeled secondary antibodies (anti-rabbit and 
anti-mouse) were purchased from Licor.  
3.1.2 GC/MS Standards 
Labeled and unlabeled commercially available standards of cytosine, 5-mC, and 
5-hmC were used to analyze epigenetic marks using GC/MS. Unlabeled standards of 
 
59 
 
cytosine and 5-mC were purchased from Sigma Aldrich (St. Louis, MO), while unlabeled 
5-hmC was purchased from MP Biomedical (Santa Ana, CA). Isotopically labeled 
standards were purchased from three different vendors: [2-13C, 1, 3-15N] cytosine from 
Cambridge Isotope Laboratories (Tewksbury, MA), [2-13C, 1, 3-15N] 5-hmC from 
Moravek Biochemicals Inc. (Brea, CA), and 5-methyl-d3-cytosine-6-d1 from CDN 
Isotopes (Pointe-Claire, QC, Canada).  
 
3.2 Methods for global quantification of cytosine, 5-mC, and 5-hmC  
3.2.1 Subject Data 
Tissue specimens of short (< 4 h) post mortem interval (PMI) autopsies of age-
matched NC subjects, as well as PCAD, MCI, LOAD, FTLD and DLB subjects, were 
obtained through the University of Kentucky Alzheimer’s Disease Center (UK-ADC) 
Neuropathology Core. All specimens were obtained in compliance with Institutional 
review board approved protocols and in agreement with The Code of Ethics of the World 
Medical Association (Declaration of Helsinki). All participants or their legally authorized 
representatives provided written informed consent. For all longitudinally followed 
subjects in the UK-ADC, biannual physical examinations and annual neuropsychological 
testing were completed.  
All subject diagnoses were based on UK-ADC postmortem consensus 
conferences between social workers, neurologists, neuropathologists, and 
neuropsychologists. NC subjects had normal range scores for mental status test battery 
exams, including 14 neuropsychological tests, and showed no evidence of memory 
 
60 
 
decline [31]. Normal control subjects also showed low Braak staging scores (0-II) and 
only age-associated histopathological changes. PCAD subjects, as described by the UK-
ADC, met intermediate to high National Institute of Aging-Reagan Institute (NIA-RI) 
criteria [203] for advanced AD pathologic changes at autopsy, as well as frequent to 
moderate neuritic plaque burden by the Consortium to Establish a Registry for 
Alzheimer’s disease (CERAD) guidelines [204]. PCAD subjects had normal range 
psychometric test scores when corrected for age and education [31], but had Braak 
staging scores between III-VI. Additionally, MCI subjects had Braak staging scores 
between II-V, increased NFT density in the entorhinal cortex, hippocampus, and 
amygdala, as well as increased neuritic plaque density in neocortical regions compared to 
NC subjects. MCI subjects do not meet criteria for clinical diagnosis of dementia, but 
showed increased memory impairment upon clinical cognition and memory exams, 
specifically objective memory test impairment (based on word learning task exams) [35, 
36]. Unlike MCI, LOAD subjects showed decreased cognition and memory impairment 
for clinical diagnosis of dementia and probable AD [203, 205], as well as advanced 
neuropathology (Braak stage scores V and VI), meeting CERAD and NIA-RI guidelines 
for intermediate to high likelihood of AD. 
Elevation of AD-related pathologic markers including Braak NFT stage scoring 
[45] and counts of neuritic and diffuse plaques, as well as NFTs, were determined by the 
UK-ADC Neuropathology Core. Mini Mental State Examination (MMSE) scores [206] 
were used to determine global cognitive status for all subjects, provided by the UK-ADC. 
At autopsy, tissues from the hippocampus/parahippocampal gyrus (HPG), superior and 
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middle temporal gryus (SMTG), inferior parietal lobe (IPL), and cerebellum (CER) were 
flash frozen in liquid nitrogen and stored at -80°C until processed for analysis.  
3.2.2 DNA isolation 
Frozen tissue specimens were homogenized in 1 mL of digestion buffer (0.05 M 
Tris-HCl, 0.1 M Na2EDTA, 0.5% sodium dodecyl sulfate) and 0.5 mg/mL proteinase K 
solution using a mechanical homogenizer and incubated overnight at 56°C as described 
previously [185, 186]. Following tissue digestion, 5 M NaCl was added to the samples to 
a final concentration of 0.08 M and vortexed. To extract DNA, three 1 mL phenol/ 8-
hydroxyquinoline extractions were followed by three 1 mL 24:1 chloroform: isoamyl 
alcohol extractions. DNA was precipitated from supernatant with 5 M NaCl and 1.5 mL 
of cold ethanol. The samples were hand mixed and precipitated overnight at -20°C. To 
remove impurities and excess salt, the DNA pellet was washed three times with 60% 
ethanol, dried, suspended in deionized water, and incubated for 15 min at 40°C. Purity of 
DNA and concentration were measured using the ND1000 NanoDrop UV-Vis 
Spectrophotometer (Fisher Scientific, NY).  
3.2.3. Internal standard (IS) solutions 
To prepare stock solutions of isotopically labeled standards, approximately 5 mg 
of each standard was dissolved in 2.5 mL of sterile double distilled water. To determine 
molar concentration of internal standard solutions, the absorbance was measured in 
triplicate at 270 nm for cytosine and 5-mC [108] and 274 nm for 5-hmC [207] using a 
Genesys 10uv Thermo Spectronic UV-Vis Spectrophotometer (Thermo Scientific). To 
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compare retention times and fragmentation of labeled and unlabeled standards, solutions 
of unlabeled standards of cytosine, 5-mC, and 5-hmC were prepared as described above.   
3.2.4 Acid Hydrolysis 
40 µg of DNA was added to 5 mL conical glass vials, frozen, and lyophilized. To 
hydrolyze the bases, 250 µL of 90% formic acid was added to each sample. Air was 
evacuated from samples using a Teflon seal and a 60 mL syringe with a 20 gauge needle. 
Samples were heated for 30 min in a sand bath at 140°C. After cooling for 10 min at        
-80°C, labeled standards were added to the vials and frozen at -80°C for at least two 
hours. Samples were then lyophilized overnight.  
3.2.5 Derivatization of DNA bases 
To volatilize bases, 250 µL of a 50:50 solution of pyridine/BSTFA:TMCS was 
added to each sample vial and evacuated as previously described [185]. To ensure the 
reaction went to completion and all bases derivatized, samples were vortexed every 30 
min for 2 h at 21°C. Vials were then dried under nitrogen gas for 2 h. To suspend DNA 
bases, 20 µL BSTFA:TMCS was added to each vial, the vials were vortexed, and the 
solution was transferred to a GC/MS autosampler insert and capped.  
3.2.6 GC/MS Method 
Separation of derivatized bases was accomplished using an Agilent 7890A GC on 
an Agilent HP-5MSI ultra inert capillary column (0.25 mm diameter, 0.25 µm film 
thickness, 30 m length). To analyze the sample, 1 µL was injected using splitless mode 
with ultrapure helium as the carrier gas (99.999%), where the inlet pressure was set to 
11.8 psi under constant flow. To obtain separation of cytosine, 5-mC, and 5-hmC elution 
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peaks, a temperature program was developed: 100°C for 2 min hold, 5°C/min to 125°C, 
0.75°C/min to 134.75°C, 0.3°C/min to 137.15°C, 10°C/min to 307.15°C, and held at 
307.15°C for 2 min. Total run time was 47 min per sample. Retention times for the 
standards were 17 min for cytosine, 19 min for 5-mC, and 36 min for 5-hmC.  
From the GC column, samples were introduced into an Agilent 5975C inert XL 
EI/CI MSD with Triple Axis Detector mass spectrometer with an injector temperature set 
to 250°C and ion source at 230°C. Using selective ion monitoring (SIM) mode, data were 
collected for specific m/z ratios of the base peak for IS and unlabeled cytosine 
derivatives. IS m/z ratios monitored were 257 for [2-13C, 1, 3-15N] cytosine, 258 for 5-
methyl-d3-cytosine-6-d1, and 360 for [2-13C, 1, 3-15N] 5-hmC. The unlabeled cytosine 
derivatives were monitored at m/z ratios of 254 for cytosine and 5-mC, and 357 for 5-
hmC at each respective retention time. To quantify levels of each base, the integrated area 
of the signal for each analyte was normalized with respect to the IS signal and corrected 
based on standard response curves for each labeled standard. Sample values were 
calculated as pmol modification/mg DNA, taking into account 0.04 mg of DNA analyzed 
for each sample and a 20:1 dilution factor (20 µL resuspended: 1 µL injection).  
To develop standard curves for each labeled base, five replicate measures of 1:3 
serial dilutions over a range of 1.5 pmol/µL – 375 pmol/µL were used to analyze 
instrument response prior to tissue experiments. Concentration ranges were based on 
average amounts of cytosine, 5-mC, and 5-hmC in 1 µL injections of DNA from 
processed brain tissue specimens. Limit of detection and limit of quantification (LOQ) 
were calculated based on the slope of the standard curve and standard deviation of blank 
measurements.  
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3.2.7 Spike Recovery 
To determine if processing steps alter analyte recovery, a spike recovery analysis 
was utilized. Samples included an IS blank using [2-13C, 1, 3-15N] cytosine, [2-13C, 1, 3-
15N] 5-hmC, and 5-methyl-d3-cytosine-6-d1 (IS mix), a spike blank with IS mix and 
unlabeled standards mix, a DNA sample with IS mix, and a spiked sample with DNA, IS 
mix, and unlabeled standards mix. Unlabeled cytosine standards were tested at two 
concentrations. Commercially available labeled (IS) (125 pmol of each) and unlabeled 
cytosine standards (168 pmol or 336 pmol of cytosine, 100 pmol or 200 pmol of 5-mC, 
and 32 pmol or 64 pmol of 5-hmC) were added to normal control DNA extracted from 
cerebellum tissue specimens. For DNA samples, 40 μg of DNA was used per vial, where 
the sample and spiked sample came from the same stock DNA (80 μg total per set). The 
unlabeled standards mix was added to 40 μg of DNA and underwent formic acid 
treatment and derivatization to determine if processing steps altered the amount of 
analyte recovered, i.e. if acid hydrolysis converted 5-mC standard to 5-hmC during 
processing steps. Spiked samples were compared to blank samples to calculate percent 
recoveries. Each type of sample (IS blank, spike blank, sample, and spiked sample) was 
run in duplicate (blank vials) or triplicate (DNA vials) and the analysis repeated.  
3.2.8 Statistical analysis 
3.2.8.1 Power analysis and Randomization 
To limit the potential for batch differences, DNA samples were randomized by 
brain region and diagnosis and processed for acid hydrolysis and derivatization steps in 
sets of 10. When quantifying results, data were recorded by subject case number with no 
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indication of diagnosis to minimize subjective bias. No formal power analysis was 
utilized and sample sizes were based on tissue specimen availability.  
3.2.8.2 Subject demographic analysis 
To determine statistical differences in subject demographic data between 
diagnosis groups, ANOVA was used for parametric distributions (PMI and age), while 
ANOVA on Ranks was used for non-parametric distributions within the data (MMSE 
scores, Braak stage scores, and pathologic burden counts). In the event the ANOVA test 
was significant (p < 0.05), Dunn’s post hoc analysis was performed. SigmaPlot version 
13.0® (Systat Software Inc., San Jose, CA) was used to perform statistical analysis tests 
on subject demographic data.  
3.2.8.3 General Linear Regression Models 
To test associations between epigenetic marks (5-mC and 5-hmC) in brain regions 
(HPG, SMTG, IPL) with mean brain region-specific NP and NFT counts, general linear 
regression models (GLM) were used. Six regression models were fitted to the data, one in 
each brain region for each dependent variable (NP and NFT counts). Models 
simultaneously estimated the association between NP/NFT counts and 5-mC and 5-hmC 
while adjusting for age at death and gender. To test associations between MMSE scores 
(global cognition measurement) near death and epigenetic marks (5-mC and 5-hmC), 
GLMs were also used and adjusted for age at death and gender.  
3.2.8.4 Repeated measures analysis 
Due to the complexity of the data, a repeated measures analysis with brain region 
as the repeated factor within subjects was used to analyze significant differences in levels 
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of cytosine, 5-mC, and 5-hmC across four brain regions (HPG, SMTG, IPL, CER) from 
five subject groups (NC, PCAD, MCI, LOAD, FTLD/DLB). Separate models were fitted 
for cytosine, 5-mC, and 5-hmC. An unstructured covariance matrix was used to account 
for correlations within the four measurements taken on each subject. Models tested the 
main effect of brain region and subject group, as well as their two-way interaction 
(adjusted for gender and age). GLMs and repeated measures analysis was performed in 
SAS version 9.4®.  
 
3.3 Methods for genome-wide profiling of 5-hmC  
3.3.1 Subject Data 
Tissue specimens of hippocampus/parahippocampal gyrus (HPG) from LOAD 
(n=3) and NC (n=2) subjects were obtained as described previously (Methods 3.2.1).  
3.3.2 DNA isolation 
Nuclear DNA was extracted from HPG tissue specimens using dounce 
homogenizer in 1 mL digestion buffer/ proteinase K solution as previously described 
[176, 185]. Extraction of DNA using phenol:chloroform:isoamyl alcohol protocol was 
performed as described above (Methods 3.2.2).  
3.3.3 5-hmC whole genome profiling: RRHP 
To analyze sites of 5-hmC modification in LOAD subjects, 1 µg of nDNA was 
sent to Zymo Research Corporation (ZRC) (CA, USA) for analysis by their in-house 
reduced representation hydroxymethylation profiling (RRHP) technique, where specific 
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restriction endonuclease enzymes were used to analyze epigenetic modifications at the 
internal cytosine of CCGG sequences [188]. Glucosylation of 5-hmC at the internal 
cytosine (CCGG) protects it from cleavage by MspI, whereas without protection, MspI 
cleaves between the CC bases within CCGG sequences. Library construction, 
sequencing, alignment to the human genome (hg19), and count reads were performed by 
ZRC. More than two million sites of possible 5-hmC modification were analyzed across 
the genomes of three LOAD and two NC subjects. Data files (BAM files) were 
downloaded from ZRC.  
3.3.4 Data analysis: negative binomial distribution 
To analyze genome data files, the free bedtools PERL script bamtobed [208] was 
used to convert downloaded ZRC BAM files to BED format. BED files were analyzed 
using an exact negative binomial test [209] with a sliding window approach in diffReps 
v1.55.4 [194]. Window size was set to 200 base pairs (bp) with a slide of 20 bp. To 
normalize data, raw read counts within 200 bp windows were linearly scaled by the 
geometric mean of all the reads in the specified window for each sample. Only windows 
that passed an initial cutoff (p < 1e-04) were retained. To correct for multiple comparisons, 
p values were adjusted using Benjamini-Hochberg false discovery rate (FDR) [210]. 
Annotation of windows to genomic regions was performed using the freely available 
regionanalysis PYTHON script, a now standalone script initially developed for diffReps. 
All scripts were run using command line calling in Terminal v2.6.1 (Apple, Inc., 
Cupertino, CA, USA). A conservative cutoff was chosen (adj p ≤ 1e-04) for downstream 
analysis due to the small samples size of subjects and to limit the potential of reporting 
falsely significant windows. Gene annotations with significant windows aligning to 
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promoter or genebody locations were filtered based on a published microarray of 
differentially expressed genes in the hippocampus of sporadic AD subjects [59]. The 
resulting list of genes was used for pathway enrichment analysis. 
3.3.5 Functional Interaction Network Analysis 
A network of functionally related genes was created using the Reactome 
Functional Interaction (RFI) plugin app available win Cytoscape® v3.0. Using linker 
genes provided by RFI, 322 of the 329 significant genes from our analysis were used to 
create the gene network. Utilizing spectral partition clustering [211], the gene network 
was divided into six related modules and enrichment scores for module pathways were 
analyzed excluding linker genes to prevent bias and only report pathways relevant to the 
322 gene targets. Using a binomial test [212] within RFI, statistical significance was 
determined and multiple comparisons were corrected using a permutation test to give 
FDR adjusted p values [213, 214]. Pathways with adjusted p < 0.05 were retained.  
3.3.6 Subject Demographic analysis 
All normally distributed values (age, PMI, NP and NFT burden) were analyzed 
using Student’s t test, while nonparametric data were analyzed using Mann-Whitney U 
tests (MMSE scores and Braak staging scores) to determine significant differences 
between LOAD and NC subjects. All significance tests were performed in SigmaPlot 
v.13 (Systat Software, Inc., CA, USA).  
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3.4 Methods for qPCR analysis of cytosine, 5-mC, and 5-hmC 
3.4.1 Subject Data 
Tissue specimens of superior and middle temporal gyrus (SMTG) from PCAD 
(n=7), MCI (n=10), LOAD (n=9), and NC (n=9) subjects were obtained as described 
previously (Methods 3.2.1).  
3.4.2 DNA isolation 
DNA was extracted from frozen tissue specimens using the 
phenol:chloroform:isoamyl alcohol protocol as described above (Methods 3.2.2). 
3.4.3 Protein extraction 
SMTG frozen tissue specimens were suspended in 350 µL of RIPA buffer (1mM 
Na2EDTA, 1mM EGTA, 150mM NaCl, 1% NP40, 20mM Tris-HCl, 1mM B-
glycerophosphate, 1% sodium deoxycholate, 1ug/mL leupeptin, 2.5mM sodium 
pyrophosphate, 1mM sodium orthovanadate) with 1 mM PMSF dissolved in ethanol 
added immediately before protein extraction. While on ice, samples were homogenized 
using Heat Systems-Ultrasonics, Inc. W-380 Sonicator and centrifuged at 10k x g for 30 
min at 4°C. Supernatant was collected and protein concentration measured using Pierce 
BCA protein assay (Thermo Fisher) on UV-Vis plate reader (Thermo) for each sample.  
3.4.4 Primer design 
Gene sequences for primer design of target genes were obtained from the National 
Center for Biotechnology Information (NCBI) reference database: ABCA7 (accession 
number: NC000019.10), PS1 (accession number: NG007386.2). Exon primer pairs were 
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designed using Integrated DNA Technologies (IDT) PrimerQuest software and 
theoretical non-specificity was determined using PrimerBlast [215]. 
3.4.5 Primer sequences  
 Primer sequences for forward and reverse designed synthetic primers for PS1 and 
ABCA7 are given in Table 3.1. Only primers specific to designed PS1 or ABCA7 target 
sequences based on PrimerBlast results were purchased.   
3.4.6 Endpoint PCR 
To determine specificity of synthetic primer pairs, human DNA was amplified 
using 5X GoTaq Flexi PCR reaction mix (Promega) on the Mastercycler Pro PCR 
(Eppendorf). Product amplicon molecular weights were determined via SDS-PAGE gel 
separation and NEB low molecular weight standard DNA ladder (New England Biolabs). 
A 2% agarose gel was made using tris-acetate-EDTA buffer and loaded with 20 µL of 
sample. Band separation was achieved with a 30 min run at 150V. Ethidium bromide, an 
intercalating fluorescent dye, was used with UV excitation to image amplicon bands 
within agarose gels.  
3.4.7 Primer and DNA optimization 
To optimize primer concentrations, solutions of 50, 100, 150, 200, and 250 nM 
forward and reverse primers were run in triplicate using 100 ng of NC DNA. Using melt 
curves and Ct values for each concentration of primer pairs, optimized primer 
concentrations were determined for each exon. DNA concentration optimization was 
determined using a 1:3 serial dilution beginning with 150 ng of DNA, run in triplicate 
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Table 3.1 Primer sequences and target amplicon size for ABCA7 and PS1 exons. 
Gene Location Primer Sequence Amplicon Size 
ABCA7  
Exon 12 
FWD - CTTCTTGGGACCTGAGGA 
REV - CTCGTGACCACGTCAATG 
108 bp 
Exon 14 
FWD - GTTCCTGCGTGTGCTGAG 
REV - ACTCTCAGTGTCACGGAGT 
75 bp 
Exon 18 
FWD - TGCAGTGCTGGTAGAAGA 
REV - GATGTGGCCCTGGTAGAA 
133 bp 
Exon 19 
FWD - TCTATCCACAGGTCCATCTT 
REV - AACAGCACGTTGTACTGAG 
137 bp 
Exon 37 
FWD - CTTGAAACAGGTCTTCCTTATCTTC 
REV - CAAGCGCTCAAAGGCATC 
100 bp 
PS1  
Exon 1 
FWD - AATGACGACAACGGTGAG 
REV - TAGCTCAGGTTCCTTCCA 
111 bp 
Exon 4 Site 1 
FWD - GCCACCCTGAGCCATTATCT 
REV - TGTCAGCTCCTCATCTTCTTCC 
89 bp 
Exon 4 Site 2 
FWD - TATGGCGCCAAGCATGTGAT 
REV - AGCCACACTGGCTTTGAGAAT 
154 bp 
Exon 9 
FWD - ATATGGCAGAAGGAGACCCG 
REV- ACAGCGACCCTGAAAAATCAAGATA 
113 bp 
Exon 12 Site 2 
FWD - CTCGGTGCAGAAACTA 
REV - GCAGTGTCAGTGAAATC 
119 bp 
Exon 12 Site 3 
FWD - GAAGCAACAACTGAAGAG 
REV - CTGTTTGGGCATCTATTG 
107 bp 
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Reaction efficiencies were determined from response curves of DNA serial dilutions 
using Life Technologies RT-PCR Handbook guidelines (Invitrogen, Inc).  
3.4.8 Glucosylation of 5-hmC  
To quantify cytosine, 5-mC, and 5-hmC at target CCGG exon sites, the EpiMark 
5-mC and 5-hmC quantification kit (New England Biolabs) was used per manufacturer’s 
instructions with the exception of replacing NEB Buffer 4 with CutSmart Buffer (NEB). 
For each sample, 5 µg of DNA was added to CutSmart Buffer and UDP-Glucose. This 
solution was split into two tubes, one reaction analysis, where T4-βGT was added to 
glucosylate 5-hmC modifications, and one control analysis without the glucosylation 
enzyme. Utilizing the specificity of MspI and HpaII endonuclease enzymes and q-PCR, 
5-hmC and 5-mC were quantified.  
3.4.9 Quantitative Polymerase Chain Reaction 
To quantify levels of cytosine, 5-mC, and 5-hmC at target sites, Fast SYBR Green 
Master Mix (Applied Biosystems) was used, where ROX reference dye within the master 
mix corrects for instrument fluctuations in fluorescence. Forward and reverse primers, 
master mix, water, and DNA were combined according to manufacturer’s specifications 
(Applied Biosystems). For each reaction plate, a 1:3 DNA serial dilution curve was used 
to determine reaction efficiency and quantification of analyte signal, where dilution curve 
samples were run in triplicate. DNA, master mix, and primer pairs were added to 96 well 
q-PCR plates (Applied Biosystems) in duplicate and total reaction volume per well was 
20 µL.  
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3.4.10 ViiA7 qPCR method 
Plates were sealed with MicroAmp optical adhesive film (Applied Biosystems) 
and centrifuged using RT-PCR plate MiniSpin (Applied Biosystems). Plates were loaded 
into the Life Technologies ViiA7 Real Time PCR System. The run method included a 
hold stage for 20 sec at 95°C, followed by a denaturation step for 3 sec at 95°C, and an 
annealing step at 60°C for 30 sec for 40 cycles, followed by a melt curve analysis with 
stage set to 95°C for 3 sec, 60°C for 1 min, and 95°C for 15 sec. Total run time was 57 
min per plate. 
3.4.11 Western blot 
Protein samples (20 µg for PS1 blot and 33.75 µg for ABCA7 blot) were added to 
2-mercaptoethanol loading buffer and PBS. Samples were denatured at 37°C for PS1 and 
56°C for ABCA7 in a dry bath for 5 min and loaded onto premade gels. Novex protein 
standards (Invitrogen) were used to identify molecular weights of protein bands. For PS1 
blots, 16 µL of sample was separated using 4-12% Nupage Novex gels (Invitrogen) with 
average runtimes of 40 min at 200V. Blots were transferred to nitrocellulose membranes 
using iBlot dry transfer systems (Life Technologies). For ABCA7 blots, 25 µL of protein 
samples were separated using 3-8% Nupage Tris-Acetate gels (Invitrogen) with runtimes 
averaging 1 h at 115V. Proteins were transferred to 0.2 µm nitrocellulose membranes 
using tank transfer at 70V for 4 h on ice. Blots were blocked for 1 h using 15 mL 
Odyssey PBS blocking buffer solution (Licor). After three washes of TTBS, primary 
antibody (1:1000) was reacted with membranes overnight at 4°C. Membranes were 
washed again with TTBS three times and secondary antibody was added (1:10000) and 
incubated at 21°C in the dark for 1 h. Excess secondary antibody was removed by three 
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washes of TTBS and membranes suspended in PBS for analysis using LiCor Imaging 
System (Odyssey Imaging, Licor). Band density measurements were compared using 
Scion Imaging® software. A reference protein (GAPDH) was used to correct for possible 
loading volume alterations.  
3.4.12 Data Analysis 
Reaction efficiencies were calculated for each plate using the DNA standard 
curve slope. Quantification of cytosine, 5-mC, and 5-hmC levels at each target site were 
calculated by using the average Ct value of the samples and the DNA standard curve. 
Raw values were calculated as percentages of total DNA, determined from the reaction 
tube without endonuclease restriction enzyme digestion. To normalize values across 
multiple data sets, percentages were corrected for uncut DNA (unprotected MspI 
digestion) for each reaction.  
3.4.13 Statistical Analysis 
3.4.13.1 Subject demographics 
To determine if there were significant differences in subject demographic data 
between the subject groups, a series of analyses of variance tests were performed using 
SigmaPlot v13. While ANOVA was used to determine significant differences in mean 
age and PMI values, the gender distribution between the subject groups was determined 
using ANOVA on Ranks, where women were encoded as 0 while men were encoded as 
1. All significant differences were reported as (p < 0.05). 
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3.4.13.2 MANOVA models 
Due to the multivariate nature of the analysis, where cytosine, 5-mC, and 5-hmC 
were measured at single CCGG sequences, a multivariate statistical analysis was chosen. 
To determine statistical significance between the subject groups at each target site, a 
multivariate analysis of variance (MANOVA) test was used in SPSS v24. Models for 
each exon were tested, including five models for exons of PS1 and four models for exons 
of ABCA7. The main effects of the three dependent variables (cytosine, 5-mC, and 5-
hmC) within the subject groups (independent variable) were tested using a conservative 
multivariate analysis (Pillai’s Trace test). In the event of an overall significant difference 
among the subject groups, least square regression models were fit to the data and 
pairwise comparisons were made using least significant difference analyses. All 
significant differences were reported as (*p < 0.05) or trending toward significance as 
(#p ≤ 0.1). 
 3.4.13.3 Protein level analysis 
 To determine significant differences in protein levels of PS1 and ABCA7 between 
the subject groups, ANOVA was used. In the event the omnibus test was significant, 
pairwise comparisons using Holmes-Sidak post-hoc analyses were used to compare 
means against NC subjects. All significant differences were reported as (*p < 0.05). 
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CHAPTER 4: RESULTS 
[Some of these results were originally published in Journal of Neurochemistry.    
EM Ellison, EL Abner, and MA Lovell. J Neurochem. (2017) 140: 383-394 © John 
Wiley and Sons] 
 
4.1 Global quantification of cytosine, 5-mC, and 5-hmC  
4.1.1 GC/MS Standards Characterization  
Commercially available standards were purchased and characterized using 
GC/MS method described previously (Methods 3.2). Synthetic stable labeled cytosine 
standards and unlabeled cytosine standards were characterized using chromatographic 
separation retention times within the column and fragmentation patterns of m/z ratios 
produced from electron ionization within the mass spectrometer. Based on fragmentation 
pattern, the most abundant ion (m/z) was used for quantification (Table 4.1). 
Chromatographic peak separation via the described temperature gradient resulted in three 
well-separated peaks for cytosine (~17 min), 5-mC (~19 min), and 5-hmC (~37 min). 
Retention time values listed in Table 4.1 reflect the elution time of each standard from a 
single run. Overlay of chromatograms of stable labeled standards and of a mixture of 
stable labeled and unlabeled standards showed agreement in retention times and well 
separated peaks. Retention time agreement between stable labeled and unlabeled 
standards was shown, as well as m/z shifts identical to number of isotopically labeled 
atoms in each stable labeled cytosine standard, i.e. three mass units heavier for [2-13C, 1, 
3-15N]  cytosine compared to cytosine, as well as [2-13C, 1, 3-15N] 5-hmC compared to  
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Table 4.1 Characterization of unlabeled and stable labeled cytosine bases using GC/MS. 
Analyte  
Retention 
time 
(min) 
 Molecular Ion [M]+  
Identification  
Ions  
Quantification 
Ion 
         
cytosine  16.97  255  254 and 240  254 
13C 15N 
cytosine  16.96  258  257 and 243  257 
         
5-mC  18.87  269  269 and 254  254 
2H 5-mC  18.75  273  273 and 258  258 
         
5-hmC  36.53  357  357 and 342  357 
13C 15N 5-hmC  36.52  360  360 and 345  360 
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5-hmC, corresponding to two 15N and a single 13C labels (Table 4.1). Likewise, 5-methyl-
d3-cytosine-6-d1 compared to 5-mC showed four mass units difference, corresponding to 
four 2H labels for the stable labeled standard (Table 4.1).  
To ensure correct peak assignment, mass spectra were compared to database 
references [216-218] for cytosine and 5-mC, however a 5-hmC spectrum was not 
available in the MS database. In the absence of a database reference to confirm m/z ratios 
for 5-hmC, a previously published 5-hmC analysis by GC/MS showed similar m/z ratios 
to the current study [219]. Commercially available stable labeled cytosine standards 
showed high percentage of labeling when compared to amount of unlabeled material 
within each standard: [2-13C, 1, 3-15N] cytosine (99.8%), 5-methyl-d3-cytosine-6-d1 
(99.3%), and [2-13C, 1, 3-15N] 5-hmC (99.8%).  
To identify peaks within chromatograms, several m/z ratios characteristic to each 
cytosine modification were used based on fragmentation patterns shown in the mass 
spectra. Fragmentation of [2-13C, 1, 3-15N] cytosine produced two abundant ions, m/z 257 
and 243 (Figure 4.1) in a ratio of 55:45, whereas unlabeled cytosine fragmentation 
produced m/z ratios 254 and 240 in a similar ratio. For 5-methyl-d3-cytosine-6-d1, the 
most abundant ions produced from EI fragmentation were m/z 273 and 258 (Figure 4.2) 
where the ratio of ions is 25:75. Similarly, unlabeled 5-mC produced m/z ratios of 269 
and 254 were observed at a ratio of 20:80. Finally, for [2-13C, 1, 3-15N] 5-hmC, 
fragmentation of the molecular ion at m/z ratio of 360 produced an abundant daughter ion 
at m/z 345 (Figure 4.3) where the ratio of ions was 70:30, while the unlabeled ions  
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Figure 4.1 Mass spectra of cytosine and [2-13C, 1,3-15N] cytosine. Mass spectra 
obtained from GC/MS full scan of cytosine standard (a) and [2-13C, 1, 3-15N] cytosine (b). 
Base ion [M-1]+ and several daughter ions ([M-15]+, [M-73]+) were labeled. 
Derivatization groups (trimethylsilyl) are labeled as TMS in chemical structures.  
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Figure 4.2 Mass spectra of 5-mC and 5-methyl-d3-cytosine-d1. Mass spectra obtained 
from GC/MS full scan of 5-mC standard (a) and 5-methyl-d3-cytosine-d1 (b). Molecular 
ion [M]+ and several daughter ions ([M-15]+, [M-73]+) were labeled. Derivatization 
groups (trimethylsilyl) are labeled as TMS in chemical structures.  
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Figure 4.3 Mass spectra of 5-hmC and [2-13C, 1,3-15N] 5-hmC. Mass spectra obtained 
from GC/MS full scan of 5-hmC (a) and [2-13C, 1, 3-15N] 5-hmC (b) standards. Molecular 
ion [M]+ and several daughter ions ([M-15]+, [M-73]+, [M-89]+, [M-103]+) were labeled. 
Derivatization groups (trimethylsilyl) are labeled as TMS in chemical structures.  
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were m/z 357 and 342 at a comparable ratio.  Although multiple m/z ratios were 
monitored for peak identification and characterization SIM runs, the most abundant ion 
(base ion) was used to quantify each analyte. The base ion m/z ratios were 257 for  [2-
13C, 1, 3-15N] cytosine, which corresponds to the loss of one hydrogen from the 
molecular ion ([M-1]+), 258 for 5-methyl-d3-cytosine-6-d1, corresponding to the loss of 
one methyl group from the molecular ion ([M-15]+), and 360 for [2-13C, 1, 3-15N] 5-hmC, 
corresponding to the molecular ion ([M]+).  
Once characterized and separated, instrument response curves were analyzed over 
a concentration range of 1.5 – 375 pmol/μL for each stable labeled standard. Five 
replicate measures were taken at each concentration (1.5, 4.6, 13.9, 41.7, 125, and 375 
pmol/μL) and averaged. Calibration curves showed a linear response based on linear 
regression analysis in SigmaPlot for [2-13C, 1, 3-15N] cytosine (Figure 4.4), 5-methyl-d3-
cytosine-6-d1 (Figure 4.5), and [2-13C, 1, 3-15N] 5-hmC (Figure 4.6). All instrument 
response curves showed a linear relationship throughout the concentrations analyzed for 
[2-13C, 1, 3-15N] cytosine (Adj R2 = 0.993), 5-methyl-d3-cytosine-6-d1 (Adj R2 = 0.995), 
and [2-13C, 1, 3-15N] 5-hmC (Adj R2 = 0.993).  Limit of quantification (LOQ) values 
were calculated for each standard based on slope of calibration curve and standard 
deviation of blank measurements. The LOQ for [2-13C, 1, 3-15N] cytosine was calculated 
as 3.4 pmol/ μL, which corresponds to 1709 pmol/ mg DNA. The LOQ 5-methyl-d3-
cytosine-6-d1 was calculated to be 0.4 pmol/ μL, corresponding to 201 pmol/mg DNA. 
Finally, the LOQ for [2-13C, 1, 3-15N] 5-hmC was calculated to be 0.8 pmol/ μL, 
corresponding to 402 pmol/mg DNA.  
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Figure 4.4 Stable labeled cytosine standard curve. Linear instrument response curve 
for [2-13C, 1, 3-15N] cytosine standard. Data points represent the mean ± SD (n = 5). 
Linear regression (solid line) shown with 95% confidence interval (dashed line). Insert 
shows 1.5 – 125 pmols of standard range.  
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Figure 4.5 Stable labeled 5-mC standard curve. Linear instrument response curve for 
5-methyl-d3-cytosine-6-d1 standard. Data points represent the mean ± SD (n = 5). Linear 
regression (solid line) shown with 95% confidence interval (dashed line). Insert shows 
1.5 – 125 pmols of standard range. 
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Figure 4.6 Stable labeled 5-hmC standard curve. Linear instrument response curve for 
[2-13C, 1, 3-15N] 5-hmC standard. Data points represent the mean ± SD (n = 5). Linear 
regression (solid line) shown with 95% confidence interval (dashed line). Insert shows 
1.5 – 125 pmols of standard range. 
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4.1.2 Spike Recovery Analysis 
To determine if processing steps alter analyte recovery, a spike recovery analysis 
was carried out. Commercially available stable labeled and unlabeled cytosine standards 
were added to 40 μg of DNA at two concentrations. Samples included an IS blank with 
only stable labeled standards, a spike blank with IS mix and unlabeled standards mix, a 
DNA sample with IS mix, and a spiked sample with DNA, IS mix, and unlabeled 
standards mix. For each cytosine base, percent recoveries were calculated based on blank 
measurements and reported as mean ± SD over three repeated experiments for a total of 
n=8 measurements per base. The average recovery for all three cytosine bases fell within 
the suggested 80-120% range according to current literature for both concentrations of 
unlabeled (spiked) bases (cytosine, 94.2 ± 10.1%; 5-mC, 102.7 ± 4.5%; 5-hmC, 99.1 ± 
19.8%).  
4.1.3 Subject demographics analysis 
 Age is the most important risk factor for developing AD, therefore NC subjects 
were age-matched to correct for potential age associated epigenetic modifications in brain 
tissue specimens. To analyze the specificity of alterations in epigenetic marks to AD or 
general neurodegenerative diseases, diseased control tissue specimens from FTLD and 
DLB subjects were analyzed. As shown in Table 4.2, no statistically significant 
differences were observed for age or PMI among the subject groups using ANOVA. 
Table values for age and PMI reflect mean ± SD for each subject group.  
 Significant differences were observed in comparing pathology burden markers 
between the subject groups. Braak staging scores were elevated in PCAD, MCI, and 
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LOAD subjects compared to NC (p < 0.05), while no difference was observed between 
FTLD/DLB and NC subjects. MMSE scores, a measure of global cognition, were 
significantly decreased in dementia subjects (LOAD and FTLD/DLB) compared to NC (p 
< 0.05) using ANOVA on Ranks and Dunn’s post hoc analysis (Table 4.2), while PCAD 
and MCI showed no significant difference in MMSE scores compared to NC subjects. 
Table values for MMSE scores reflect median and interquartile range for each subject 
group (Table 4.2). In addition, the number of subjects with the Ԑ4 allele of APOE in each 
subject group were also reported in Table 4.2.  
 Quantitative measures of neuropathologic burden, specifically regional NP and 
NFT counts representing the arithmetic mean of plaques and tangles within most severely 
affected brain regions, were provided by the UK-ADC. Counts of NP and NFT burden in 
the HPG, SMTG, and IPL were compared among the subject groups using ANOVA on 
Ranks with post-hoc analysis using Dunn’s analysis, reported as median with 
interquartile range in Table 4.3. For all NP and NFT counts, the omnibus test was 
significant (p < 0.05). For NP counts, all brain regions showed significant differences in 
LOAD compared to NC subjects (HPG, p = 0.021; SMTG, p = 0.026; IPL, p = 0.024). 
NFT counts were also elevated in LOAD subjects compared to NC in the SMTG (p < 
0.001) and IPL (p < 0.001) brain regions (Table 4.3).  
  To analyze the role epigenetic modifications to cytosine play in the progression 
of AD, three brain regions susceptible to AD pathologic markers (HPG, SMTG, and IPL) 
and one brain region considered non-vulnerable (CER) to plaque and tangle pathology 
were chosen. When available, complete sets of CER, IPL, SMTG, and HPG tissue 
specimens were analyzed for NC, PCAD, MCI, LOAD, and FTLD/DLB subjects. 
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Table 4.2 Demographic data for each subject group.  
 
 
 
 
 
 
 
 
 
 
 
*p < 0.05
 
 
 
NC 
(N=10) 
PCAD 
(N=8) 
MCI 
(N=11) 
LOAD 
(N=10) 
FTLD/DLB 
(N=11) 
Subject Demographics     
Age (years) 82.8 ± 8.9 85.4 ± 6.6 89.5 ± 6.4 82.5 ± 8.4 80.7 ± 12.8 
Gender 5W / 5M 6W / 2M 8W / 3M 5W / 5M 3W / 8M 
PMI (h) 2.7 ± 0.9 3.0 ± 0.5 2.6 ± 0.5 2.8 ± 0.8 3.6 ± 1.1 
MMSE Score 29.5 [28 - 30] 30 [28.25 - 30] 28 [26 - 28] 16* [3 - 25.5] 17* [1.5 - 26.5] 
APOE-Ԑ4 allele 1  2  5  6  3  
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Table 4.3 Pathology burden data for each subject group.  
 
 
 
  
 
 
 
 
 
 
*p < 0.05 
   
   
  
 NC PCAD MCI LOAD FTLD/DLB 
Pathology Burden     
Braak Stage II [0-II] IV* [III-V] III* [II-V] VI* [V-VI] II [0-III] 
NP – HPG 0 0 [0-1] 0.3 [0-5.0] 2.8* [0.9-4.1] 0 [0-0.8] 
NP – SMTG 0 [0-5.0] 10.3 [7.5-19.5] 5.6 [2.3-12.4] 16.4* [6.1-30.8] 3.4 [0-17.8] 
NP – IPL 0 [0-7.2] 13.1 [7.4-31.4] 6 [2-14.3] 19.8* [8.6-30.9] 5.8 [1.6-13.2] 
NFT – HPG 3.2 [0.7-6.8] 2.6 [0.6-8.9] 24.3 [2.3-78.9] 20.7 [10.6-50.8] 1.8 [0-4] 
NFT – SMTG 0 0.7 [0.1-1.5] 1.2 [0.5-9.4] 18.2* [11.0-24.6] 0 [0-0.8] 
NFT – IPL 0 0.5 [0.2-1.3] 0 [0-5.8] 15.1* [9.6-25.6] 0 [0-0.4] 
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Incomplete sets included MCI (HPG, n=5), PCAD (HPG, n=5), and FTLD/DLB (HPG, 
n=6; SMTG, n=10) subject groups. The total number of subjects per group is reported in 
(Table 4.2). 
4.1.4 Raw levels of cytosine modifications  
 Levels of cytosine bases were quantified as pmols / mg DNA (Halliwell and 
Dizdaroglu 1992) in HPG, SMTG, IPL, and CER brain regions for NC, PCAD, MCI, 
LOAD, and FTLD/DLB subjects. A representative DNA sample with internal standards 
is shown in Figure 4.7, where peaks contained DNA levels of respective cytosine base 
and the stable labeled standard. Raw values were calculated from the signal intensity of 
the sample compared to the internal standard, the instrument response of the standard 
curve, a dilution factor of 20:1 (solution volume: injected volume), as well as the amount 
of DNA analyzed. Raw calculated values were averaged for each subject group in each 
analyzed brain region and reported in Table 4.4. Table values reflect mean ± SD (pmol 
modification / mg DNA) and were rounded to whole numbers for simplicity.  
4.1.5 Association of pathologic burden, MMSE scores, and epigenetic marks 
 Correlations of average NP and NFT counts, as well as MMSE scores, with 5-mC 
and 5-hmC levels in AD pathology susceptible brain regions (HPG, SMTG, IPL) were 
tested using general linear models. 5-mC was significantly associated with mean NP 
counts in the SMTG (p = 0.021), although NFT counts showed no significant association. 
For 5-hmC, there was no association with either measure in the HPG, SMTG, or IPL. In 
HPG and IPL regions, 5-mC was not significantly associated with average NP or NFT  
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Table 4.4. Mean ± SD of cytosine, 5-mC, and 5-hmC for each subject group by brain 
region.  
 HPG SMTG IPL CER 
    Cytosine (pmols / mg DNA)   
NC 95056 ±  21963 84034 ± 13661 99634 ± 21729 91869 ± 16517 
PCAD 81788 ± 25440 73660 ± 13319 94545 ± 25434 94247 ± 38731 
MCI 74496 ± 14108 77930 ± 12408 87374 ± 18830 81711 ± 23190 
LOAD 94926 ± 16336 96526 ± 20066 107957 ± 30112 85145 ± 16431 
FTLD/DLB 94971 ± 27815 82071 ± 10903 74392 ± 10121 74896 ± 14954 
     
    5-methylcytosine (pmols / mg DNA)   
NC 6139 ± 2037 7020 ± 1568 8088 ± 3852 9563 ± 2269 
PCAD 7735 ± 3121 5486 ± 657 6799 ± 2556 8115 ± 3580 
MCI 5386 ± 1288 6794 ± 1262 7256 ± 1738 7009 ± 2718 
LOAD 6027 ± 1494 8787 ± 1958 8901 ± 4296 8950 ± 2651 
FTLD/DLB 6336 ± 2131 5580 ± 1016 5512 ± 1503 5935 ± 1613 
     
    5-hydroxymethylcytosine (pmols / mg DNA)   
NC 751 ± 135 915 ± 234 1135 ± 258 1302 ± 260 
PCAD 1065 ± 136 1316 ± 321 1252 ± 193 1474 ± 257 
MCI 828 ± 210 1345 ± 202 1280 ± 264 1474 ± 302 
LOAD 787 ± 224 1111 ± 215 1082 ± 297 1251 ± 249 
FTLD/DLB 1147 ± 226 1218 ± 167 1126 ± 327 1540 ± 217 
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Figure 4.7 Total Ion Chromatogram of representative DNA sample. Peaks of 
cytosine (a), 5-mC (b), and 5-hmC (c) in a representative DNA sample combined with 
stable labeled standards were well resolved using SIM GC/MS method.  
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counts. Similarly, MMSE scores were not associated with 5-mC or 5-hmC in any of the 
three brain regions analyzed.  
4.1.6 Repeated Measures Analysis: Model Results 
 4.1.6.1 Cytosine 
Using an unstructured covariance matrix, estimated means (EM) and standard 
errors (SE) were calculated for each subject group across the brain regions analyzed (EM 
± SE pmol / mg DNA). Average cytosine levels for NC subjects were 91,886 ± 3,004 
pmols/ mg DNA, while PCAD subjects averaged 85,037 ± 3,618 pmol cytosine / mg 
DNA, and MCI subjects showed 82,655 ± 3,242 pmol / mg DNA. LOAD subjects 
average cytosine levels were 97,153 ± 3,006 pmol / mg DNA, while FTLD/DLB subjects 
showed an average of 80,505 ± 3,215 pmol cytosine / mg DNA. Brain region specific 
cytosine levels were calculated from the model, where average levels of cytosine were 
determined for HPG (88,834 ± 3,548 pmol / mg DNA), SMTG (83,315 ± 2,148 pmol / 
mg DNA), IPL (92,567 ± 3,188 pmol / mg DNA), and CER (85,037 ± 3,338 pmol / mg 
DNA).  
According to the repeated measures analysis, cytosine levels did not change 
across brain regions (p = 0.133), although they were significantly altered between subject 
groups (p = 0.0018).  Compared to NC, MCI subjects showed significantly decreased 
levels of cytosine (p = 0.042) as did FTLD/DLB subjects (p = 0.012). No significant 
differences were detected between PCAD (p = 0.149) or LOAD (p = 0.218) subjects 
compared to NC (Figure 4.8). Between group effects showed significant differences 
between MCI and LOAD subjects (p = 0.002) as well as PCAD and LOAD subjects (p = 
0.0128). Comparing dementia cases, FTLD/DLB subjects showed significantly decreased 
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Figure 4.8 Global levels of cytosine throughout brain regions. Adjusted mean ± SE 
(pmol / mg DNA) of cytosine were averaged across HPG, SMTG, IPL, and CER brain 
regions for each subject group. Statistical significance is compared to NC based on 
repeated measures analysis model (*p < 0.05).  
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levels of cytosine across the brain regions studied compared to LOAD subjects (p = 
0.0004). 
4.1.6.2 5-mC  
Average 5-mC levels for each subject group were calculated based on the 
repeated measures analysis model, to give EM values in pmol 5-mC / mg DNA for NC 
(7389 ± 360 pmol / mg DNA), PCAD (6543 ± 428 pmol / mg DNA), MCI (6857 ± 390 
pmol / mg DNA), LOAD (8356 ± 356 pmol / mg DNA), and FTLD/DLB (5846 ± 388 
pmol / mg DNA) subjects across analyzed brain regions. Brain region specific levels 
were calculated by pooling all subjects to give mean 5-mC levels in HPG (6010 ± 387 
pmol/mg DNA), SMTG (6785 ± 211 pmol / mg DNA), IPL (7307 ± 416 pmol / mg 
DNA), and CER (7893 ± 381 pmol / mg DNA) brain regions.  
For 5-mC levels, significant differences were detected by brain region (p = 
0.0054) and by subject group (p = 0.0002) according to repeated measures analysis 
model. For brain region differences, in the CER, 5-mC levels were significantly increased 
compared to SMTG (p = 0.0079) and HPG (p = 0.0011). HPG levels of 5-mC were also 
significantly decreased in HPG (p = 0.0265) compared to IPL, however no significant 
difference was detected between levels of 5-mC in the HPG and SMTG (p = 0.1006) 
regions. For subject group differences, FTLD/DLB levels of 5-mC were significantly 
decreased compared with NC subjects (p = 0.0011), but PCAD (p = 0.1244), MCI (p = 
0.3043), and LOAD (p = 0.0529) were not significantly different compared to NC 
subjects (Figure 4.9). Between group effects showed significantly decreased levels of 5-
mC in PCAD (p = 0.0016), MCI (p = 0.0054), and FTLD/DLB cases (p < 0.0001) 
compared to LOAD.  
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Figure 4.9 Global levels of 5-mC throughout brain regions. Adjusted mean ± SE 
(pmol / mg DNA) of 5-mC were averaged across HPG, SMTG, IPL, and CER brain 
regions for each subject group. Statistical significance is compared to NC based on 
repeated measures analysis model (#p < 0.1, *p < 0.05).  
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4.1.6.3 5-hmC 
Subject group and brain region specific levels of 5-hmC were estimated based on 
the repeated measures analysis model to give EM ± SE pmol 5-hmC / mg DNA values. 
Subjects group levels were estimated for NC (1028 ± 35 pmol / mg DNA), PCAD (1276 
± 44 pmol / mg DNA), MCI (1243 ± 39 pmol / mg DNA), LOAD (1066 ± 36 pmol / mg 
DNA), and FTLD/DLB (1244 ± 38 pmol / mg DNA) subjects across brain regions 
analyzed. Brain region specific levels were estimated from pooled subjects to give 
average 5-hmC levels in HPG (914 ± 33 pmol / mg DNA), SMTG (1185 ± 33 pmol / mg 
DNA), IPL (1176 ± 41 pmol / mg DNA), and CER (1411 ± 36 pmol / mg DNA) brain 
regions.  
Similarly to the 5-mC model, levels of 5-hmC were significantly altered in both 
brain region (p < 0.0001) and subject group (p < 0.0001) analyses. For brain region 
comparisons, levels of 5-hmC were significantly higher in the CER compared to HPG (p 
< 0.0001), SMTG (p < 0.0001), and IPL (p = 0.0001). HPG levels of 5-hmC were the 
lowest of the four regions, showing significantly decreased levels compared to SMTG (p 
< 0.0001) and IPL (p < 0.0001). For subject group differences, levels of 5-hmC were 
significantly higher in PCAD (p < 0.0001), MCI (p = 0.0002), and FTLD/DLB (p = 
0.0001) compared to NC, but not LOAD (p = 0.4286) subjects (Figure 4.10). Elevated 
levels of 5-hmC were also shown in PCAD (p = 0.0006), MCI (p = 0.0019), and 
FTLD/DLB (p = 0.0015) subjects compared to LOAD for between group effects.  
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Figure 4.10 Global levels of 5-hmC throughout brain regions. Adjusted mean ± SE 
(pmol / mg DNA) of 5-hmC were averaged across HPG, SMTG, IPL, and CER brain 
regions for each subject group. Statistical significance is compared to NC based on 
repeated measures analysis model (*p < 0.05).  
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4.1.6.4 Effects of AD specific epigenetic marks 
 To determine the relationship between 5-mC and 5-hmC levels in brain regions 
susceptible to AD pathologic markers in relation to AD progression, FTLD/DLB cases 
were excluded from the repeated measures analysis and significant differences between 
brain regions of NC, PCAD, MCI, and LOAD subjects were tested. Cytosine levels were 
not reported because statistically significant differences were not detected in the original 
repeated measures model.  
 Brain region specific average levels of 5-mC and 5-hmC were calculated based on 
repeated measures analysis model, pooling NC and AD subjects. Average 5-mC levels 
were calculated for HPG (5969 ± 428 pmol / mg DNA), SMTG (7084 ± 250 pmol / mg 
DNA), IPL (7840 ± 539 pmol / mg DNA), and CER (8429 ± 460 pmol / mg DNA). 
Average 5-hmC levels were also calculated using repeated measures model to give values 
for HPG (869 ± 33 pmol / mg DNA), SMTG (1176 ± 40 pmol / mg DNA), IPL (1195 ± 
43 pmol / mg DNA), and CER (1380 ± 43 pmol / mg DNA).   
For 5-mC, levels in the CER were significantly elevated compared to HPG (p = 
0.0002) and SMTG (p = 0.0075). There was also a significant decrease in 5-mC levels in 
HPG compared to IPL (p = 0.0057) and compared to SMTG (p = 0.0342) (Figure 4.11). 
For 5-hmC, CER levels of 5-hmC were significantly increased compared to all other 
brain regions (HPG, p < 0.0001; SMTG, p = 0.0003; IPL, p = 0.0079). Similarly, levels 
of 5-hmC were significantly lower in the HPG compared to SMTG (p < 0.0001) and IPL 
(p < 0.0001) (Figure 4.12).  
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Figure 4.11 AD specific levels of 5-mC. Adjusted mean ± SE (pmol / mg DNA) of 5-
mC were averaged across NC, PCAD, MCI, and LOAD subjects groups and compared 
between brain regions based on repeated measures analysis model (*p < 0.05).  
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Figure 4.12 AD specific levels of 5-hmC. Adjusted mean ± SE (pmol / mg DNA) of 5-
hmC were averaged across NC, PCAD, MCI, and LOAD subjects groups and compared 
between brain regions based on repeated measures analysis model (*p < 0.05).  
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[Some of these results were originally submitted to Journal of Molecular 
Neuroscience. EM Ellison, MA Bradley-Whitman, and MA Lovell. J Mol Neuro. 
(2017) Submitted.] 
 
4.2 Genome-wide analysis of 5-hmC 
4.2.1 Subject demographics analysis 
 To analyze genome-wide levels of 5-hmC modifications in HPG of LOAD 
subjects, an initial study of LOAD (n = 3) and NC (n = 2) subjects were compared (Table 
4.5). Significant differences were not detected in PMI or age between the subject groups 
using Student’s t test. For pathologic markers, NFT burden in the subiculum (Sub) was 
significantly higher in LOAD compared to NC subjects (p = 0.02), although NFT burden 
in CA1 was not significantly different between the groups. While there is a clear 
difference between the median Braak staging scores as well as the MMSE scores of 
LOAD and NC subjects, the small sample sizes lacked sufficient power to test differences 
using Mann-Whitney U tests (p = 0.2).  
4.2.2 RRHP analysis 
 Genome-wide RRHP analysis of 5-hmC modifications in hippocampal DNA of 
LOAD (n = 3) and NC (n = 2) subjects identified more than 2 million sites of CCGG 
sequences throughout the genome. BAM (binary version of sequence alignment map) 
files were downloaded from Zymo Research Corporation for each subject, which 
included annotated counts of 5-hmC identifications. The total number of unique CpG  
 
103 
 
 
 
 
Table 4.5 Subject demographic data for RRHP analysis.  
    
Demographics  NC LOAD 
    
Gender  2F 2F/1M 
Age (y)  84.5 ± 0.7 85.3 ± 4.0 
PMI (h)  2.5 3.0 ± 0.7 
MMSE  29 5 
Braak Stage  0 VI 
NFT (CA1)  0 66.5 ± 38.9 
NFT (Sub)  0 109.5 ± 30.6* 
    
         
*p < 0.05 
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Table 4.6 Genomic distribution of sites of 5-hmC modifications determined by RRHP analysis.  
 
 NC1 NC2 LOAD1 LOAD2 LOAD3 
Total Unique CpG sites 2,001,592 1,836,178 2,122,829 1,650,574 1,571,910 
CpG Island 192470 226829 177154 196115 192180 
Promoter 151942 177465 143138 151640 147500 
5UTR 214435 204048 223353 184042 174395 
Exon 121968 119666 123193 113473 104889 
Intron 896143 822705 949917 749531 709913 
3UTR 98460 96829 100528 86442 82564 
H3k4me3 283204 292654 284383 263598 248927 
H3k27me3 520180 467504 554629 419013 394663 
High CpG Promoter 113764 142706 103664 118508 118072 
Intermediate CpG Promoter 25316 23605 25690 22354 19841 
Low CpG Promoter 13832 12154 14735 11723 10433 
Bivalent Site 60195 58735 61643 53572 49919 
7X Regulatory Potential 56693 66134 52718 56906 56312 
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sites for each subject is reported in Table 4.6, as well as CpGs annotated to specific 
genomic elements, provided by Zymo Research Corporation. As described by Petterson 
et al. [188], analyzed sites included CCGG sequences within 5’UTR (untranslated 
region), 3’UTR, promoter, exon, and intron genomic regions for known genes, as well as 
CpG islands. The promoter sites, defined as ± 1 kb from the transcription start site of a 
known reference gene, were further characterized as sites within high, intermediate, and 
low CpG content promoters. Utilizing histone-binding site sequencing data, CCGG sites 
within regions of the genome assigned to H3K4me3 and H3K27me3 binding sites were 
reported, as well as sites common to both H3K4me3 and H3K27me3, termed bivalent 
regions. Finally, CCGG sites within regions conserved across multiple species, termed 7x 
regulatory potential regions, were also reported (Table 4.6).   
4.2.3 Negative binomial analysis of DhmRs 
 A negative binomial distribution was applied to the RRHP data files using a 
sliding window approach in the diffReps program [194]. Window size was set to 200 
base pairs, with a slide of 20 bases, resulting in 3.29e08 windows analyzed. DiffReps 
utilizes an initial uncorrected statistical cutoff of p < 1e-04 to define differential sites, that 
resulted in 1.65e06 windows in our analysis. These windows were then corrected for 
multiple comparisons using false discovery rate to produce adjusted p values. 
Overlapping windows were combined and the best-adjusted p value assigned to the 
combined window [194], resulting in 1.26e05 windows in our analysis. These windows 
were then annotated to the hg19 genome using PERL script regionanlaysis.  
 Using the initial predefined cutoff, the estimated false positive rate for the 
negative binomial test was reported as 0.2% by Shen et al. [194]. However, due to the 
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small sample size in our analysis, a conservative adjusted p value (p ≤ 1e-04) was chosen 
to further limit the risk of identifying potentially falsely identified significant windows. 
This cutoff resulted in 43,112 windows or differentially hydroxymethylated regions 
(DhmRs). Annotation of these windows using Ensembl gene IDs and Ensembl transcript 
IDs by regionanalysis, including known splice variants of each gene, resulted in 
duplication of some windows. To correct for this, repeated windows based on splice 
variants were removed, resulting in 15,158 unique DhmRs. The 15,158 DhmRs were 
sorted into increased or decreased levels of 5-hmC in LOAD compared to NC subjects. 
For clarity, a schematic of the data processing involved in this analysis is shown in Figure 
4.13. 
4.2.4 Distribution of 5-hmC in DhmRs 
Of the 15,158 DhmRs in LOAD subjects, the majority of these regions showed 
increased levels of 5-hmC (64% overall) confined to intragenic locations, including 
promoter, intron, and exon genomic regions, and intergenic regions (Figure 4.14). 
Promoter regions included sites ± 3 kbp (kilobase pair) from the transcription start site of 
a specified gene, while genebody regions included all sites between the promoter and 1 
kbp from the transcription end site for the gene. Significantly increased DhmRs included 
9,629 windows, while decreased levels of 5-hmC resulted in 5,529 windows passing the 
conservative adjusted p value cutoff (FDR p ≤ 1e-04). Considering all sites with 
significantly altered 5-hmC, 85% of sites were located in genomic regions assigned to 
known genes (promoter and genebody regions). The genomic distribution of significant 
DhmRs is shown in Figure 4.14. Intragenic DhmRs were assigned to annotated genes, 
resulting in 5999 genes with altered hydroxymethylomes in the hippocampus of LOAD 
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Figure 4.13 Workflow of RRHP data processing using diffReps. More than 3e08 
windows were analyzed using a negative binomial distribution analysis and a sliding 
window approach in the diffReps program to analyze RRHP count data. Using a 
predefined uncorrected p value cutoff, windows were reduced to 1.65e06 and p values 
were corrected using FDR. Overlapping windows were combined to reduce the total 
window count to 1.26e05. A conservative adjusted p value (FDR p ≤ 1e-04) resulted in 
43,112 windows retained. Duplicated windows based on splice variants were removed, 
resulting in 15,158 unique windows or differentially hydroxymethylated regions 
(DhmRs).  
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Figure 4.14 Distribution of DhmRs. Distribution of the 15,158 DhmRs showed 64% 
overall increased (white) levels of 5-hmC in LOAD compared to NC, while the 
remaining 36% were decreased (gray). These sites were further characterized by genomic 
locations of promoter, genebody (exons and introns), and intergenic regions, where 85% 
of altered DhmRs were associated with known genes (promoter and genebody).  
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compared to NC subjects using regionanalysis PERL script.  Intergenic DhmRs were not 
annotated with a gene name but location of site was labeled as “OtherIntergenic”, 
“GeneDesert”, “Pericentromere”, or “Subtelomere” in diffReps output file. For 
simplicity, all intergenic windows with significant adjusted p values were grouped as 
“Increased Intergenic” or “Decreased Intergenic” in Figure 4.14.  
4.2.5 Reactome FI Gene Network analysis 
To correlate epigenetic modifications with altered expression, genes with DhmRs 
were sorted according to a published microarray of altered hippocampal gene expression 
in sporadic AD [59]. This filtered our initial list of 5999 to 329 genes with altered gene 
expression and altered levels of 5-hmC. To determine the biological significance of this 
list of genes in AD, Reactome FI was used to create a gene network of likely interactions 
utilizing linker genes provided by Reactome FI [220, 221]. The curated network, using 
322 of the 329 genes (Table 4.7), was organized into six clusters, or modules, and 
pathway enrichment analysis was performed on each module excluding linker genes to 
prevent bias and only report pathways relevant to list of target genes (Figure 4.15). The 
322 target genes were shown as circles in Figure 4.15a, while linker genes were depicted 
as diamonds.  
Statistical significance was determined in RFI using a binomial test and p values 
assigned to each enriched pathway. Only significant pathways with adjusted p values 
(FDR p < 0.05) were retained. The six modules included in the curated network 
contained genes relevant to signaling (blue), energy metabolism (red), cell cycle (purple), 
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Table 4.7 Modules and genes from Reactome FI network analysis.  
 
  
RFI Network Module Gene List 
 
Module 0: Signaling 
 
ABL1, ABLIM1, ACTR2, ADCY2, APBA2, ARHGEF10, ARHGEF16, 
C4B, CACNA1A, CDH10, CDH13, CDH4, CLIC2, CNTNAP2, CR1, CSK, 
DGKG, DIAPH2, DLGAP1, ENAH, F2R, GAK, GNA12, GNA14, GNAL, 
GNAO1, GNAS, GNAZ, GPR4, GRIA3, GRIN2A, GRM6, HTR2A, 
IQGAP1, ITPK1, JPH3, KCNA6, KCNAB1, KCNAB2, KCNJ14, LRP1B, 
LRP6, MADCAM1, MAP2K3, MYO1C, MYO1F, MYO9B, NFATC1, 
NMB, PDE4C, PLCB1, PLCE1, PLCG2, PLCL2, PRKAR1B, PRKAR2B, 
PTN, RAB22A, RALBP1, RALGDS, RAMP1, RANBP3, RTN1, SH3BP2, 
SHANK2, STK11, TRPV1, ULK2, WNT7B 
Module 1: Energy 
Metabolism 
AATK, ACAT1, ANK3, AP2B1, APC2, ATP1A2, ATP2B2, ATP5B, ATP5J, 
ATP5J2, BAIAP3, BGN, CADPS, CAP2, CEPT1, CHST3, CSNK1E, 
EDAR, EHD1, ELF2, EPS15, FEZ2, FOLH1, FRAT1, FYCO1, G6PD, 
GHITM, GOSR2, GPM6B, HADHA, INSR, IRS2, ITPR1, KIF13B, 
L1CAM, MGA, MKNK2, NDUFA10, NDUFA3, NDUFB3, NME4, 
OGDH, PLXNA1, PLXNB2, POLRMT, QARS, RPS6KA1, SCAMP3, 
SDHD, SEMA3B, SEMA3F, SLC12A7, SLC1A7, SLC25A12, SLC25A6, 
SLC7A5, STK10, TCEAL1, TPD52, TUBG2, TYK2, UQCRC2, USP3, 
UST, WFS1, ZNF142 
Module 2: Cell Function AK5, AKAP12, AMPD3, BIN1, BRD4, CAMKK2, CCND3, CEBPD, 
CHD2, CLU, CPT1B, CREBBP, DAPK2, DAPK3, DRAP1, FADS1, 
FGFR3, GDF1, HBA1, IL6R, IRF7, JUND, KCNN3, KLF1, LDLR, 
LPIN1, LTBP2, MAGED1, MAPRE3, MTF1, NCOR2, NFIC, NOTCH4, 
NPAS2, NPAS3, NR2F6, OGG1, OSBPL10, PKNOX2, PPP1R15A, RBL1, 
RREB1, SH3GLB2, SPIB, SREBF1, SREBF2, SSBP1, STK24, TCF3, 
TDG, TGFB1, THRA, TRIM26, UNG, WFDC1 
Module 3: Gene 
Expression 
BANP, BCL7A, CCNA1, CDC5L, CDK7, COMT, CPSF1, CTBP1, 
CTBP2, DDX27, DGCR6, FSTL1, GPI, H2AFX, HDAC4, LMNA, LZTS1, 
MBD3, MPST, MTA1, MUC3A, MYT1L, NELL1, PAX6, PML, PRPF8, 
PTBP1, PTRF, REC8, SIRT6, SIRT7, SLC19A1, SMARCA2, SNRPD2, 
STAG2, SYN2, TCF7, TFAP2A, TLE3, VARS2 
Module 4: Protein 
degradation 
AGPAT2, AMFR, ARIH2, BTRC, CDC34, CUL5, ENSA, FBXL2, FZR1, 
GLI2, GMEB2, MGLL, NME3, ODC1, PER1, PLOD3, PPP2R2B, 
PRDX3, PRL, PRPF4B, PSMA1, PSMD14, RNF11, SPTLC2, TIMM44, 
TTC3, UBE3B, WWOX, ZIC1 
Module 5: Cell Structure 
and Stabilization 
ACTN1, COL21A1, COL4A1, COL4A3, COL6A2, DAG1, DMD, FLNA, 
FLNC, GPC5, GPR56, ITGB4, ITGB5, ITGB8, LIMK2, LRP8, MAFF, 
MAFG, MAP2K7, MAP3K11, NDST1, NRXN1, PACSIN2, PAK4, RGS12, 
SNTA1, SORBS1, TNXB, VWF 
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Figure 4.15 Reactome FI network and significantly enriched pathways. Of the 329 
genes with significantly altered gene expression [59] and DhmRs from RRHP analysis, 
322 target genes (circles) and linker genes (diamonds) were used to curate a gene 
network of likely interaction in the Reactome Functional Interaction (RFI) plugin app 
from CytoScape (a). The network was clustered into six modules and pathway 
enrichment within the modules was determined by a binomial test, excluding linker 
genes, and p values were corrected for multiple comparisons using a permutation test to 
calculate FDR p values (p < 0.05) (b). As described in the text, similar pathways were 
grouped, including synapse signaling and neurodegenerative diseases, and the least 
significant adjusted p value was retained (╪).  
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gene expression (green), protein degradation (yellow), and cell structure and stabilization 
(orange) pathways (Figure 4.15). Enriched pathways relevant to neurodegeneration, 
specifically AD, are discussed below. For a complete list of significantly enriched 
pathways and the full gene names of the 329 genes with altered 5-hmC and altered 
expression in HPG of LOAD compared to NC subjects, please refer to Appendices B and 
C.  
 The signaling module included enriched pathways of calcium signaling (adj. p = 
2.23e-06), long-term depression (adj. p = 1.15e-05), Wnt signaling (adj. p = 3.89e-03), and 
synapse signaling (adj. p = 7.59e-03). Pathways within the energy metabolism module 
were TCA cycle and electron transport (adj. p = 1.53e-05), neurodegenerative diseases 
(adj. p = 1.15e-04), cGMP-PKG signaling (adj. p = 7.72e-03) and axon guidance (adj. p = 
1.19e-02). For the cell cycle module, enriched pathways included base excision repair, AP 
site formation (adj. p = 5.56e-04), generic transcription (adj. p = 1.01e-02), NOTCH 
signaling (adj. p = 2.26e-02), and endocytosis (adj. p = 4.92e-02). The gene expression 
module contained significant pathways related to RNA Polymerase I and III and 
mitochondrial transcription (adj. p = 7.4e-03) as well as processing of pre-mRNA (adj. p = 
7.4e-03). Module 4, containing genes relevant to protein degradation, highlighted 
pathways related to ubiquitin mediated proteolysis (adj. p = 9.68e-04) and degradation of 
cell cycle proteins (adj. p = 2.50e-02). Finally, the cell structure and stabilization module 
contained enriched pathways of focal adhesion (adj. p = 8.18e-12), extracellular matrix 
organization (adj. p = 6.77e-10), regulation of actin cytoskeleton (adj. p = 2.4e-04) and 
NCAM signaling for neurite outgrowth (adj. p = 1.43e-02). 
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 Similar genes were highlighted in several enriched pathways, including signaling 
pathways for four types of neurons (serotonergic, dopaminergic, cholinergic, and 
glutamatergic neurons) and three neurodegenerative diseases (Alzheimer’s disease, 
Huntington’s disease, and Parkinson’s disease). These pathways were combined and the 
least significant adjusted p value reported (denoted with ╪ in Figure 4.15).  
 
4.3 Loci-specific levels of cytosine, 5-mC, and 5-hmC  
4.3.1 Primer specificity and method validation 
4.3.1.1 PS1 primers 
 Synthetic PS1 primers (Table 3.1) purchased from IDT were tested for specificity 
using the PrimerBlast tool from NCBI. No hits for known products matching primer 
sequences except for the designed targets were discovered. To test for the specificity of 
primers against unknown products, each primer set was amplified using GoTaq Flexi 
PCR master mix with human DNA and separated via SDS-PAGE gels using endpoint 
PCR. Primer sets for exon 4, 9, and 12 showed no nonspecific product amplification 
(Figure 4.16). As highlighted in Figure 4.16, the primer set for exon 1 showed 
nonspecific amplification of a large amplicon near 700 bp and was excluded from 
downstream analysis. While endpoint PCR showed no indication of primer-dimer 
formation, a qPCR melt curve analysis was utilized to determine specificity of primer 
pairs throughout the 0.2 – 150 ng DNA linear range (Figure 4.17). As depicted in melt 
curves, no nonspecific product amplification was observed throughout the 0.2 – 150 ng   
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Figure 4.16 PS1 primer specificity via endpoint PCR. PS1 exon primer pairs showed 
amplification of target amplicon in expected bp range with no nonspecific amplification 
and no primer-dimer formation in negative control lanes (left of labeled product) for 
exons 4 site 1 (4_1), 4 site 2 (4_2), 9, 12 site 2 (12_2), and 12 site 3 (12_3). Exon 1, 
however, showed non-specific amplification of large product near 450 bp.  
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Figure 4.17 Melt curves of PS1 in qPCR optimization. Specificity of target 
amplification was determined using melt curve analysis for exon 4 site 1 (A), exon 4 site 
2 (B), exon 9 (C), exon 12 site 2 (D), and exon 12 site 3 (E) for PS1. As shown above, a 
single peak for each analysis indicated specific amplification of target amplicon with no 
primer-dimer formation. A shoulder peak was shown in the exon 4 site 2 melt curve (B), 
likely indicating a low complexity region causing non-uniform melting.  
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DNA curve. Over a concentration range of 0.2 – 150 ng of input DNA, a linear response 
was observed for all primer pairs (Figure 4.18, 4.19, and 4.20). Endpoint PCR and melt 
curve analyses showed specific target recognition for all PS1 primers, while response 
curves showed linearity across a wide DNA range and acceptable reaction efficiencies for 
all primer sets.   
4.3.1.2 ABCA7 primers 
ABCA7 synthetic primers (Table 3.1) were tested for specificity by analyzing 
forward and reverse primer sequences in NCBI’s website tool PrimerBlast. Besides 
intended target amplicon, no other product matched designed primer pairs. Endpoint PCR 
was used to validate PrimerBlast results, showing no nonspecific amplification of 
products other than targeted amplicons for ABCA7 exons 12, 18, 19, and 37 (Figure 
4.21). Similar to PS1 primers, ABCA7 primers show specific amplification of target 
sequence with the exception of primers for exon 14, where nonspecific amplification of a 
large amplicon excluded exon 14 from further analysis. As described above, melt curves 
were analyzed for ABCA7 primers to ensure specificity of primers for intended target 
sequence (Figure 4.22). Response curves were analyzed over the same concentration 
range (0.2 – 150 ng DNA) and showed linear responses and acceptable reaction 
efficiencies for optimized primer concentrations (Figure 4.23, 4.24, 4.25, and 4.26). 
Primer pair and DNA optimization using SYBR Green Fast Master mix and qPCR 
resulted in linear response curves, reaction efficiencies between accepted 90-110% range, 
and no primer-dimer formation in product melt curves or endpoint PCR analysis. 
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Figure 4.18 PS1 exon 4 qPCR response curves. Over a concentration range of 0.2 – 
150 ng of DNA, response curves for PS1 primers of exon 4 site 1 (a) and exon 4 site 2 (b) 
showed linear responses (R2 < 0.9) and reaction efficiencies within acceptable range (90-
110%) at optimized primer pair concentrations. Data points represent mean ± SD (n=3).  
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Figure 4.19 PS1 exon 9 qPCR response curve. Over a concentration range of 0.2 – 150 
ng of DNA, the response curve for PS1 primers of exon 9 showed a linear response (R2 < 
0.9) and reaction efficiency within acceptable range (90-110%) at optimized primer pair 
concentrations. Data points represent mean ± SD (n=3). 
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Figure 4.20 PS1 exon 12 qPCR response curves. Over a concentration range of 0.2 – 
150 ng of DNA, response curves for PS1 primers of exon 12 site 2 (a) and exon 12 site 3 
(b) showed linear responses (R2 < 0.9) and reaction efficiencies within acceptable range 
(90-110%) at optimized primer pair concentrations. Data points represent mean ± SD 
(n=3). 
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Figure 4.21 ABCA7 primer specificity via endpoint PCR. ABCA7 exon primer pairs 
showed amplification of target amplicon in expected bp range with no nonspecific 
amplification and no primer-dimer formation in negative control lanes (left of labeled 
product) for exons 12, 18, 19, and 37. Exon 14, however, showed non-specific 
amplification of large product near 600 bp.  
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Figure 4.22 Melt curves of ABCA7 in qPCR optimization. Specificity of target 
amplification was determined using melt curve analysis for exon 12 (A), exon 18 (B), 
exon 19 (C), and exon 37 (D) for ABCA7. As shown above, a single peak for each 
analysis indicated specific amplification of target amplicon with no primer-dimer 
formation.  
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Figure 4.23 ABCA7 exon 12 qPCR response curve. Over a concentration range of 0.2 
– 150 ng of DNA, the response curves for ABCA7 primers of exon 12 showed a linear 
response and reaction efficiency within acceptable range (90-110%) at optimized primer 
pair concentrations. Data points represent mean ± SD (n=3). 
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Figure 4.24 ABCA7 exon 18 qPCR response curve. Over a concentration range of 0.2 
– 150 ng of DNA, the response curves for ABCA7 primers of exon 18 showed a linear 
response and reaction efficiency within acceptable range (90-110%) at optimized primer 
pair concentrations. Data points represent mean ± SD (n=3). 
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Figure 4.25 ABCA7 exon 19 qPCR response curve. Over a concentration range of 0.2 
– 150 ng of DNA, the response curves for ABCA7 primers of exon 19 showed a linear 
response and reaction efficiency within acceptable range (90-110%) at optimized primer 
pair concentrations. Data points represent mean ± SD (n=3). 
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Figure 4.26 ABCA7 exon 37 qPCR response curve. Over a concentration range of 0.2 
– 150 ng of DNA, the response curves for ABCA7 primers of exon 37 showed a linear 
response and reaction efficiency within acceptable range (90-110%) at optimized primer 
pair concentrations. Data points represent mean ± SD (n=3). 
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4.3.2 EpiMark kit validation  
 To determine efficiency of enzymes in the EpiMark 5-hmC and 5-mC Analysis 
kit, characterized mouse DNA and primer sequences from NEB were requested and 
tested against kit enzymes MspI and HpaII. NEB primer sequences (Forward primer: 
TGTTTCCTTACCCTGAATGACTCCC, Reverse primer: 
TTGCAACCCACACTATTCCCTTG) were specific for the mouse gene alpha-2-
macroglobulin receptor-associated protein precursor. Enzyme reactions were carried out 
using NEB4 (New England Biolabs buffer 4), the buffer supplied in the EpiMark 
quantification kit, as well as NEB’s new CutSmart® buffer. The use of CutSmart buffer 
compared to NEB4 lead to enzyme stability and reproducible results (Figure 4.27) and 
was used in place of NEB4.  
4.3.3 Subject demographics analysis 
 To compare loci-specific levels of 5-mC and 5-hmC in SMTG throughout the 
progression of AD, tissue specimens from NC, PCAD, MCI, and LOAD subjects were 
obtained from the UK-ADC (Table 4.8). Statistical analysis of subject demographic 
information showed no significant difference in age (p = 0.274, ANOVA), gender 
distribution (p = 0.788, ANOVA on Ranks), or PMI (p = 0.655, ANOVA) between the 
subject groups. Significant differences were detected in MMSE scores and Braak staging 
scores compared to NC subjects using ANOVA on Ranks analyses. Braak staging scores 
were significantly increased in PCAD and LOAD subjects compared to NC, as well as a 
significant decrease in MMSE scores for LOAD compared to NC subjects according to 
Dunn’s post-hot analyses (*p < 0.05). 
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Table 4.8 Subject demographic data for gene-specific qPCR study. 
 
  NC  (n=9) 
PCAD  
(n=7) 
MCI  
(n=10) 
LOAD  
(n=9) 
Gender  4M / 5F 2M / 5F 3M / 8F 4M / 5F 
Age (y)  84.1 ± 8.3 85.1 ± 7.1 89.5 ± 6.4 83.2 ± 8.5 
PMI (h)  2.7 ± 1.0 3.0 ± 0.5 2.6 ± 0.5 2.6 ± 0.6 
MMSE  29.5 [28 - 30] 30 [28 – 30] 28 [26 – 28] 16* [3 – 25] 
Braak 
Staging Score  II [I – II] IV* [IV – V] III [II – IV] VI* [V – VI] 
 
*p < 0.05 
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Figure 4.27 EpiMark reaction buffer comparison. To determine the most effective 
reaction buffer for restriction enzyme digestion experiments, NEB4 and CutSmart buffers 
supplied by New England Biolabs were compared. Characterized mouse DNA was 
supplied from New England Biolabs as well as forward and reverse primer sequences 
used in EpiMark kit product development. Light blue bars indicate cleavage of CCGG 
site (MspI) and 5-hmC modifications (MspI+T4βGT). Green bars indicate combined 5-
mC and 5-hmC modifications (HpaII and HpaII+T4βGT). Purple bars indicate total DNA 
(no enzyme and only T4βGT). As shown above, CutSmart buffer yields better 
reproducibility and stability of enzymes compared to NEB4.  
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4.3.4 Quantification of SMTG levels  
 Extracted DNA samples from SMTG of NC, PCAD, MCI, and LOAD subjects 
were treated with EpiMark kit restriction enzymes to analyze levels of cytosine, 5-mC, 
and 5-hmC at target CCGG sequences within exons 4, 9, and 12 of PS1 and exons 12, 18, 
19, and 37 of ABCA7. Initial DNA concentrations were determined from response curves 
over an input range of 0.2 – 150 ng of DNA. A representative qPCR amplification plot 
was shown in Figure 4.28, where Ct values for treated DNA, including MspI digested 
DNA, glucose protected MspI digested DNA, and HpaII treated DNA, as well as 
untreated DNA, were used to determine the percent of cytosine, 5-mC, and 5-hmC at 
specific CCGG sequences within PS1 and ABCA7 exons. Percentages of each 
modification were calculated based on total amount of DNA (no enzyme) and normalized 
to MspI cutting efficiency (unprotected Msp1 digestion).  
4.3.5 Statistical analysis - MANOVA 
At each CCGG target sequence within the analyzed exons of PS1, three 
dependent variables were measured; cytosine, 5-mC, and 5-hmC. For this reason, a 
multivariate analysis was chosen, specifically, a multivariate analysis of variance 
(MANOVA). The data met assumptions for MANOVA, including continuous data with 
independent observations for dependent variables, included more than two independent 
variables, showed no evidence of multicollinearity of the dependent variables via 
regression analyses, contained no multivariate outliers based on Mahalanobis distances 
and data showed homogeneity of covariance as tested by Levene’s test [222]. However, 
multivariate normality criteria were not met, thus the more 
 
131 
 
 
 
 
 
 
Figure 4.28 qPCR amplification plot of representative treated DNA sample. Utilizing 
EpiMark restriction enzymes digestion protocol, cycle threshold values were used to 
determine levels of 5-mC and 5-hmC at CCGG sequences of AD and NC subjects. One 
untreated sample (a) and three treated DNA samples, including HpaII digested DNA (b), 
glucose protected MspI digested DNA (c), and unprotected MspI digested DNA (d), were 
used to determine total DNA (a), methylated and hydroxymethylated DNA (b), only 
hydroxymethylated DNA (c), and MspI digestion efficiency (d) for each sample (blue 
curves). Initial concentration of modifications in each reaction and qPCR reaction 
efficiencies were determined using DNA response curves (red and yellow curves) over a 
concentration range of 0.2 – 150 ng of DNA. Response curve concentrations were run in 
triplicate, while treated and untreated DNA samples were run in duplicate.  
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conservative multivariate test, Pillai-Trace, was used. Four MANOVA models were 
tested for the exons of ABCA7 and five models for the exons of PS1.  
To determine significant differences of cytosine, 5-mC, and 5-hmC percentages at 
target sequences in exons of PS1 and ABCA7, MANOVA models were used to calculate 
mean ± SE (% modification of CCGG) values for 5-hmC, 5-mC, and cytosine for each 
subject group. In the event the multivariate analysis was significant, a test of between 
subject effects was performed for each dependent variable using least square regression. 
In the event the subject groups made a significant difference for each dependent variable 
within the model, a pairwise comparison of least square differences between the subject 
groups was performed.  
4.3.5.1 PS1 Exon 4: Site 1  
To determine levels of cytosine, 5-mC, and 5-hmC at site 1 of exon 4, mean ± SE 
(% modification of CCGG) were compared using multivariate analysis model. The 
MANOVA model was significant for the omnibus multivariate test (p < 0.001, Pillai’s 
Trace) and a significant subject group effect within the model was shown for all three 
dependent variables (5-hmC, p < 0.001; 5-mC, p < 0.001; cytosine, p < 0.05). However, 
pairwise comparison of between subject effects did not produce a significant result for 
cytosine, 5-mC, or 5-hmC. Mean cytosine levels of NC subjects were 4.31 ± 2.89 % and 
were not statistically different from levels of 3.64 ± 3.19 % for PCAD, 7.19 ± 2.63 % for 
MCI, or 4.70 ± 2.82 % for LOAD subjects according to pairwise comparison within 
MANOVA model. Likewise, 5-mC levels were 33.64 ± 4.31 % for NC, and no 
statistically significant difference was found for levels of 33.94 ± 4.77 % for PCAD, 
31.65 ± 3.94 % for MCI, and 36.06 ± 4.21 % for LOAD subjects. Levels of 5-hmC were 
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62.06 ± 3.71 % for NC subjects, 62.42 ± 4.11 % for PCAD, 61.16 ± 3.38 % for MCI, and 
59.24 ± 3.62 % for LOAD and no significant differences were detected between levels of 
5-hmC for any of the subject groups (Figure 4.29).  
4.3.5.2 PS1 Exon 4: Site 2 
To determine levels of cytosine, 5-mC, and 5-hmC at site 2 of exon 4, mean ± SE 
(% modification of CCGG) were compared using multivariate analysis model. The 
MANOVA model for exon 4: site two of PS1 was significant for the omnibus 
multivariate test (p < 0.001, Pillai’s Trace) and a significant subject group effect within 
the model was shown for all three dependent variables (p < 0.001). Pairwise comparison 
of between subject effects for cytosine model yielded no significant differences between 
the mean levels of 5.42 ± 2.38 % for NC, 7.81 ± 2.64 % for PCAD, 4.04 ± 2.17 % for 
MCI, and 6.17 ± 2.33 % for LOAD subjects. However, trending towards significant 
differences in mean levels of 5-mC of MCI compared to NC subjects was detected, where 
decreased levels of 5-mC in MCI (33.76 ± 4.80 %) compared to 42.22 ± 5.26 % for NC 
subjects (#p ≤ 0.1). Mean 5-mC levels of 29.91 ± 5.82 % for PCAD and 35.53 ± 5.13 % 
for LOAD subjects, however, were not significantly different from NC subjects. Lastly, 
5-hmC levels were 53.83 ± 4.58 % for NC subjects, 62.28 ± 5.07 % for PCAD, 62.20 ± 
4.18 % for MCI, and 59.59 ± 4.47 % for LOAD subjects, but pairwise comparison 
analyses showed no significant differences between 5-hmC levels of the subject groups 
(Figure 4.30).  
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Figure 4.29 SMTG cytosine modification levels in exon 4 site 1 of PS1. Estimated 
mean ± SE (% modification) for 5-hmC, 5-mC, and cytosine levels via qPCR analysis.  
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Figure 4.30 SMTG cytosine modification levels in exon 4 site 2 of PS1. Estimated 
mean ± SE (% modification) for 5-hmC, 5-mC, and cytosine levels via qPCR analysis. 
Trending towards significance shown compared to NC subjects (#p ≤ 0.1). 
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4.3.5.3 PS1 Exon 9 
To determine levels of cytosine, 5-mC, and 5-hmC of target sequence of exon 9, 
mean ± SE (% modification of CCGG) were compared using multivariate analysis model. 
The MANOVA model for exon 9 of PS1 was significant for the omnibus multivariate test 
(p < 0.001, Pillai’s Trace) and a significant subject group effect within the model was 
shown for all three dependent variables (p < 0.001). Pairwise comparison of cytosine 
levels of 9.56 ± 2.72 % for NC, 9.96 ± 3.01 % for PCAD, 5.34 ± 2.48% for MCI, and 
6.86 ± 2.65 % for LOAD subjects showed no statistically significant difference between 
the subject groups. Likewise, analysis of 5-mC levels of 27.01 ± 5.64 % for NC, 30.76 ± 
6.24 % for PCAD, 30.74 ± 5.15 % for MCI, and 34.44 ± 5.50 % for LOAD subjects in 
the MANOVA pairwise comparison produced no significant difference between the 
subject groups. Mean levels of 5-hmC were 63.87 ± 4.41 % for NC subjects, 59.29 ± 4.88 
% for PCAD, 63.92 ± 4.02 % for MCI, and 59.71 ± 4.30 % for LOAD subjects and no 
statistically significant difference was detected during pairwise comparison (Figure 4.31).  
4.3.5.4 PS1 Exon 12: Site 2 
To determine levels of cytosine, 5-mC, and 5-hmC at site 2 of exon 12, mean ± 
SE (% modification of CCGG) were compared using multivariate analysis model. The 
MANOVA model for exon 9 of PS1 was significant for the omnibus multivariate test (p 
< 0.001, Pillai’s Trace) and a significant subject group effect within the model was 
shown for all three dependent variables (p < 0.001). Mean ± SE cytosine levels were 
21.42 ± 7.14 % for NC, 17.63 ± 7.90 % for PCAD, 23.94 ± 6.51 % for MCI, and 27.47 ± 
6.96 % for LOAD subjects and were not significantly different from pairwise comparison 
analysis.  Likewise, 5-mC levels were 40.58 ± 6.56 % for NC, 44.54 ± 7.26 % for PCAD,  
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Figure 4.31 SMTG cytosine modification levels in exon 9 of PS1. Estimated mean ± 
SE (% modification) for 5-hmC, 5-mC, and cytosine levels via qPCR analysis.  
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36.24 ± 5.98 % for MCI, and 38.24 ± 6.40 % for LOAD subjects, while levels of 5-hmC 
were 38.00 ± 7.57 % for NC subjects, 37.84 ± 8.37 % for PCAD, 39.82 ± 6.90 % for 
MCI, and 34.30 ± 7.38 % for LOAD subjects. Pairwise comparison of 5-mC and 5-hmC 
levels showed no statistically significant difference between groups for either dependent 
variable at target sequence site 2 of exon 12 (Figure 4.32). 
4.3.5.5 PS1 Exon 12: Site 3 
To determine levels of cytosine, 5-mC, and 5-hmC at site 3 of exon 12, mean ± 
SE (% modification of CCGG) were compared using multivariate analysis model. The 
MANOVA model for exon 9 of PS1 was significant for the omnibus multivariate test (p 
< 0.001, Pillai’s Trace) and a significant subject group effect within the model was 
shown for all three dependent variables (p < 0.001). Pairwise comparison analysis of 
each dependent variable showed no statistically significant difference in mean levels of 
cytosine, 5-mC, or 5-hmC between the sets of subject groups. Mean levels of cytosine of 
52.14 ± 5.81 % for NC, 53.73 ± 6.43 % for PCAD, 49.06 ± 5.30 % for MCI, and 57.54 ± 
5.67 % for LOAD subjects were compared, yet no difference was detected between the 
subject groups. Likewise, 5-mC levels were 27.88 ± 5.35 % for NC, 32.59 ± 5.92 % for 
PCAD, 34.95 ± 4.88 % for MCI, and 25.94 ± 5.22 % for LOAD subjects, while levels of 
5-hmC were 19.99 ± 3.90 % for NC subjects, 13.68 ± 4.32 % for PCAD, 15.99 ± 3.56 % 
for MCI, and 16.53 ± 3.81 % for LOAD subjects and no difference between the means of 
each subject groups were statistically significant for either 5-mC or 5-hmC models 
(Figure 4.33). 
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Figure 4.32 SMTG cytosine modification levels in exon 12 site 2 of PS1. Estimated 
mean ± SE (% modification) for 5-hmC, 5-mC, and cytosine levels via qPCR analysis.  
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Figure 4.33 SMTG cytosine modification levels in exon 12 site 3 of PS1. Estimated 
mean ± SE (% modification) for 5-hmC, 5-mC, and cytosine levels via qPCR analysis.  
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4.3.5.6 ABCA7 Exon 12 
Similar to analyses of PS1 exons, levels of cytosine, 5-mC, and 5-hmC in exons 
of ABCA7, mean ± SE (% modification of CCGG) were compared using multivariate 
analysis model. The MANOVA model for exon 12 of ABCA7 was significant for the 
omnibus multivariate test (p < 0.001, Pillai’s Trace) and a significant subject group effect 
within the model was shown for all three dependent variables (5-hmC, p < 0.001; 5-mC, 
p < 0.001; cytosine, p < 0.05). Pairwise comparison of cytosine levels of 2.28 ± 1.79 % 
for NC, 1.35 ± 1.98 % for PCAD, 3.24 ± 1.56 % for MCI, and 4.18 ± 1.75 % for LOAD 
subjects showed no significant difference between the subject groups. However, 
statistically significant differences were detected in 5-mC levels of 56.20 ± 3.69 % for 
MCI compared to 68.64 ± 4.14 % for LOAD subjects (*p < 0.05), while trending towards 
significant differences were detected in 5-mC levels of MCI compared to mean levels of 
65.25 ± 4.24 % for NC subjects (#p ≤ 0.1), but 5-mC levels of 64.10 ± 4.92 % for PCAD 
subjects were not statistically significant between the subject groups. Lastly, levels of 5-
hmC of 34.55 ± 3.53 % for PCAD, 40.56 ± 2.78 % for MCI, or 30.98 ± 3.11 % for 
LOAD compared to levels of 34.21 ± 2.98 % for NC subjects were not statistically 
significant (Figure 4.34). Interestingly, there was a statistically significant increase in 
MCI levels of 5-hmC compared to LOAD subjects in exon 12 of ABCA7 (*p < 0.05). 
4.3.5.7 ABCA7 Exon 18 
Levels of cytosine, 5-mC, and 5-hmC were analyzed in exon 18 of ABCA7 using 
a multivariate analysis of variance statistical analysis. The MANOVA model for exon 18 
was significant for the omnibus multivariate test (p < 0.001, Pillai’s Trace) and a 
significant subject group effect within the model was shown for all three dependent  
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Figure 4.34 SMTG cytosine modification levels in exon 12 of ABCA7. Estimated 
mean ± SE (% modification) for 5-hmC, 5-mC, and cytosine levels via qPCR analysis. 
Trending towards significance shown compared to NC subjects (#p ≤ 0.1). 
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variables (p < 0.001). Pairwise comparison of cytosine levels of 16.99 ± 3.90 % for NC, 
7.80 ± 4.33 % for PCAD, 9.03 ± 3.40 % for MCI, and 13.19 ± 3.81 % for LOAD subjects 
gave trending towards significant differences in MCI and PCAD levels compared to NC 
(#p ≤ 0.1) (Figure 4.35). However, neither the 5-mC nor 5-hmC models gave statistically 
significant pairwise comparisons between the subject groups. 5-mC levels were 60.72 ± 
4.71 % for NC, 70.71 ± 5.22 % for PCAD, 64.89 ± 4.11 % for MCI, and 65.27 ± 4.60 % 
for LOAD subjects, while levels of 5-hmC were 22.29 ± 3.00 % for NC subjects, 21.48 ± 
3.32 % for PCAD, 26.09 ± 2.61% for MCI, and 21.54 ± 2.93 % for LOAD subjects 
according to pairwise comparisons of multivariate analysis.  
4.3.5.8 ABCA7 Exon 19 
Levels of cytosine, 5-mC, and 5-hmC from qPCR analyses were analyzed using a 
multivariate analysis. The MANOVA model for exon 19 of ABCA7 was significant for 
the omnibus multivariate test (p < 0.001, Pillai’s Trace) and a significant subject group 
effect within the model was shown for all three dependent variables (5-hmC, p < 0.001; 
5-mC, p < 0.001; cytosine, p < 0.01). Pairwise comparisons of each dependent variable, 
however, did not produce statistically significant results (Figure 4.31). Mean levels of 
cytosine were 7.34 ± 2.16 % for NC, 4.92 ± 2.39 % for PCAD, 3.38 ± 1.88 % for MCI, 
and 4.54 ± 2.11 % for LOAD subjects. Additionally, 5-mC levels were 46.28 ± 4.43 % 
for NC, 50.57 ± 4.91% for PCAD, 44.19 ± 3.86 % for MCI, and 48.71 ± 4.33 % for 
LOAD subjects, while levels of 5-hmC were 46.38 ± 4.09 % for NC subjects, 44.51 ± 
4.53 % for PCAD, 52.52 ± 3.56 % for MCI, and 46.75 ± 3.99 % for LOAD subjects.  
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Figure 4.35 SMTG cytosine modification levels in exon 18 of ABCA7. Estimated 
mean ± SE (% modification) for 5-hmC, 5-mC, and cytosine levels via qPCR analysis. 
Trending towards significance shown compared to NC subjects (#p ≤ 0.1). 
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Figure 4.36 SMTG cytosine modification levels in exon 19 of ABCA7. Estimated 
mean ± SE (% modification) for 5-hmC, 5-mC, and cytosine levels via qPCR analysis.  
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4.3.5.9 ABCA7 Exon 37 
Finally, levels of cytosine, 5-mC, and 5-hmC within target sequence of ABCA7 
exon 37 were analyzed using a multivariate analysis. The MANOVA model for exon 37 
of ABCA7 was significant for the omnibus multivariate test (p < 0.001, Pillai’s Trace) 
and a significant subject group effect within the model was shown for all three dependent 
variables (p < 0.001). Pairwise comparisons of cytosine levels of 20.02 ± 3.43 % for NC, 
19.50 ± 3.80 % for PCAD, 14.73 ± 2.99 % for MCI, and 15.09 ± 3.35 % for LOAD 
subjects produced no statistically significant differences between mean values of subject 
groups. Likewise, no significant differences were shown between 5-mC levels of 67.01 ± 
3.43 % for NC, 65.28 ± 3.80 % for PCAD, 67.72 ± 3.36 % for MCI, and 70.72 ± 3.35 % 
for LOAD subjects. Pairwise comparison of 5-hmC levels gave trending towards 
significant values for MCI compared to NC subjects, where an increase in 5-hmC was 
shown between mean levels of 17.55 ± 1.54 % for MCI subjects compared to 12.98 ± 
1.77 % for NC (#p ≤ 0.1) (Figure 4.37). Mean 5-hmC of 15.23 ± 1.96 % for PCAD and 
14.20 ± 1.73 % for LOAD subjects were not significantly different from NC subjects.  
4.3.6 Protein Expression 
 4.3.6.1 PS1 protein 
 To determine whether significant alterations of epigenetic changes within exons 
correlated to fluctuations in gene expression, SMTG levels of PS1 protein from NC, 
PCAD, MCI, and LOAD subjects were analyzed via band density measurements of 
protein bands separated via electrophoresis and polyacrylamide gel separation of Western 
blot protocol. Normalized to the reference protein GAPDH, PS1 expression was   
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Figure 4.37 SMTG cytosine modification levels in exon 37 of ABCA7. Estimated 
mean ± SE (% modification) for 5-hmC, 5-mC, and cytosine levels via qPCR analysis. 
Trending towards significance shown compared to NC subjects (#p ≤ 0.1). 
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calculated as percent of NC were mean ± SE was 100.00 ± 6.19 % for NC, 107.47 ± 8.56 
% for PCAD, 119.50 ± 5.50 % for MCI, and 97.44 ± 3.34 % for LOAD. To determine 
statistically significant differences between the subject groups compared to NC subjects, 
ANOVA was utilized. The omnibus test was significant (p < 0.05) and a Holm-Sidak 
post-hoc analysis was performed. Statistically significant differences were observed for 
MCI compared to NC subjects, were PS1 protein levels were elevated in MCI subjects 
(*p < 0.05) (Figure 4.38).  
 4.3.6.2 ABCA7 protein 
 To determine whether significant alterations of epigenetic changes within exons 
correlated to fluctuations in gene expression, SMTG levels of ABCA7 protein from NC, 
PCAD, MCI, and LOAD subjects were analyzed via band density measurements. 
Normalized to a the reference protein GAPDH, ABCA7 expression was calculated as 
percent of NC to give values of 100.00 ± 6.18 % for NC, 110.35 ± 7.16 % for PCAD, 
97.29 ± 8.18 % for MCI, and 60.59 ± 10.60 % for LOAD. To determine statistically 
significant differences between the subject groups compared to NC subjects, ANOVA 
was used and significant across the subject groups (*p < 0.05). Protein levels of ABCA7 
were significantly decreased in LOAD subjects compared to NC via post-hoc Holm-
Sidak test (*p < 0.05) (Figure 4.39).  
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Figure 4.38 PS1 protein expression in SMTG. Representative Western blot of PS1 (N-
terminal fragment) and GAPDH (a). Mean ± SE (% NC) of PS1 protein in SMTG of NC, 
PCAD, MCI, and LOAD subjects (b). PS1 expression was normalized to GAPDH protein 
and reported as percent of NC. Statistical significance was determined using ANOVA 
and Holm-Sidak post-hoc analysis (*p < 0.05).  
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Figure 4.39 SMTG protein expression of ABCA7. Representative Western blot of 
ABCA7 and GAPDH proteins (a). Mean ± SE (% of NC) of ABCA7 protein in SMTG of 
NC, PCAD, MCI, and LOAD subjects (b). ABCA7 expression was normalized to 
GAPDH and reported as percent of NC. Statistical significance was determined using 
ANOVA and Holm-Sidak post-hoc analysis (*p < 0.05). 
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CHAPTER 5: DISCUSSION 
 Alzheimer’s disease is the sixth leading cause of death in the United States, and 
the only disease in the list of top ten causes of death with no therapeutic option or means 
of halting or slowing progression of the disease [13]. While the discovery of inherited 
genetic mutations in the rare familial form have advanced the understanding of how 
characteristic pathologic lesions, including amyloid-beta plaques, form in susceptible 
brain regions [9, 14, 15], decades of research have yet to lead to a therapeutic treatment 
option for AD patients [46]. Development of the disease in the sporadic form may be 
causal to micro-environmental influences, where deregulation of gene expression 
mechanisms within brain cells lead to lesion development and disease progression [55]. 
Analysis of post-mortem tissue of sporadic AD subjects showed alterations in 
transcription in brain regions susceptible to pathologic lesion development, even in 
preclinical stages of AD [58-60, 62, 68].  
 Epigenetic regulation of gene expression by cytosine methylation has been 
associated with gene silencing mechanisms in normal cellular function and disease 
studies [134, 144, 145] as shown through bisulfite conversion sequencing techniques 
[123, 124]. However, with the recent discovery of oxidized derivatives of 5-mC in 
mammalian genomes [113, 114, 117], particularly 5-hmC, the role of cytosine 
modification in regulating transcription again became unclear, partially due to the 
seemingly opposing roles 5-mC and 5-hmC in regulating transcription [121, 144, 145]. 
Another complication in elucidating the role 5-mC and 5-hmC may play in regulating 
gene expression comes from the discovery that bisulfite conversion does not distinguish 
between these two modifications [125], where previously reported levels of 5-mC were 
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better described as cytosine modifications. Levels of 5-hmC, the most abundant 5-mC 
derivative, remain relatively low throughout tissue and cell types, although some studies 
reported as high as 40% of all 5-mC in the brain as hydroxymethylated [149, 153].  
 Interest in DNA methylation and derivatives of 5-mC as a possible means of 
transcription regulation in neurodegenerative diseases, specifically AD, seems probable 
for several reasons. In blood and tissue samples of AD patients, increased levels of 
homocysteine and deregulation of SAM/SAH ratios in the methionine cycle (Figure 1.4) 
were detected [161-163], likely altering DNA methylation states in AD subjects. 
Furthermore, mammalian levels of 5-hmC were the most abundant in brain cells 
compared to other organs and cell types [149, 153]. Finally, due to the non-replicative 
nature of neurons, means of quickly responding to influences of the microenvironment 
surrounding neurons via regulating gene expression gives credence to the suggested role 
cytosine modifications play in the brain, particularly in neurodegenerative diseases.  
 In order to determine whether epigenetic modifications to cytosine are 
deregulated in AD, it was the aim of this dissertation to quantify levels of cytosine, 5-mC, 
and 5-hmC in post-mortem brain tissues of AD subjects compared to normal controls at 
the global and gene-specific levels. The global study of cytosine, 5-mC, and 5-hmC in 
multiple brain regions at early and late stages of AD progression would confirm 
differences in epigenetic landscapes in AD compared to NC, as well as provide 
epigenetically altered brain regions for further study. The genome-wide study of 5-hmC 
levels in the hippocampus of late stage AD compared to NC subjects would identify 
biological pathways with gene-specific altered hydroxymethylomes relevant to AD and 
neurodegeneration. Additionally, the loci-specific quantification of cytosine 
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modifications within exons of target genes in the temporal lobe would show site specific 
alterations in cytosine, 5-mC, and 5-hmC in early and late stages of AD progression.  
 
5.1 Global levels of 5-mC and 5-hmC are altered in early stages of disease 
progression in AD  
Initial findings regarding the role global levels of epigenetic modifications play in 
sporadic AD were controversial [173-176, 178]. Some studies showed an increase in 5-
mC and/or 5-hmC [175-177], others showed an overall decrease of modifications [173, 
178], while one study showed no changes in AD compared to NC subjects. Variations in 
immunochemical techniques, tissue processing procedures, and semi-quantitative 
analyses across the studies, as well as the use of a single brain region in several of the 
studies, likely led to the inconsistent findings and leave the question unanswered: are 
epigenetic modifications to DNA altered in sporadic AD? To answer this question, a 
specific quantitative study was essential to determine whether 5-mC and 5-hmC levels 
were altered in brain regions relevant to AD.  
 Pairing GC/MS and stable isotope labeled cytosine bases, a sensitive and selective 
method to analyze cytosine, 5-mC, and 5-hmC was validated using temperature 
programmed peak separation (Figure 2.3), linear standard curve analyses (Figure 4.4, 4.5, 
and 4.6), and limit of quantification calculations (Results 4.1.1). Quantification of 
cytosine, 5-mC, and 5-hmC from four brain regions (HPG, SMTG, IPL, and CER) in 
early (PCAD and MCI) and late (LOAD) stages of AD progression were compared to 
age-matched NC subjects, as well as disease control subjects (FTLD/DLB). To determine 
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statistically significant differences between mean levels of each epigenetic mark, 
repeated measures analyses were used.  
As this study verified, epigenetic modifications to cytosine were globally altered 
in early stages of disease progression throughout the brain, as well as in other forms of 
neurodegenerative diseases, including FTLD and DLB. While both PCAD and MCI 
subjects showed a statistically significant increase in global levels of 5-hmC compared to 
NC subjects (Figure 4.10), this also correlated to a significant decrease in cytosine levels 
for MCI subjects compared to NC (Figure 4.8). While no statistically significant 
differences were observed for LOAD subjects in the cytosine, 5-mC, or 5-hmC models 
compared to NC levels, a marginally significant increase in 5-mC (p = 0.053) was 
observed (Figure 4.9). All models showed significant differences for FTLD/DLB 
subjects, where both cytosine and 5-mC were significantly decreased and global 5-hmC 
levels were significantly increased compared to NC subjects. These findings were in 
agreement with current literature suggesting alterations of epigenetic mechanisms are 
relevant to dementia, neurological psychosis, and genetic diseases leading to neurological 
disorders [223-228].  
Compared to LOAD, epigenetic marks in PCAD and MCI subjects showed 
increased levels of 5-hmC and decreased global levels of cytosine and 5-mC. This 
suggests that alterations to epigenetic mechanisms affect early stages of AD progression 
and return to basal conditions in the later stage of disease. While 5-mC and 5-hmC may 
play a role in the earliest stages of disease progression, alterations in epigenetic marks 
seem to have less of a global impact on the brain after rampant cell death and 
neurodegeneration observed in late stage disease.  
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As Figure 4.11 and Figure 4.12 showed, levels of 5-mC and 5-hmC varied across 
brain regions for NC, PCAD, MCI, and LOAD subjects. Interestingly, brain regions 
susceptible to AD pathology later in disease progression (SMTG and IPL) showed 
increased levels of 5-mC and 5-hmC compared to one of the earliest affected brain 
regions (HPG). In brain regions susceptible to deposition of pathologic lesions (HPG, 
SMTG, and IPL), levels of 5-mC and 5-hmC were significantly decreased compared to a 
typically non-vulnerable region (CER). In agreement with current studies [180, 229], 
human cerebellum levels of 5-mC and 5-hmC were elevated compared to other brain 
regions. However, these alterations may reflect variations in cell type distributions 
between the brain regions analyzed. While levels of 5-mC and 5-hmC varied across brain 
regions and were significantly decreased in AD-pathologic susceptible regions compared 
to a non-vulnerable region, the biological significance of these results is unclear.  
Typically, an overall increase in 5-mC was associated with gene silencing, while 
hydroxymethylation was shown to have the opposite effect, where increases in 5-hmC 
were associated with gene activation. However, it has been suggested that regulation of 
transcription may depend more on site-specific alterations rather than global measures 
[144, 146, 147, 151, 230]. Several studies showed rampant deregulation of transcription 
in post-mortem tissue analyses of AD compared to NC subjects, as well as in AD animal 
models [59-61, 63-68]. In a microarray study of expression profiles in the medial frontal 
gyrus of subjects with varying degrees of AD pathology (Braak staging scores 0-VI), an 
increase in expression of synaptic activity and plasticity genes were associated with early 
stages of NFT development (i.e. low Braak staging scores), although as pathology burden 
increased, expression levels of these genes decreased [58]. While the regulation of genes 
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at various stages of disease progression in AD could be linked to the deregulation of 
epigenetic marks described in our study, more research is needed to understand these 
multifaceted mechanisms.  
As age is the most significant risk factor for development of AD, it is no surprise 
that genes relevant to aging mechanisms have altered transcription [231-234]. While it 
was argued that epigenetic alterations in neurodegenerative diseases were likely due to 
aging or epigenetic drift, our data clearly demonstrated that epigenetic alterations were 
specific to neurodegeneration, including AD and FTLD/DLB dementias, as data were 
controlled for age in repeated measures analyses and NC subjects were age-matched with 
no significant difference detected between mean ages of subject groups (Table 4.2). 
While age associated epigenetic changes are likely more relevant to individual subject 
variability, this would only be detectable in longitudinal studies of living patients, where 
analytes could be measured in the same subject across the time-span of the study. 
However, this type of analysis would be impossible for brain tissue studies and limited to 
bodily fluid samples (i.e. blood, urine, or CSF).  
As described above, our data confirmed significant alterations in global levels of 
epigenetic modifications to cytosine in post-mortem tissue of several types of 
neurodegenerative diseases, including AD. These changes were more associated with 
early stages of AD development rather than late stage AD. This study also describes an 
overall decrease in levels of 5-mC and 5-hmC in brain regions susceptible to AD 
pathologic lesions, including the hippocampus and temporal lobe, compared to a brain 
region typically considered non-vulnerable to the development of pathologic lesions, the 
cerebellum. In addition, while age associated epigenetic drift may play a role in 
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alterations to 5-mC and 5-hmC, significant differences shown in our study were corrected 
for age, and were neurodegenerative disease specific, including AD and FTLD/DLB 
subjects. While previous literature showed epigenetic marks varied across cell types and 
brain regions, to our knowledge, no study has used a selective and quantitative technique 
to analyze levels of 5-mC and 5-hmC in multiple brain regions of PCAD, MCI, and 
LOAD compared to NC subjects.  
While this study determined alterations in global levels of 5-mC and 5-hmC in 
neurodegenerative diseases compared to normal control subjects, it provided no 
information as to biological pathways or genes epigenetically altered in 
neurodegeneration, specifically pathways and genes that may be relevant to the 
pathogenesis of AD. In the following sections, however, two gene-specific studies will 
discuss pathways and loci-specific alterations of epigenetic marks in AD.  
 
5.2 Genome-wide levels of 5-hmC are altered in hippocampus of LOAD 
subjects 
While bisulfite sequencing techniques allowed researchers to study 5-mC over the 
past several decades, the discovery of oxidized derivatives of 5-mC, namely 5-hmC, have 
again clouded the role epigenetic modifications play in regulating gene expression in 
normal cellular function and in disease, specifically in the brain. In AD, three studies 
using bisulfite conversion of 5-mC to sequence regions of altered methylation within 
genomes of AD subjects compared to NC provided gene targets that may be 
epigenetically regulated in AD within the prefrontal cortex [175, 182, 183]. As discussed 
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previously, bisulfite conversion does not distinguish between 5-mC and 5-hmC [125], so 
the term “methylation” should be considered as “cytosine modification” to incorporate 
the underrepresentation of 5-hmC in these studies. Given the high concentrations of 5-
hmC in mammalian brain cells and the opposing roles 5-mC and 5-hmC have in 
regulating transcription, specific analysis of genome-wide hydroxymethylation is 
essential to elucidating biologically relevant pathways epigenetically regulated in AD.  
With the advancement of sequencing techniques able to distinguish 5-mC from 5-
hmC, a sensitive single-base resolution mapping of hydroxymethylation modifications 
was utilized to evaluate sites of altered 5-hmC in the hippocampus of LOAD subjects 
compared to NC. Fragmentation of DNA using 5-hmC specific restriction endonuclease 
enzymes paired with the deep sequencing capability of the Illumina platform allowed for 
more than 2 million sites of potential 5-hmC modifications to be identified. Statistically 
significant sites of hydroxymethylation were mapped to a gene interaction network using 
freely available software to determine biologically relevant pathways with altered 
hippocampal levels of 5-hmC in late stage AD.  
Using a negative binomial distribution analysis, differentially hydroxymethylated 
genomic regions were analyzed and annotated to the human genome. Of the sites 
analyzed by the RRHP analysis, more than 15,000 regions were significantly altered in 
LOAD subjects compared to NC, mapping to more than five thousand genes. Distribution 
of the statistically significant sites, or differentially hydroxymethylated regions (DhmRs), 
showed an overall increase (64 %) in 5-hmC in LOAD subjects, including 9,629 DhmRs, 
where the remaining 5,529 sites showed decreased levels of 5-hmC in the hippocampus 
of LOAD compared to NC subjects (Figure 4.14).  
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Interestingly, eighty-five percent of the altered sites were confined to genomic 
regions associated with known reference genes, including sites assigned to promoter and 
genebody locations. Since alterations in hydroxymethylation within gene-associated 
genomic locations correlated to altered transcription and gene expression [230], sites 
were filtered based on a previously published microarray of hippocampal gene expression 
in AD [59]. This study in particular was used due to the similarities in diagnosis criteria 
of late stage AD and NC subjects as well as similar PMI time frames used by the UK-
ADC. After filtering the statistically significant DhmRs with Blalock et al.’s list of 
differentially expressed genes, 329 genes with significantly altered levels of 5-hmC and 
changes in gene expression in the hippocampus of LOAD compared to NC subjects 
remained.  
To determine biologically meaningful pathways that may be relevant to AD 
progression, the 329 target genes were used to curate a gene network of likely 
interactions using Reactome’s Functional Interaction (RFI) network builder from 
Cytoscape®. Of the 329 genes from our analysis, 322 genes were used to create the gene 
network while the remaining seven genes were unrecognized by RFI and excluded from 
the network build. Network genes involved in similar pathways were grouped into six 
modules (Figure 4.15a) and pathway enrichment showed modules were related to 
signaling, energy metabolism, cell cycle, gene expression, protein degradation, and cell 
structure and stabilization pathways (Figure 4.15b). Relevance to AD and 
neurodegeneration of significantly enriched pathways within these modules, as well 
specific genes identified in our analysis within the pathways, will be discussed below.  
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Several genes within significantly enriched pathways in the signaling and cell 
cycle modules were also implicated as genes of interest that may play a role in the 
pathophysiology of sporadic AD. These genes included bridging integrator 1 (BIN1), 
clusterin (CLU), and compliment receptor 1 (CR1). These genes, involved in immune 
function, lipid processing, endocytosis, and clearances mechanisms [73], were also 
reported as target genes in genome-wide methylation mapping studies [183, 235, 236] as 
well as in genome-wide association studies of single nucleotide polymorphisms (SNPs) 
relevant to sporadic AD [71, 237]. Additionally, DLGAP1 (discs large associated protein 
1), a postsynaptic density regulator, was also suggested as a gene of interest in a smaller 
genome-wide association study of SNPs relevant to sporadic AD, although not as 
strongly associated as BIN1, CLU, and CR1 [238].  
Common to most neurodegenerative diseases and neuropsychological disorders, 
the deregulation of cellular signaling, predominantly at the synapse, leads to adverse 
effects. Alterations in levels of adenylate cyclase (ADCY2, ADCY3, ADCY7, ADCY9), 
G proteins (GNAO1, GNA14, GNAL, GNAS, GNAZ, GNB1), and phospholipase C 
(PLCB1, PLCE1, PLCG2) protein families within synaptic and calcium signaling 
cascades alters mechanisms of exocytosis, long-term depression, and gene expression in 
neurons according to curated KEGG pathways. Specific ion channel regulators, including 
genes regulating calcium (CACNA1), potassium (KCNJ14, KCNQ2, KCNA6), and 
sodium (GRIA3) ion channels, fell within significantly enriched signaling pathways 
according to our analysis. Of these genes, KCNA6, the potassium voltage-gated channel 
subfamily A member 6 gene, was identified as a hub gene in a recent 5-hmC mapping 
study of the prefrontal cortex of AD subjects [239], and was suggested to play a role in 
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neurotransmitter release and insulin secretion [240]. Additionally, several genes 
highlighted in the synaptic signaling pathway (including cholinergic, dopaminergic, 
glutamatergic, and serotonergic neurons) of our enrichment analysis were also gene 
targets in other neurodegenerative and neuropsychological disorder studies, including 
SH3 and multiple ankyrin repeat domains 2 (SHANK2) and 5-hydroxytryptamine 
receptor 2A (HTR2A). SHANK2 levels were elevated in AD subjects, likely from 
destruction of the Shank-postsynaptic platform enhanced by glutamate receptor 
dysfunction, ultimately contributing to synapse loss in AD [241]. Loss of HTR2A 
receptors in AD brain correlated to decreased cognitive performance [242], while 
epigenetic dysregulation of HTR2A was associated with early onset schizophrenia and 
bipolar disorder [243].  
Critical cellular processes, including adhesion, survival, proliferation, 
differentiation, and apoptotic pathways utilize Wnt signaling genes [244, 245]. Due to the 
crucial role Wnt pathways play in healthy cellular homeostasis, it is not surprising that 
many genes involved in this pathway were implicated in AD. Alterations to Wnt 
signaling pathways deregulated synaptic development and were suggested to play a role 
in the progression of AD [246]. As one of the susceptibility gene identified for sporadic 
AD from SNP studies discussed previously, CLU was shown to regulate Aβ toxicity via 
the non-canonical Wnt/phospholipase C pathway, as well as contributed to tau 
phosphorylation and cognitive decline [247]. Downregulation of WNT7B in an APP/PS1 
transgenic mouse model of AD was associated with synapse organization [248, 249], as 
well as altered expression of hippocampal WNT7B in AD subjects [250]. Finally, genetic 
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variations in LRP6 (LDL receptor related protein 6) were associated with APOE-ε4 allele 
and increased risk of developing sporadic AD [251]. 
Properly regulated energy mechanisms are essential to cellular function which is 
why deregulation of energy metabolism processing and mitochondrial function are major 
hallmarks of neurodegenerative diseases, including AD, Huntington’s disease, and 
Parkinson’s disease [252]. Key mechanisms, including electron transport chain processes, 
regulation of insulin signaling pathways, as well as the TCA cycle, are essential to the 
production of energy needed for healthy cellular function and maintaining homeostasis. 
Decreased expression of OGDH (oxoglutarate dehydrogenase), a TCA cycle regulator, 
was observed in brain regions of AD subjects as well as in a mouse model of AD 
pathology [253, 254]. Genes heavily involved in the electron transport chain, i.e. 
mitochondrial complexes I-V, had altered gene expression across several neurological 
dysfunction disorders, including NADH dehydrogenases (NDUFA3, NDUFA10, 
NDUFB3), ATP synthases (ATP5J and ATP5B), succinate dehydrogenase (SDSH), and 
ubiquinol-cytochrome c reductase (UQCRC2) [68, 255, 256]. Several insulin regulator 
genes, including INSR (insulin receptor) and IRS2 (insulin receptor substrate 2), 
necessary for synaptic plasticity and learning [257], also recruited GABA receptors to 
postsynaptic sites and controlled neurotransmitter release/uptake in glutamate receptors 
[258]. Although no conclusive studies have provided a link between AD and diabetes, 
insulin regulated pathways overlapping between the two diseases suggests a potential role 
in energy metabolism dysfunction and neurodegeneration [259].   
In addition to providing energy for cellular processes, energy metabolism 
pathways regulate axon guidance and development, as well as neuron stabilization where 
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deregulation of energy mechanisms adversely affects neuronal function. Several axon 
guidance regulators, including a family of axon guidance cues termed plexins and 
semaphorins, are upstream of tau phosphorylation pathways, and when deregulated, led 
to microtubule destabilization [260]. As an activator of Rho-GTPase pathways, PLXNB2 
was suggested to deregulate dendrite formation and maintenance [261], while genes of 
the SEMA3 family, including SEMA3B and SEMA3F, facilitated repulsive and attractive 
guidance mechanisms [262]. In a mouse model of AD, Aβ plaques disrupted the 
formation of axon initial segments, which require the scaffolding protein ANK3 (ankryin 
3 or ankryin G), ultimately reducing axon lengths and overall excitability of neurons 
[263].   
Cell cycle mechanisms ensure proper timing of cellular events and processes 
through a series of checkpoints to maintain healthy cellular function. Alterations to these 
mechanisms and cell function pathways are key characteristics of many diseases, 
including neurodegeneration and cancer [264, 265]. Some of these deregulated pathways 
include endocytosis, base excision repair (BER), NOTCH signaling, gene expression, and 
transcription. Oxidative damage to DNA and deregulated BER mechanisms are 
established features of neurodegeneration, including early stages in the progression of 
AD [52-54, 266]. Genes involved in BER processes, including OGG1 (8-oxoguanine 
glycosylase), TDG (thyamine dehydrogenase), and UNG (uracil-DNA glycosylase), 
showed decreased expression throughout the progression of AD [54, 267], as well as 
regulated epigenetic modifications to cytosine in the TET demethylation pathway [268]. 
Genes involved in endocytosis processes, a mechanism of active transport of extracellular 
substances brought into the cell, including TGFB1 and FGFR3, showed altered levels of 
 
164 
 
expression in an AD mouse model [248, 249, 269], while levels of TGFB1 were also 
elevated in CSF samples of clinically diagnosed probable AD patients [270]. As 
discussed previously, BIN1 was recently identified as a possible risk gene of sporadic 
AD, but studies also showed elevated expression of BIN1 [271] which may play a role in 
tau pathology development in AD [73].  
Along with DNA damage repair and trafficking mechanisms, cell cycle pathways 
also play a role in signaling and gene expression. Signaling cascades involving NOTCH 
regulate presenilin proteins and likely contribute to amyloid production and plaque 
formation. In a northern Israeli population, where an atypically high prevalence of 
sporadic AD occurs, SNPs in NOTCH4 were associated with sporadic AD [272]. 
Alterations in transcriptional regulatory genes, including NCOR2, TCF3, CREBBP, and 
NR2F6, showed adverse effects in neurodegenerative disease studies. In AD brain, 
NCOR2 affected memory formation [273], while hippocampal levels of TCF3 expression 
were increased [250]. Deficits in early memory and learning were associated with altered 
expression of CREBBP and NR2F6 in an animal model of AD [274], as well as lead to 
neuronal apoptosis [275]. While CDK7 is a component of the transcription factor 
complex activating RNA polymerase II as well as a cell cycle regulator, expression was 
increased in the hippocampus of AD subjects [276]. Mechanisms involving RNA 
polymerase also affect splicing pathway genes, including PTBP1, PRPF8, and CDC5L, 
where deregulation of these genes altered cell proliferation, neuron differentiation 
pathways, and repressed pre-mRNA splicing mechanisms [277, 278].  
Disruption of clearance mechanisms and pathways involved in protein 
degradation, including the ubiquitin-proteasome system, lead to accumulation of 
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aggregate-prone proteins within the cell, ultimately contributing to cell loss and 
neurodegeneration, however the exact mechanism is not well understood [279, 280]. 
While ubiquitination of proteins was associated with protein degradation, it was also 
shown to be an essential pathway for DNA repair, endocytosis, signaling, and trafficking 
mechanisms [281-283]. Compared to cognitively normal subjects, the proteasome protein 
PSMA1 was decreased in serum of mild cognitive impairment and probable AD subjects 
[284]. In addition, regulatory genes BTRC and FZR1, involved in ubiquitination 
mechanisms, also regulate Wnt signaling pathways. Levels of phosphorylated β-catenin 
were regulated by BTRC [285] and increased phosphorylated β-catenein lead to 
proteasome dysfunction [286].  
Lastly, the sixth module highlighted by enrichment analysis of epigenetically and 
transcriptionally deregulated genes in sporadic AD was related to cell structure and 
stabilization. Focal adhesions form between the actin cytoskeleton and membrane 
receptors within cells. By utilizing signaling mechanisms, focal adhesions reorganize the 
actin cytoskeleton as well as regulate gene expression by growth factor mediated 
signaling [287]. Upstream of actin polymerization and Wnt pathways, collagen proteins 
(COL4A1, COL4A3, COL6A2) and integrin receptors (ITGB4, ITGB5, ITGB8) also 
regulate extracellular matrix organization mechanisms. The phosphorylation of p21 
activated protein kinase 4 (PAK4) resulted in the dephosphorylation of slingshot protein, 
which led to the activation of cofilin, an actin severing protein, ultimately causing actin 
filament turnover [288]. In contrast, phosphorylation of LIM domain kinase proteins, 
including LIMK2, inactivated cofilin via phosphorylation and allowed for actin 
cytoskeleton reorganization [289]. In AD, current studies showed deregulation of cofilin 
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led to alterations in cytoskeleton maintenance and organization [290]. In addition to actin 
regulatory mechanisms, deregulation of neurexins and neuroligins led to alterations in 
dendritic spine morphology and NRXN1, a presynaptic ligand and component of the 
synaptic regulatory pathway, was linked to autism in a recent study [291-293].  
While this study was the first, to our knowledge, to analyze genome-wide 5-hmC 
levels in the hippocampus of sporadic AD subjects compared to NC, similar genome-
wide studies of AD post-mortem tissue showed related trends, where the majority of 
alterations showed increased levels of 5-hmC, although analysis techniques (single-base 
resolution mapping and 5-hmC enrichment analyses) and brain regions (hippocampus and 
prefrontal cortex) differed between the studies [239, 294]. Common to all three analyses, 
MYT1L (myelin transcription factor 1-like) showed altered 5-hmC levels in AD 
compared to NC subjects. While the function of MYT1L in AD has yet to be determined, 
one study used MYT1L to produce induced neuronal cells and described the gene as a 
neuronal fate-inducing factor [295].  
 While global levels of epigenetic modifications were altered in neurodegenerative 
disease subjects compared to NC using the GC/MS quantitative analysis described 
previously, no information about potential pathways specifically relevant to AD could be 
inferred. However, using a sensitive and selective 5-hmC mapping technique, altered 
hydroxymethylomes of LOAD subjects compared to NC were analyzed, and significantly 
altered levels of 5-hmC within genes with altered expression levels were mapped to 
pathways involved in signaling, energy metabolism, cell cycle mechanisms, gene 
expression, protein degradation, and cell structure and stabilization. Many target genes 
within these pathways were previously reported as genes of interest in neurodegenerative 
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disease studies as well as in studies of neuropsychological disorders. Epigenetic 
modifications to cytosine likely alter transcriptional states in these pathways in AD, 
leading to deregulated gene expression and may play a role in the pathogenesis of the 
disease.  
 While small sample sizes were a limitation of this study, it did provide gene 
targets to further characterize epigenetic modifications in AD using larger sample sizes. 
In the final section of this chapter, results of the qPCR and restriction endonuclease 
digestion study analyzing levels of 5-mC and 5-hmC at specific sequences within the 
exons of two genes relevant to sporadic AD will be discussed.  
 
5.3 Altered sites of 5-mC and 5-hmC in exons of PS1 and ABCA7 in early 
stages of AD 
 While sequencing technologies have advanced steadily, especially in analyses 
able to distinguish 5-mC from 5-hmC like RRHP previously described, costs remain 
high.  Since studies of human diseases require biological replicates for statistical analyses 
to draw meaningful conclusions, the use of currently available deep sequencing analyses 
are not ideal for larger subject group studies. In order to analyze gene-specific epigenetic 
modifications to DNA using multiple replicates, qPCR paired with specific restriction 
endonuclease digestion was used to analyze levels of cytosine, 5-mC, and 5-hmC within 
exons of two genes relevant to sporadic AD, PS1 and ABCA7. Both genes were shown to 
have altered expression in AD studies, as discussed below. While qPCR analyses were 
limited to one target amplicon for each reaction, analysis of single sites at several stages 
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of AD progression compared to NC subjects allowed for identification of possible targets 
of epigenetic regulation that may play role in the deregulation of transcription in AD.  
Mutations in PS1 are linked to the development of familial AD [14, 15], however 
various studies suggested alteration in this gene may play a role in the sporadic form of 
the disease as well. In a study of sporadic AD subjects compared to NC, mRNA and 
protein levels of PS1 and γ-secretase activity were elevated in the frontal cortex of AD 
cases, likely contributing to an overproduction of Aβ in sporadic AD brain [195]. A 
neuroblastoma cell culture study that manipulated the methionine pathway showed 
decreased levels of SAM deregulated the methylation status of the promoter of PS1, 
causing an increase in the expression of PS1 to increase production of Aβ [296], whereas 
another study found hypermethylation of the promoter of PS1 decreased expression and 
subsequently decreased Aβ production in neuroblastoma cells [297]. It should be noted 
that “methylation” in these studies would be better described as “modification” since the 
restriction enzyme used for methylation analyses, HpaII, is not specific for 5-mC, but 
rather modified (5-mC and 5-hmC) cytosine bases. Additionally, PS1 showed 
significantly altered (FDR p < 0.05) 5-hmC levels in our RRHP analysis of DhmRs 
within the hippocampus of LOAD subjects compared to NC (ellisonRRHPEDT.pdf), 
however did not meet criteria for the conservative adjusted p value cutoff used for 
network analysis. Collectively, these studies suggest a role of epigenetic modification in 
the regulation of PS1 in sporadic AD.  
While not as widely characterized as PS1, recent studies suggested a role of 
ABCA7 in sporadic AD, through genome-wide association studies as well as epigenetic 
modification analyses. ABCA7 is a transporter protein that may play a role in cholesterol 
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transport and phagocytosis mechanisms [73, 74]. In a mouse model of AD, deletion of 
ABCA7 led to an increase in Aβ accumulation, suggesting a possible role for ABCA7 in 
Aβ clearance in the brain [298]. Several genome-wide association studies found SNPs in 
ABCA7 associated with sporadic AD [71, 299, 300]. Several of these SNPs were 
associated with loss of function of ABCA7 in sporadic AD as well as altered mRNA 
expression [63, 197, 301]. Although increased and decreased mRNA expression levels of 
ABCA7 were reported in sporadic AD, loss of function variants likely lead to a decrease 
in overall protein expression [300]. In a recent bisulfite sequencing analysis of genome-
wide epigenetic modifications in the prefrontal cortex, ABCA7 was found as a target 
gene associated with sporadic AD [183]. In addition, a 5-mC enrichment study found 
ABCA7 to be hypermethylated in prefrontal cortex of AD subjects [235]. Similar to PS1, 
sites within ABCA7 were significantly altered (FDR p < 0.05) according to our RRHP 
study of LOAD compared to NC subjects, however did not meet criteria for the 
conservative adjusted p value cutoff used for network analysis.  
Single target recognition via specific primer sequence design is an essential 
component of qPCR analyses. Therefore, synthetic primers designed to target exon 
sequences within PS1 and ABCA7 genes were tested for specificity using endpoint PCR. 
As shown in Figure 4.16, nonspecific amplification was not detected for primer pairs 
targeting exon 4, 9, or 12 of PS1. Similarly, primer pairs designed to target sequences 
within exon 12, 18, 19, and 37 for ABCA7 showed no nonspecific amplification as 
depicted in Figure 4.21. Melt curve analyses were also conducted during qPCR 
experiments to test for specificity of primer pairs, but also to account for primer-dimer 
formations that may alter fluorescent detection of target amplification. Much like the 
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endpoint PCR analyses, melt curves for PS1 primers (Figure 4.17) and ABCA7 primers 
(Figure 4.22) showed no non-specific target amplification and no primer-dimer 
formation.  
 Multivariate analyses of epigenetic modifications within exon target sequences of 
NC, PCAD, MCI, and LOAD subject groups were conducted to determine statistically 
significant relationships between cytosine, 5-mC, and 5-hmC and the subject groups. To 
account for non-normal data distributions within the three dependent variables, Pillai’s 
Trace, the most robust multivariate test for MANOVA assumption violations [302], was 
used to determine statistically significant relationships. For all target sequences in exons 
of PS1 and ABCA7, the effect of subject group showed a statistically significant 
relationship to the multiple dependent variables (Pillai’s Trace, p < 0.001). Taking into 
account each dependent variable from the models, alterations among the subject groups 
were also detected for cytosine, 5-mC, and 5-hmC (Least Squares Regression, p < 0.05). 
To determine statistically significant differences between the subject groups, a least 
square difference (LSD) analysis was used. Results from these analyses are discussed 
below.  
 While significant relationships were shown between the subject groups and 
combined modifications (Pillai’s Trace) as well as between subject groups and each 
dependent variable (Least Squares Regression), significant differences of mean levels of 
each subject group were not detected for cytosine, 5-mC, or 5-hmC at target sequences of 
PS1, including either site of exon 4, exon 9, as well as both sites of exon 12. However, a 
trending towards significant difference was detected at the second site of exon 4, were 
levels of 5-mC were seemingly decreased in PCAD subjects compared to NC (p ≤ 0.1) 
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(Figure 4.30). To determine whether this difference may correlate to SMTG protein 
expression of PS1, isolated proteins were measured using Western blot analysis. As 
shown in Figure 4.38, no significant difference was shown between protein levels of 
PCAD compared to NC subjects, although elevated levels of PS1 were shown in MCI 
subjects compared to NC. 
 Epigenetic modifications within exons of ABCA7 showed similar results. While 
the multivariate analyses showed significant relationships between the subject groups and 
combined modifications (Pillai’s Trace), as well as for each cytosine base and subject 
groups (Least Squares Regression), statistically significant relationships were not 
observed between AD compared to NC subjects for cytosine, 5-mC, and 5-hmC levels in 
ABCA7 exons, including exon 12, 18, 19, and 37. However, multiple trending towards 
significant (p ≤ 0.1) relationships were discovered between PCAD and MCI subjects 
compared to NC. Levels of 5-mC were decreased in exon 12 of ABCA7 for MCI subjects 
compared to NC (Figure 4.34). In addition, levels of cytosine were also decreased in exon 
18 for both PCAD and MCI subjects compared to NC (Figure 4.35). Finally, levels of 5-
hmC were elevated for MCI subjects compared to NC in exon 37 of ABCA7 (Figure 
4.37). Interestingly, significant differences were detected between MCI and LOAD 
subjects in exon 12 of ABCA7, where elevation of 5-hmC was shown with a decrease in 
5-mC levels in MCI subjects compared to LOAD (p < 0.05).  To determine whether these 
suggested alterations were associated with altered SMTG levels of protein for each 
subject group, Western blot analysis was used. As shown in Figure 4.39, no significant 
differences were detected in protein levels of PCAD or MCI compared to NC subjects, 
but significantly decreased levels of ABCA7 were shown in LOAD subjects.  
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 While statistically significant differences in mean levels of cytosine, 5-mC, and 5-
hmC were not shown between stages of AD progression compared to NC subjects, this 
study does highlight subtle alterations in each epigenetic mark at various stages of AD, 
mainly confined to PCAD and MCI stages. Another interesting finding of this study was 
the variation in ratios of cytosine, 5-mC, and 5-hmC within exons of the same gene. 
While levels of each mark in ABCA7 showed little fluctuation between ratios in exons 
12, 18, and 37, where levels were 10% cytosine, 70% 5-mC, and 20% 5-hmC (Figure 
4.34, 4.35, and 4.37), levels of each mark in exon 19 shifted to 45% 5-mC and 45% 5-
hmC (Figure 4.36). In comparison, levels of each epigenetic mark remained relatively 
stable at both sites within exon 4 as well as exon 9, where levels were about 10% 
cytosine, 30% 5-mC, and 60% 5-hmC (Figure 4.29, 4.30, and 4.31). However, within 
exon 12, at site 2, levels shifted to 20% cytosine, 40% 5-mC, and 40% 5-hmC (Figure 
4.32), while at site 3, a large shift in epigenetic marks were observed compared to earlier 
exon levels, shifting to 50% cytosine, 35% 5-mC, and 15% 5-hmC (Figure 4.33). Not 
only do epigenetic patterns change within similar genomic elements of single genes (i.e. 
between exons of the same gene), but also patterns change within single exons, as shown 
in the shift in ratios of each mark within exon 12 of PS1. This shifting pattern may 
explain the discrepancy observed in previous studies attempting to correlate location 
specific 5-mC and 5-hmC modifications with gene expression data [144, 146, 147].  
 While SMTG protein levels of PS1 (Figure 4.33) and ABCA7 (Figure 4.34) were 
significantly altered compared to NC for some of the AD subject groups, these changes 
did not correlate to statistically significant epigenetic changes within exons of various 
stages of AD progression according to the MANOVA analyses. However, this study did 
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show that interrogation of specific target sites within genes of interest was possible and 
future analysis of site-specific alterations may lead to a better understanding of the role 
epigenetic modifications to cytosine play throughout the stages of AD progression.  
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CHAPTER SIX: CONCLUSIONS 
 Alzheimer’s disease currently affects more than 5 million patients, is the most 
common form of dementia and the sixth leading cause of death in the United States [13]. 
Accumulation of pathologic lesions of plaques and tangles within brain regions of AD 
patients leads to synapse and cell loss, eventually causing memory impairment and 
cognitive decline. With the baby boom generation approaching or at the age of onset of 
clinical indications of the disease, the effect on the healthcare system is projected to reach 
more than $250 billion by 2050 [13]. Although decades of research provided insight into 
facets of the disease mechanism, a lack of understanding of the etiology and aspects of 
pathogenesis have resulted in no viable therapeutic option to slow or halt 
neurodegeneration in AD [46].  
 While development of plaques in rare cases of familial AD were linked to gene 
mutations in amyloid processing genes, the same pathologic features occur in the brains 
of sporadic AD patients who lack these causal mutations. Efforts to find a genetic 
component of sporadic AD led to numerous genome-wide association studies of single 
nucleotide polymorphisms in post-mortem brain tissues and blood samples of AD 
subjects [71, 299, 300]. While several risk genes were discovered, including APOE-ε4, 
variations in these genes account for only 30 % of sporadic AD cases [13, 70]. Clearly, 
additional non-genetic factors must play a role in the deregulation of gene expression and 
transcription mechanisms found to be altered in early and late stages of AD progression. 
Associated with gene silencing, 5-mC was thought to be passively removed from 
DNA, allowing for gene expression mechanisms to be activated [106]. In 2009, with the 
discovery of enzymatic oxidization of 5-mC in mammalian genomes, oxidized 
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derivatives of 5-mC, including 5-hmC, were thought to be intermediates in an active 
TET-assisted demethylation pathway [113, 117]. However, current studies suggest 5-
hmC as a stable epigenetic mark within mammalian genomes, adding another layer of 
complexity to the role cytosine modifications assume in regulating transcription. While 5-
mC remains associated with gene repression, 5-hmC was suggested to activate genes, 
although regulation of either mark to gene expression likely depends on genomic location 
of modifications [147, 151]. The majority of studies analyzing 5-mC used bisulfite 
conversion to determine methylation states, but it was revealed this technique does not 
distinguish between 5-mC and 5-hmC [125], thus findings are more accurately described 
as cytosine modification rather than methylation. This is especially problematic in 
neurodegenerative disease studies of post-mortem brain tissues as levels of 5-hmC were 
found to be highly concentrated within mammalian brain and CNS samples.  
Previously reported analyses of 5-mC and 5-hmC levels in sporadic AD showed 
inconclusive findings, likely due to the semi-quantitative nature of immunochemical 
analyses. This dissertation, using a quantitative method pairing GC/MS and stable labeled 
cytosine standards, validates the suggested interaction between epigenetic modification 
and AD. Global alterations of cytosine, 5-mC, and 5-hmC were shown in early and late 
stages of AD compared to NC subjects. While significantly decreased levels of global 
cytosine in MCI subjects compared to NC were found, significantly elevated levels of 5-
hmC were quantified in PCAD and MCI subjects, and 5-mC levels were suggested to be 
elevated in LOAD subjects. This study also confirms neurodegenerative disease-specific 
alterations to cytosine modifications, in contrast to epigenetic changes explained by age-
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related epigenetic drift, where NC subjects were age-matched for AD subject groups, in 
addition to controlling for age and gender in the repeated measures analysis.  
Global alterations in cytosine modifications in FTLD and DLB subjects compared 
to NC show epigenetic modifications were not specific to AD but were common to 
several forms of neurodegeneration. Levels of cytosine and 5-mC were significantly 
decreased in FTLD/DLB subjects compared to NC, while global levels of 5-hmC were 
elevated. It should be noted that analyzed brain regions were chosen based on pathologic 
lesion susceptibility in AD progression, however AD affected brain regions may not be 
relevant to other types of neurodegeneration. Finally, as this dissertation shows, levels of 
5-mC and 5-hmC varied across brain regions, where compared to CER, regions 
susceptible to plaque and tangle pathology exhibited decreased levels of 5-mC and 5-
hmC, especially in the HPG and SMTG. Whether these findings reflect altered cell type 
distributions between brain regions or suggest epigenetic regulation plays more of a role 
in one brain region compared to another has yet to be determined.  
 While global analyses were used to confirm relevance of epigenetic modifications 
to neurodegenerative diseases, including but not specific to AD, global levels give no 
indication of possible pathways of interest that may be epigenetically regulated in 
neurodegeneration. While global alterations were shown to be common to 
neurodegenerative diseases, it is likely that pathways and genes are altered specifically 
related to AD. Several studies have shown genome-wide alterations in cytosine 
modifications in AD, however through bisulfite sequencing studies of the prefrontal 
cortex providing no information of whether sites were methylated or hydroxymethylated 
[175, 182, 183]. This dissertation shows an overall increase in significantly altered 
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genomic levels of hippocampal 5-hmC in LOAD compared to NC subjects, mainly 
confined to gene-associated regions. Interestingly, 85% of significantly altered regions of 
hydroxymethylation in LOAD compared to NC subjects were associated with promoter 
and genebody locations. This finding suggests a regulatory role of hydroxymethylation in 
altering gene expression and transcription mechanisms in the brain, although the exact 
function of 5-hmC within genomic elements remains poorly understood.  
A network analysis of interactions between the identified genes provided 
significantly altered pathways, both epigenetically and transcriptionally altered, relevant 
to AD mechanisms. Altered pathways were related to signaling cascades, energy 
metabolism and consumption, cell cycle mechanisms, gene expression and transcription, 
protein degradation and clearance pathways, as well as cell structure and stabilization 
mechanisms. Several of the genes identified in the aforementioned bisulfite studies, as 
well as genes identified in genome-wide association studies of sporadic AD, were 
significantly altered in our analysis, providing further evidence of altered 
hydroxymethylation in AD. In addition, similar mechanisms and pathways overlapped 
between two other hydroxymethylation mapping studies of sporadic AD subjects [239, 
294], even though mapping techniques and brain regions analyzed varied. To our 
knowledge, this is the first study to analyze genome-wide hydroxymethylation at single-
base resolution within the hippocampus of LOAD compared to NC subjects. This study 
also provided pathways and specific genes to target in future analyses, particularly in 
early stages of AD progression, including PCAD and MCI, to determine how 5-hmC 
affects pathogenesis mechanisms in AD and potentially lead to therapeutic discoveries.  
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To better understand gene specific roles epigenetic modifications may play 
throughout stages of AD progression, a quantitative method pairing qPCR and specific 
restriction enzyme digestion was used to determine levels of cytosine, 5-mC, and 5-hmC 
at specific target sequences within exons of two epigenetically regulated genes relevant to 
sporadic AD. As described previously, this study suggested subtle alterations in SMTG 
levels of cytosine, 5-mC, and 5-hmC in early stages of AD progression, including PCAD 
and MCI, compared to NC subjects. Although statistically significant differences between 
subject groups compared to NC were not shown according to the MANOVA analyses, 
suggested alterations warrant further analysis in future studies, particularly of epigenetic 
modifications within PCAD and MCI subjects. This study did highlight interesting 
aspects of the epigenetic landscape within exons of PS1 and ABCA7. Within similar 
genomic elements (i.e. exons) of one gene, epigenetic patterns shifted and ratios of 
cytosine/ 5-mC/ 5-hmC were altered depending on the exon analyzed for PS1 and 
ABCA7. In addition, epigenetic patterns changed within exons, as shown by two sites 
within exon 12 of PS1 with very different ratios of cytosine modifications. These findings 
indicate site-specific alterations within genes not only vary across exons of a single gene, 
but also within a single exon of the same gene. Whereas previous studies have used 
single locations to determine methylation or hydroxymethylation levels within genomic 
locations, i.e. one site to determine methylation of a promoter [296, 297], caution should 
be taken in extrapolating epigenetic patterns from a single CpG sequence.  
In conclusion, this dissertation provides evidence of altered epigenetic 
modifications in AD on global and gene specific scales, particularly in early stages of 
disease progression, including PCAD and MCI, compared to NC subjects. It also 
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indicates probable involvement of epigenetic mechanisms regulating gene expression of 
deregulated pathways implicated in the pathogenesis of AD. Future analyses of gene 
targets within these epigenetically regulated pathways, including signaling cascades, 
energy metabolism and consumption, cell cycle functions, and cytoskeletal structures and 
stabilization, may aid in the advancement of elucidating the disease mechanism, 
potentially contributing to the identification of a therapeutic option for combatting AD.  
 Looking to the future, the role cytosine modifications play in regulating gene 
expression within specific cell types, including neurons and glia, needs to be further 
elucidated, particularly with respect to AD pathology. To clarify a cell specific role of 
cytosine modification and development of AD pathology, cultures of pure neurons and 
glia could be treated with toxic oligomeric Aβ to induce an epigenetic response. To 
determine the response of Aβ-treatment in mixed cell types, a combined culture of 
neurons and glia could be used. Quantification of global levels of 5-mC and 5-hmC in 
Aβ-treated and untreated cells would be analyzed by mass spectrometry. In addition, gene 
specific alterations of cytosine modifications could be mapped throughout the genome 
using bisulfite conversion of cytosine modifications (5-mC + 5-hmC) by Zymo Research 
Corporations’ Methyl-MidiSeq technique, as well as 5-hmC specific modifications using 
the RRHP protocol. Epigenetic alterations could then be correlated with mRNA 
expression data and protein levels to distinguish between neuron-specific and glia-
specific fluctuations of 5-mC and 5-hmC, providing cell-type specific gene targets and 
biological pathways deregulated by toxic Aβ exposure. Analysis of induced epigenetic 
responses within each cell type would identify genes and pathways deregulated 
epigenetically as well as at the transcription and protein level during a key stage of AD 
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pathologic lesion development. Comparison with gene targets and pathways identified 
previously by RRHP in this dissertation, including pathways related to signaling, energy 
metabolism, cellular homeostasis, expression and cell structure, insight of neuron-specific 
alterations in LOAD subjects compared to NC could be elucidated. Together, these data 
would clarify the effect of early AD pathology development in deregulating the 
epigenetic machinery of brain cells, likely leading to targetable biological mechanisms 
for future AD prevention and/or treatment therapies. 
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APPENDIX A: ABBREVIATIONS 
[M]+ – molecular ion 
5-caC – 5-carboxylcytosine 
5-fC – 5-formylcytosine 
5-ghmC – glucosylated 5-hydroxymethylcytosine 
5-hmC – 5-hydroxymethylcytosine 
5-mC – 5-methylcytosine 
ABCA7 – ATP binding cassette subfamily A member 7 
AD – Alzheimer’s disease 
AICD – amyloid precursor protein intracellular domain 
ANOVA – analysis of variance  
APOE-Ԑ4 – apolipoprotein E allele Ԑ4 
APP – amyloid precursor protein   
Aβ – amyloid beta 
BAM – binary version of sequence alignment map 
BED – binary version of pedigree data 
BER – base excision repair 
bp – base pair 
BSTFA:TMCS – N,O-Bis(trimethylsilyl)trifluoroacetamide:Trimethylchlorosilane 
CCGG – cytosine cytosine guanine guanine sequence 
CER – cerebellum 
CERAD – Consortium to Establish a Registry for Alzheimer’s disease 
ChIP-seq – chromatin immunoprecipitation sequencing 
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CNS – central nervous system 
CpG – cytosine phosphate guanine sequence 
CSF – cerebral spinal fluid 
Ct – cycle threshold number  
DhmR – differentially hydroxymethylated region 
DLB – dementia with Lewy bodies 
DNA – deoxyribonucleic acid 
DNMT – DNA methyltransferase 
EC – entorhinal cortex 
ELISA – enzyme-linked immunosorbent assay 
EM – estimated mean 
FDA – Federal Drug Administration 
FDR – false discovery rate 
FTLD – frontal temporal lobar degeneration 
GAPDH - Glyceraldehyde 3-phosphate dehydrogenase 
GC/MS – gas chromatography mass spectrometry 
GLM – general linear regression model 
H3K27me1 – histone 3 lysine 27 single methylation 
H3K27me3 – histone 3 lysine 27 triple methylation 
HpaII - Haemophilus parainfluenzae type II restriction endonuclease 
HPG – hippocampus/parahippocampal gyrus 
IDH – isocitrate dehydrogenase 
IDT – Integrated DNA Technologies 
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IPL – inferior parietal lobe 
IS – internal standard 
LOAD – late onset Alzheimer’s disease 
LOQ – limit of quantification  
m/z – mass to charge ratio 
MANOVA – multivariate analysis of variance 
MCI – mild cognitive impairment 
MeCP2 – methyl CpG binding protein-2 
miRNA – micro ribonucleic acid 
MMSE – Mini Mental State Examination 
mRNA – messenger ribonucleic acid 
MspI - Moraxella species 1 type II restriction endonuclease  
NC – normal control 
ncRNA – noncoding ribonucleic acid 
NEB – New England Biolabs 
NFT – neurofibrillary tangle 
NIA-RI – National Institure of Aging-Reagan Institute 
nm – nanometer 
NMDA - N-methyl-D-aspartate 
oxBS-Seq – oxidative bisulfite sequencing 
PCAD – preclinical Alzheimer’s disease 
PD – Parkinson’s disease 
PERL – Practical Extraction and Reporting Language 
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PMI – post-mortem interval 
PS1 – presenilin-1 
PS2 – presenilin-2 
qPCR – quantitative polymerase chain reaction 
RFI – Reactome functional interaction  
ROS – reactive oxygen species 
RRHP – reduced representation hydroxymethylation profiling 
RT-PCR – real time polymerase chain reaction 
SAH – S-adenosyl homocysteine 
SAM – S-adenosyl methionine 
SD – standard deviation 
SDS-PAGE – sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SE – standard error 
SIM – single ion monitoring 
siRNA – short interfering ribonucleic acid 
SMTG – superior and middle temporal gyrus 
SNP – single nucleotide polymorphism 
SP – senile plaque 
SYBR green – N’,N'-dimethyl-N-[4-[(E)-(3-methyl-1,3-benzothiazol-2-
ylidene)methyl]-1-phenylquinolin-1-ium-2-yl]-N-propylpropane-1,3-diamine 
T4-βGT – T4 Phage beta glucose transferase 
TAB-Seq – TET assisted bisulfite sequencing 
TDG – thymine DNA-glycosylase 
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TET – ten eleven translocase 
TF – transcription factor 
UDP - Uridine diphosphate 
UHP – ultra high purity 
UK-ADC – University of Kentucky Alzheimer’s disease Center 
UTR – untranslated region 
UV – ultraviolet 
ZRC – Zymo Research Corporation 
αKG – alpha keto-glutarate 
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APPENDIX B: GENE SYMBOL AND NAME 
Symbol Gene Name 
AATK apoptosis associated tyrosine kinase(AATK) 
ABL1 ABL proto-oncogene 1, non-receptor tyrosine kinase(ABL1) 
ABLIM1 actin binding LIM protein 1(ABLIM1) 
ACAT1 acetyl-CoA acetyltransferase 1(ACAT1) 
ACTN1 actinin alpha 1(ACTN1) 
ACTR2 ARP2 actin related protein 2 homolog(ACTR2) 
ADCY2 adenylate cyclase 2(ADCY2) 
ADGRB3 Adhesion G Protein-Coupled Receptor B(ADGRB3) 
ADGRG1 Adhesion G Protein-Coupled Receptor G1 
AGPAT2 1-acylglycerol-3-phosphate O-acyltransferase 2(AGPAT2) 
AK5 adenylate kinase 5(AK5) 
AKAP12 A-kinase anchoring protein 12(AKAP12) 
AMFR autocrine motility factor receptor(AMFR) 
AMPD3 adenosine monophosphate deaminase 3(AMPD3) 
ANK3 ankyrin 3(ANK3) 
AP2B1 adaptor related protein complex 2 beta 1 subunit(AP2B1) 
APBA2 amyloid beta precursor protein binding family A member 2(APBA2) 
APC2 APC2, WNT signaling pathway regulator(APC2) 
ARHGEF10 Rho guanine nucleotide exchange factor 10(ARHGEF10) 
ARHGEF16 Rho guanine nucleotide exchange factor 16(ARHGEF16) 
ARIH2 ariadne RBR E3 ubiquitin protein ligase 2(ARIH2) 
ASMTL acetylserotonin O-methyltransferase-like(ASMTL) 
ATP1A2 ATPase Na+/K+ transporting subunit alpha 2(ATP1A2) 
ATP2B2 ATPase plasma membrane Ca2+ transporting 2(ATP2B2) 
ATP5B ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide(ATP5B) 
ATP5J ATP synthase, H+ transporting, mitochondrial Fo complex subunit F6(ATP5J) 
ATP5J2 ATP synthase, H+ transporting, mitochondrial Fo complex subunit F2(ATP5J2) 
BAIAP3 BAI1 associated protein 3(BAIAP3) 
BANP BTG3 associated nuclear protein(BANP) 
BCL11B B-cell CLL/lymphoma 11B(BCL11B) 
BCL7A BCL tumor suppressor 7A(BCL7A) 
BGN biglycan(BGN) 
BIN1 bridging integrator 1(BIN1) 
BRD1 bromodomain containing 1(BRD1) 
BRD4 bromodomain containing 4(BRD4) 
BTRC beta-transducin repeat containing E3 ubiquitin protein ligase(BTRC) 
C4B complement C4B (Chido blood group)(C4B) 
CA11 carbonic anhydrase 11(CA11) 
CACNA1A calcium voltage-gated channel subunit alpha1 A(CACNA1A) 
CADPS calcium dependent secretion activator(CADPS) 
CALM3 calmodulin 3(CALM3) 
CAMKK2 calcium/calmodulin dependent protein kinase kinase 2(CAMKK2) 
CAP2 CAP, adenylate cyclase-associated protein, 2 (yeast)(CAP2) 
CCNA1 cyclin A1(CCNA1) 
CCND3 cyclin D3(CCND3) 
CDC34 cell division cycle 34(CDC34) 
CDC5L cell division cycle 5 like(CDC5L) 
CDH10 cadherin 10(CDH10) 
CDH13 cadherin 13(CDH13) 
CDH4 cadherin 4(CDH4) 
CDK7 cyclin dependent kinase 7(CDK7) 
CEBPD CCAAT/enhancer binding protein delta(CEBPD) 
CEPT1 choline/ethanolamine phosphotransferase 1(CEPT1) 
CHD2 chromodomain helicase DNA binding protein 2(CHD2) 
CHST3 carbohydrate sulfotransferase 3(CHST3) 
CLIC2 chloride intracellular channel 2(CLIC2) 
CLU clusterin(CLU) 
CNTNAP2 contactin associated protein-like 2(CNTNAP2) 
COL21A1 collagen type XXI alpha 1 chain(COL21A1) 
COL4A1 collagen type IV alpha 1 chain(COL4A1) 
COL4A3 collagen type IV alpha 3 chain(COL4A3) 
COL6A2 collagen type VI alpha 2 chain(COL6A2) 
COMT catechol-O-methyltransferase(COMT) 
CPSF1 cleavage and polyadenylation specific factor 1(CPSF1) 
CPT1B carnitine palmitoyltransferase 1B(CPT1B) 
CR1 complement C3b/C4b receptor 1 (Knops blood group)(CR1) 
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CREBBP CREB binding protein(CREBBP) 
CRIM1 cysteine rich transmembrane BMP regulator 1(CRIM1) 
CSK c-src tyrosine kinase(CSK) 
CSNK1E casein kinase 1 epsilon(CSNK1E) 
CTBP1 C-terminal binding protein 1(CTBP1) 
CTBP2 C-terminal binding protein 2(CTBP2) 
CTPS2 CTP synthase 2(CTPS2) 
CUL5 cullin 5(CUL5) 
DAG1 dystroglycan 1(DAG1) 
DAPK2 death associated protein kinase 2(DAPK2) 
DAPK3 death associated protein kinase 3(DAPK3) 
DDX27 DEAD-box helicase 27(DDX27) 
DGCR6 DiGeorge syndrome critical region gene 6(DGCR6) 
DGKG diacylglycerol kinase gamma(DGKG) 
DIAPH2 diaphanous related formin 2(DIAPH2) 
DLEU1 deleted in lymphocytic leukemia 1(DLEU1) 
DLGAP1 DLG associated protein 1(DLGAP1) 
DLGAP2 DLG associated protein 2(DLGAP2) 
DMD dystrophin(DMD) 
DRAP1 DR1 associated protein 1(DRAP1) 
EDAR ectodysplasin A receptor(EDAR) 
EHD1 EH domain containing 1(EHD1) 
ELF2 E74 like ETS transcription factor 2(ELF2) 
EML2 echinoderm microtubule associated protein like 2(EML2) 
ENAH enabled homolog (Drosophila)(ENAH) 
ENSA endosulfine alpha(ENSA) 
ENTPD3 ectonucleoside triphosphate diphosphohydrolase 3(ENTPD3) 
EPS15 epidermal growth factor receptor pathway substrate 15(EPS15) 
F2R coagulation factor II thrombin receptor(F2R) 
FADS1 fatty acid desaturase 1(FADS1) 
FBXL2 F-box and leucine rich repeat protein 2(FBXL2) 
FEZ2 fasciculation and elongation protein zeta 2(FEZ2) 
FGFR3 fibroblast growth factor receptor 3(FGFR3) 
FGL1 fibrinogen like 1(FGL1) 
FLNA filamin A(FLNA) 
FLNC filamin C(FLNC) 
FOLH1 folate hydrolase 1(FOLH1) 
FRAT1 frequently rearranged in advanced T-cell lymphomas 1(FRAT1) 
FSTL1 follistatin like 1(FSTL1) 
FYCO1 FYVE and coiled-coil domain containing 1(FYCO1) 
FZR1 fizzy/cell division cycle 20 related 1(FZR1) 
G6PD glucose-6-phosphate dehydrogenase(G6PD) 
GAK cyclin G associated kinase(GAK) 
GBAS glioblastoma amplified sequence(GBAS) 
GDF1 growth differentiation factor 1(GDF1) 
GHITM growth hormone inducible transmembrane protein(GHITM) 
GLI2 GLI family zinc finger 2(GLI2) 
GLTSCR2 glioma tumor suppressor candidate region gene 2(GLTSCR2) 
GMEB2 glucocorticoid modulatory element binding protein 2(GMEB2) 
GNA12 G protein subunit alpha 12(GNA12) 
GNA14 G protein subunit alpha 14(GNA14) 
GNAL G protein subunit alpha L(GNAL) 
GNAO1 G protein subunit alpha o1(GNAO1) 
GNAS GNAS complex locus(GNAS) 
GNAZ G protein subunit alpha z(GNAZ) 
GOSR2 golgi SNAP receptor complex member 2(GOSR2) 
GPC5 glypican 5(GPC5) 
GPI glucose-6-phosphate isomerase(GPI) 
GPM6B glycoprotein M6B(GPM6B) 
GPR4 G protein-coupled receptor 4(GPR4) 
GRIA3 glutamate ionotropic receptor AMPA type subunit 3(GRIA3) 
GRIN2A glutamate ionotropic receptor NMDA type subunit 2A(GRIN2A) 
GRM6 glutamate metabotropic receptor 6(GRM6) 
GUK1 guanylate kinase 1(GUK1) 
H2AFX H2A histone family member X(H2AFX) 
HADHA hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), alpha subunit(HADHA) 
HBA1 hemoglobin subunit alpha 1(HBA1) 
HDAC4 histone deacetylase 4(HDAC4) 
HTR2A 5-hydroxytryptamine receptor 2A(HTR2A) 
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IL6R interleukin 6 receptor(IL6R) 
INSR insulin receptor(INSR) 
IQGAP1 IQ motif containing GTPase activating protein 1(IQGAP1) 
IRF7 interferon regulatory factor 7(IRF7) 
IRS2 insulin receptor substrate 2(IRS2) 
ITGB4 integrin subunit beta 4(ITGB4) 
ITGB5 integrin subunit beta 5(ITGB5) 
ITGB8 integrin subunit beta 8(ITGB8) 
ITPK1 inositol-tetrakisphosphate 1-kinase(ITPK1) 
ITPR1 inositol 1,4,5-trisphosphate receptor type 1(ITPR1) 
JPH3 junctophilin 3(JPH3) 
JRK Jrk helix-turn-helix protein(JRK) 
JUND JunD proto-oncogene, AP-1 transcription factor subunit(JUND) 
KCNA6 potassium voltage-gated channel subfamily A member 6(KCNA6) 
KCNAB1 potassium voltage-gated channel subfamily A member regulatory beta subunit 1(KCNAB1) 
KCNAB2 potassium voltage-gated channel subfamily A regulatory beta subunit 2(KCNAB2) 
KCNJ14 potassium voltage-gated channel subfamily J member 14(KCNJ14) 
KCNN3 potassium calcium-activated channel subfamily N member 3(KCNN3) 
KIF13B kinesin family member 13B(KIF13B) 
KLF1 Kruppel like factor 1(KLF1) 
L1CAM L1 cell adhesion molecule(L1CAM) 
LARGE1 LARGE Xylosyl- And Glucuronyltransferase 1 
LDLR low density lipoprotein receptor(LDLR) 
LILRA2 leukocyte immunoglobulin like receptor A2(LILRA2) 
LIMK2 LIM domain kinase 2(LIMK2) 
LMNA lamin A/C(LMNA) 
LPIN1 lipin 1(LPIN1) 
LRP1B LDL receptor related protein 1B(LRP1B) 
LRP6 LDL receptor related protein 6(LRP6) 
LRP8 LDL receptor related protein 8(LRP8) 
LTBP2 latent transforming growth factor beta binding protein 2(LTBP2) 
LZTS1 leucine zipper tumor suppressor 1(LZTS1) 
MADCAM1 mucosal vascular addressin cell adhesion molecule 1(MADCAM1) 
MAFF MAF bZIP transcription factor F(MAFF) 
MAFG MAF bZIP transcription factor G(MAFG) 
MAGED1 MAGE family member D1(MAGED1) 
MAN2B1 mannosidase alpha class 2B member 1(MAN2B1) 
MAP2K3 mitogen-activated protein kinase kinase 3(MAP2K3) 
MAP2K7 mitogen-activated protein kinase kinase 7(MAP2K7) 
MAP3K11 mitogen-activated protein kinase kinase kinase 11(MAP3K11) 
MAPRE3 microtubule associated protein RP/EB family member 3(MAPRE3) 
MATN2 matrilin 2(MATN2) 
MBD3 methyl-CpG binding domain protein 3(MBD3) 
MGA MGA, MAX dimerization protein(MGA) 
MGLL monoglyceride lipase(MGLL) 
MKNK2 MAP kinase interacting serine/threonine kinase 2(MKNK2) 
MLC1 megalencephalic leukoencephalopathy with subcortical cysts 1(MLC1) 
MPST mercaptopyruvate sulfurtransferase(MPST) 
MT1L metallothionein 1L (gene/pseudogene)(MT1L) 
MTA1 metastasis associated 1(MTA1) 
MTF1 metal regulatory transcription factor 1(MTF1) 
MUC3A mucin 3A, cell surface associated(MUC3A) 
MYO1C myosin IC(MYO1C) 
MYO1F myosin IF(MYO1F) 
MYO9B myosin IXB(MYO9B) 
MYT1L myelin transcription factor 1 like(MYT1L) 
NAV2 neuron navigator 2(NAV2) 
NCOR2 nuclear receptor corepressor 2(NCOR2) 
NDRG4 NDRG family member 4(NDRG4) 
NDST1 N-deacetylase and N-sulfotransferase 1(NDST1) 
NDUFA10 NADH:ubiquinone oxidoreductase subunit A10(NDUFA10) 
NDUFA3 NADH:ubiquinone oxidoreductase subunit A3(NDUFA3) 
NDUFB3 NADH:ubiquinone oxidoreductase subunit B3(NDUFB3) 
NELL1 neural EGFL like 1(NELL1) 
NFATC1 nuclear factor of activated T-cells 1(NFATC1) 
NFIC nuclear factor I C(NFIC) 
NMB neuromedin B(NMB) 
NME3 NME/NM23 nucleoside diphosphate kinase 3(NME3) 
NME4 NME/NM23 nucleoside diphosphate kinase 4(NME4) 
NOTCH4 notch 4(NOTCH4) 
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NPAS2 neuronal PAS domain protein 2(NPAS2) 
NPAS3 neuronal PAS domain protein 3(NPAS3) 
NR2F6 nuclear receptor subfamily 2 group F member 6(NR2F6) 
NRN1 neuritin 1(NRN1) 
NRXN1 neurexin 1(NRXN1) 
ODC1 ornithine decarboxylase 1(ODC1) 
OGDH oxoglutarate dehydrogenase(OGDH) 
OGG1 8-oxoguanine DNA glycosylase(OGG1) 
OSBPL10 oxysterol binding protein like 10(OSBPL10) 
PACSIN2 protein kinase C and casein kinase substrate in neurons 2(PACSIN2) 
PAK4 p21 (RAC1) activated kinase 4(PAK4) 
PAX6 paired box 6(PAX6) 
PDE4C phosphodiesterase 4C(PDE4C) 
PER1 period circadian clock 1(PER1) 
PEX10 peroxisomal biogenesis factor 10(PEX10) 
PKNOX2 PBX/knotted 1 homeobox 2(PKNOX2) 
PLCB1 phospholipase C beta 1(PLCB1) 
PLCE1 phospholipase C epsilon 1(PLCE1) 
PLCG2 phospholipase C gamma 2(PLCG2) 
PLCL2 phospholipase C like 2(PLCL2) 
PLOD3 procollagen-lysine,2-oxoglutarate 5-dioxygenase 3(PLOD3) 
PLXNA1 plexin A1(PLXNA1) 
PLXNB2 plexin B2(PLXNB2) 
PML promyelocytic leukemia(PML) 
POLRMT RNA polymerase mitochondrial(POLRMT) 
PPP1R15A protein phosphatase 1 regulatory subunit 15A(PPP1R15A) 
PPP2R2B protein phosphatase 2 regulatory subunit Bbeta(PPP2R2B) 
PRDX3 peroxiredoxin 3(PRDX3) 
PRKAR1B protein kinase cAMP-dependent type I regulatory subunit beta(PRKAR1B) 
PRKAR2B protein kinase cAMP-dependent type II regulatory subunit beta(PRKAR2B) 
PRL prolactin(PRL) 
PRPF4B pre-mRNA processing factor 4B(PRPF4B) 
PRPF8 pre-mRNA processing factor 8(PRPF8) 
PSMA1 proteasome subunit alpha 1(PSMA1) 
PTBP1 polypyrimidine tract binding protein 1(PTBP1) 
PTN pleiotrophin(PTN) 
PTRF polymerase I and transcript release factor(PTRF) 
QARS glutaminyl-tRNA synthetase(QARS) 
RAB22A RAB22A, member RAS oncogene family(RAB22A) 
RALBP1 ralA binding protein 1(RALBP1) 
RALGDS ral guanine nucleotide dissociation stimulator(RALGDS) 
RAMP1 receptor activity modifying protein 1(RAMP1) 
RANBP3 RAN binding protein 3(RANBP3) 
RBL1 RB transcriptional corepressor like 1(RBL1) 
REC8 REC8 meiotic recombination protein(REC8) 
RGS12 regulator of G-protein signaling 12(RGS12) 
RNF11 ring finger protein 11(RNF11) 
RPS6KA1 ribosomal protein S6 kinase A1(RPS6KA1) 
RREB1 ras responsive element binding protein 1(RREB1) 
RTN1 reticulon 1(RTN1) 
SCAMP3 secretory carrier membrane protein 3(SCAMP3) 
SCLY selenocysteine lyase(SCLY) 
SDHD succinate dehydrogenase complex subunit D(SDHD) 
SEC14L1 SEC14 like lipid binding 1(SEC14L1) 
SEMA3B semaphorin 3B(SEMA3B) 
SEMA3F semaphorin 3F(SEMA3F) 
SH3BP2 SH3 domain binding protein 2(SH3BP2) 
SH3GLB2 SH3 domain containing GRB2 like endophilin B2(SH3GLB2) 
SHANK2 SH3 and multiple ankyrin repeat domains 2(SHANK2) 
SIRT6 sirtuin 6(SIRT6) 
SIRT7 sirtuin 7(SIRT7) 
SLC12A7 solute carrier family 12 member 7(SLC12A7) 
SLC19A1 solute carrier family 19 member 1(SLC19A1) 
SLC1A7 solute carrier family 1 member 7(SLC1A7) 
SLC25A12 solute carrier family 25 member 12(SLC25A12) 
SLC25A6 solute carrier family 25 member 6(SLC25A6) 
SLC2A9 solute carrier family 2 member 9(SLC2A9) 
SLC6A8 solute carrier family 6 member 8(SLC6A8) 
SLC7A5 solute carrier family 7 member 5(SLC7A5) 
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SMARCA2 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2(SMARCA2) 
SNRPD2 small nuclear ribonucleoprotein D2 polypeptide(SNRPD2) 
SNTA1 syntrophin alpha 1(SNTA1) 
SNTG1 syntrophin gamma 1(SNTG1) 
SORBS1 sorbin and SH3 domain containing 1(SORBS1) 
SPIB Spi-B transcription factor(SPIB) 
SPTLC2 serine palmitoyltransferase long chain base subunit 2(SPTLC2) 
SREBF1 sterol regulatory element binding transcription factor 1(SREBF1) 
SREBF2 sterol regulatory element binding transcription factor 2(SREBF2) 
SSBP1 single stranded DNA binding protein 1(SSBP1) 
STAG2 stromal antigen 2(STAG2) 
STK10 serine/threonine kinase 10(STK10) 
STK11 serine/threonine kinase 11(STK11) 
STK24 serine/threonine kinase 24(STK24) 
SYN2 synapsin II(SYN2) 
SYNGR3 synaptogyrin 3(SYNGR3) 
TBC1D2 TBC1 domain family member 2(TBC1D2) 
TCEAL1 transcription elongation factor A like 1(TCEAL1) 
TCF3 transcription factor 3(TCF3) 
TCF7 transcription factor 7 (T-cell specific, HMG-box)(TCF7) 
TCOF1 treacle ribosome biogenesis factor 1(TCOF1) 
TDG thymine DNA glycosylase(TDG) 
TFAP2A transcription factor AP-2 alpha(TFAP2A) 
TGFB1 transforming growth factor beta 1(TGFB1) 
THRA thyroid hormone receptor, alpha(THRA) 
TIGAR TP53 Induced Glycolysis Regulatory Phosphatase 
TIMM44 translocase of inner mitochondrial membrane 44(TIMM44) 
TLE3 transducin like enhancer of split 3(TLE3) 
TNXB tenascin XB(TNXB) 
TPD52 tumor protein D52(TPD52) 
TREX2 three prime repair exonuclease 2(TREX2) 
TRIM14 tripartite motif containing 14(TRIM14) 
TRIM26 tripartite motif containing 26(TRIM26) 
TRIM36 tripartite motif containing 36(TRIM36) 
TRPV1 transient receptor potential cation channel subfamily V member 1(TRPV1) 
TTC3 tetratricopeptide repeat domain 3(TTC3) 
TUBG2 tubulin gamma 2(TUBG2) 
TYK2 tyrosine kinase 2(TYK2) 
UBE3B ubiquitin protein ligase E3B(UBE3B) 
ULK2 unc-51 like autophagy activating kinase 2(ULK2) 
UNG uracil DNA glycosylase(UNG) 
UQCRC2 ubiquinol-cytochrome c reductase core protein II(UQCRC2) 
USP3 ubiquitin specific peptidase 3(USP3) 
UST uronyl 2-sulfotransferase(UST) 
VARS2 valyl-tRNA synthetase 2, mitochondrial(VARS2) 
VWF von Willebrand factor(VWF) 
WFDC1 WAP four-disulfide core domain 1(WFDC1) 
WFDC2 WAP four-disulfide core domain 2(WFDC2) 
WFS1 wolframin ER transmembrane glycoprotein(WFS1) 
WNT7B Wnt family member 7B(WNT7B) 
WRB tryptophan rich basic protein(WRB) 
WWOX WW domain containing oxidoreductase(WWOX) 
ZDHHC11 zinc finger DHHC-type containing 11(ZDHHC11) 
ZIC1 Zic family member 1(ZIC1) 
ZNF142 zinc finger protein 142(ZNF142) 
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APPENDIX C: RFI SIGNIFICANTLY ENRICHED PATHWAYS 
 
Module Pathway FDR Target Genes 
0 Glutamatergic synapse(K) 1.14E-06 ADCY2,PLCB1,GRIN2A,GRM6,GNAS,DLGAP1, GNAO1,GRIA3,SHANK2,CACNA1A 
0 Opioid Signalling(R) 1.27E-06 GNAZ,ADCY2,PRKAR2B,PLCB1,PDE4C,GNAL, GNAO1,PRKAR1B 
0 Calcium signaling pathway(K) 2.23E-06 
GNA14,ADCY2,PLCB1,GRIN2A,GNAL,PLCE1, 
GNAS,PLCG2,CACNA1A,F2R,HTR2A 
0 Long-term depression(K) 1.15E-05 GNAZ,GNA12,PLCB1,GNAS,GNAO1,GRIA3, CACNA1A 
0 Endothelins(N) 1.15E-05 GNAZ,GNA14,ADCY2,GNA12,PLCB1,GNAL, GNAO1 
0 Phospholipase D signaling pathway(K) 1.97E-05 
ADCY2,GNA12,PLCB1,GRM6,GNAS,DGKG, 
RALGDS,PLCG2,F2R 
0 PAR1-mediated thrombin signaling events(N) 1.97E-05 GNAZ,GNA14,GNA12,PLCB1,GNAO1,F2R 
0 Integration of energy metabolism(R) 7.85E-05 
ADCY2,IQGAP1,PRKAR2B,GNAS,STK11, 
PRKAR1B,CACNA1A 
0 Inflammatory mediator regulation of TRP channels(K) 1.31E-04 
ADCY2,TRPV1,PLCB1,GNAS,MAP2K3,PLCG2, 
HTR2A 
0 Rap1 signaling pathway(K) 2.61E-04 ADCY2,PLCB1,GRIN2A,PLCE1,GNAS,GNAO1, MAP2K3,RALGDS,F2R 
0 Plasma membrane estrogen receptor signaling(N) 2.61E-04 GNAZ,GNA14,PLCB1,GNAL,GNAO1 
0 Sphingosine 1-phosphate (S1P) pathway(N) 3.39E-04 GNAZ,GNA14,GNA12,GNAO1 
0 Dopaminergic synapse(K) 5.18E-04 PLCB1,GRIN2A,GNAL,GNAS,GNAO1,GRIA3, CACNA1A 
0 S1P5 pathway(N) 5.18E-04 GNAZ,GNA12,GNAO1 
0 S1P3 pathway(N) 5.18E-04 GNAZ,GNA14,GNA12,GNAO1 
0 
Vasopressin regulates renal 
water homeostasis via 
Aquaporins(R) 
5.28E-04 ADCY2,PRKAR2B,GNAS,PRKAR1B 
0 S1P2 pathway(N) 5.28E-04 GNAZ,GNA14,GNA12,GNAO1 
0 Circadian entrainment(K) 6.69E-04 ADCY2,PLCB1,GRIN2A,GNAS,GNAO1,GRIA3 
0 cAMP signaling pathway(K) 7.41E-04 ADCY2,GRIN2A,PDE4C,PLCE1,GNAS,NFATC1, GRIA3,F2R 
0 LPA receptor mediated events(N) 9.76E-04 GNAZ,GNA14,ADCY2,GNA12,GNAO1 
0 S1P4 pathway(N) 1.79E-03 GNAZ,GNA12,GNAO1 
0 GPCR downstream signaling(R) 2.08E-03 
GNAZ,GNA14,ADCY2,GNA12,PLCB1,RAMP1, 
ARHGEF16,PDE4C,GNAL,GRM6,GNAS, 
NMB,GPR4,DGKG,F2R,HTR2A 
0 Inositol phosphate metabolism(R) 2.54E-03 PLCB1,ITPK1,PLCE1,PLCG2 
0 
Thrombin signalling through 
proteinase activated receptors 
(PARs)(R) 
2.78E-03 GNA14,GNA12,F2R 
0 Pathways in cancer(K) 2.78E-03 ADCY2,GNA12,PLCB1,RALBP1,GNAS,RALGDS, WNT7B,PLCG2,ABL1,F2R 
0 Morphine addiction(K) 3.89E-03 ADCY2,PDE4C,GNAS,GNAO1,CACNA1A 
0 Wnt signaling pathway(P) 3.89E-03 GNA14,PLCB1,CDH4,NFATC1,CDH13,WNT7B, LRP6,CDH10 
0 
Muscarinic acetylcholine 
receptor 2 and 4 signaling 
pathway(P) 
4.08E-03 PRKAR2B,PRKAR1B 
0 
Heterotrimeric G-protein 
signaling pathway-Gi alpha and 
Gs alpha mediated pathway(P) 
4.26E-03 ADCY2,PRKAR2B,GNAL,GRM6,PRKAR1B,HTR2A 
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0 Phosphatidylinositol signaling system(K) 5.00E-03 PLCB1,ITPK1,PLCE1,DGKG,PLCG2 
0 Melanogenesis(K) 5.25E-03 ADCY2,PLCB1,GNAS,GNAO1,WNT7B 
0 Retrograde endocannabinoid signaling(K) 5.25E-03 ADCY2,PLCB1,GNAO1,GRIA3,CACNA1A 
0 Oxytocin signaling pathway(K) 5.44E-03 ADCY2,KCNJ14,PLCB1,GNAS,NFATC1,GNAO1 
0 Chagas disease (American trypanosomiasis)(K) 5.44E-03 GNA14,PLCB1,GNAL,GNAS,GNAO1 
0 Cholinergic synapse(K) 7.29E-03 ADCY2,KCNJ14,PLCB1,GNAO1,CACNA1A 
0 Serotonergic synapse(K) 7.59E-03 PLCB1,GNAS,GNAO1,CACNA1A,HTR2A 
0 Vascular smooth muscle contraction(K) 9.64E-03 ADCY2,GNA12,PLCB1,RAMP1,GNAS 
0 CDC42 signaling events(N) 9.64E-03 ENAH,IQGAP1,ACTR2,MAP2K3 
0 Inositol phosphate metabolism(K) 0.0102 PLCB1,ITPK1,PLCE1,PLCG2 
0 DAG and IP3 signaling(R) 0.0105 ADCY2,PRKAR2B,PRKAR1B 
0 
Inflammation mediated by 
chemokine and cytokine 
signaling pathway(P) 
0.0112 PLCB1,PLCE1,PLCL2,PLCG2 
0 Platelet activation(K) 0.0117 ADCY2,PLCB1,GNAS,PLCG2,F2R 
0 CXCR3-mediated signaling events(N) 0.012 GNAZ,GNAO1,MAP2K3 
0 Metabotropic glutamate receptor group II pathway(P) 0.0125 PRKAR2B,PRKAR1B 
0 
Neurotransmitter Receptor 
Binding And Downstream 
Transmission In The  
Postsynaptic Cell(R) 
0.0125 ADCY2,PLCB1,GRIN2A,GNAL,GRIA3 
0 CXCR4-mediated signaling events(N) 0.0134 GNAZ,PLCB1,CSK,GNAO1 
0 Hedgehog signaling pathway(P) 0.0134 PRKAR2B,PRKAR1B 
0 
Gastrin-CREB signalling 
pathway via PKC and 
MAPK(R) 
0.0145 GNA14,PLCB1,GRIN2A,NMB,GPR4,DGKG,F2R, HTR2A 
0 Nicotine addiction(K) 0.0153 GRIN2A,GRIA3,CACNA1A 
0 Gap junction(K) 0.0172 ADCY2,PLCB1,GNAS,HTR2A 
0 Potassium Channels(R) 0.0186 KCNAB2,KCNAB1,KCNJ14,KCNA6 
0 GnRH signaling pathway(K) 0.0194 ADCY2,PLCB1,GNAS,MAP2K3 
0 Ras signaling pathway(K) 0.0219 RALBP1,GRIN2A,PLCE1,RALGDS,PLCG2,ABL1 
0 
Posttranslational regulation of 
adherens junction stability and 
dissassembly(N) 
0.0219 GNA12,IQGAP1,ABL1 
0 Estrogen signaling pathway(K) 0.0224 ADCY2,PLCB1,GNAS,GNAO1 
0 Signaling by Rho GTPases(R) 0.0266 IQGAP1,ACTR2,RALBP1,ARHGEF16,DIAPH2, MYO9B,ABL1 
0 LPA4-mediated signaling events(N) 0.0269 ADCY2,GNAL 
0 
aspirin blocks signaling 
pathway involved in platelet 
activation(B) 
0.0269 PLCB1,F2R 
0 RAC1 signaling pathway(N) 0.0269 IQGAP1,ACTR2,MAP2K3 
0 Amoebiasis(K) 0.0269 GNA14,PLCB1,GNAL,GNAS 
0 
Heterotrimeric G-protein 
signaling pathway-Gq alpha 
and Go alpha mediated 
pathway(P) 
0.0269 PLCB1,GRM6,GNAO1,CACNA1A 
0 Endothelin signaling pathway(P) 0.0269 ADCY2,PRKAR2B,PRKAR1B 
0 nitric oxide signaling pathway(B) 0.0269 PRKAR2B,GRIN2A 
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0 Alzheimer disease-presenilin pathway(P) 0.0279 ACTR2,LRP1B,WNT7B,LRP6 
0 
Factors involved in 
megakaryocyte development 
and platelet production(R) 
0.0288 PRKAR2B,ITPK1,PRKAR1B,ABL1 
0 
gata3 participate in activating 
the th2 cytokine genes 
expression(B) 
0.03 PRKAR2B,MAP2K3 
0 S1P1 pathway(N) 0.0333 GNAZ,GNAO1 
0 PDGFR-beta signaling pathway(N) 0.0365 IQGAP1,ACTR2,CSK,ABL1 
0 Canonical Wnt signaling pathway(N) 0.0367 RANBP3,LRP6 
0 
pkc-catalyzed phosphorylation 
of inhibitory phosphoprotein of 
myosin phosphatase(B) 
0.0384 PLCB1,CACNA1A 
0 Neuroactive ligand-receptor interaction(K) 0.0384 TRPV1,GRIN2A,GRM6,GRIA3,F2R,HTR2A 
0 BCR signaling pathway(N) 0.0384 CSK,NFATC1,PLCG2 
0 regulation of ck1/cdk5 by type 1 glutamate receptors(B) 0.0384 PRKAR2B,PLCB1 
0 Amphetamine addiction(K) 0.0384 GRIN2A,GNAS,GRIA3 
0 signaling pathway from g-protein families(B) 0.0384 PRKAR2B,PLCB1 
0 Signaling by Robo receptor(R) 0.0384 ENAH,ABL1 
0 Complement and coagulation cascades(K) 0.0395 C4B,CR1,F2R 
0 Cell junction organization(R) 0.041 CDH4,CDH13,CDH10 
0 Thyroid hormone synthesis(K) 0.0426 ADCY2,PLCB1,GNAS 
0 fmlp induced chemokine gene expression in hmc-1 cells(B) 0.045 PLCB1,MAP2K3 
0 Nongenotropic Androgen signaling(N) 0.045 GNAZ,GNAO1 
0 links between pyk2 and map kinases(B) 0.045 PLCB1,MAP2K3 
0 Cortocotropin releasing factor receptor signaling pathway(P) 0.045 GNA14,GNAL 
0 GPCR ligand binding(R) 0.047 RAMP1,GRM6,GNAS,NMB,GPR4,F2R,HTR2A 
0 Regulation of actin cytoskeleton(K) 0.0472 ENAH,GNA12,IQGAP1,DIAPH2,F2R 
0 Gastric acid secretion(K) 0.0476 ADCY2,PLCB1,GNAS 
1 Huntington's disease(K) 1.28E-05 UQCRC2,ATP5B,AP2B1,ATP5J,SLC25A6, NDUFA10,NDUFB3,NDUFA3,ITPR1,SDHD 
1 
The citric acid (TCA) cycle 
and respiratory electron 
transport(R) 
1.53E-05 UQCRC2,ATP5B,OGDH,ATP5J,NDUFA10, NDUFB3,ATP5J2,NDUFA3,SDHD 
1 Oxidative phosphorylation(K) 3.44E-05 UQCRC2,ATP5B,ATP5J,NDUFA10,NDUFB3, ATP5J2,NDUFA3,SDHD 
1 Parkinson's disease(K) 4.18E-05 UQCRC2,ATP5B,ATP5J,SLC25A6,NDUFA10, NDUFB3,NDUFA3,SDHD 
1 Alzheimer's disease(K) 1.15E-04 UQCRC2,ATP5B,ATP5J,NDUFA10,NDUFB3, NDUFA3,ITPR1,SDHD 
1 Non-alcoholic fatty liver disease (NAFLD)(K) 5.12E-04 
UQCRC2,INSR,IRS2,NDUFA10,NDUFB3,NDUFA3, 
SDHD 
1 cGMP-PKG signaling pathway(K) 7.72E-03 ATP2B2,INSR,IRS2,SLC25A6,ATP1A2,ITPR1 
1 Carbon metabolism(K) 8.87E-03 OGDH,G6PD,ACAT1,HADHA,SDHD 
1 Metabolic pathways(K) 9.56E-03 
UQCRC2,ATP5B,QARS,OGDH,ATP5J,NDUFA10, 
NME4,FOLH1,G6PD,NDUFB3,ACAT1, 
HADHA,CEPT1,ATP5J2,NDUFA3,SDHD 
1 Axon guidance(K) 0.0119 PLXNA1,L1CAM,SEMA3F,SEMA3B,PLXNB2 
1 Tryptophan metabolism(K) 0.0255 OGDH,ACAT1,HADHA 
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1 Lysine degradation(K) 0.0486 OGDH,ACAT1,HADHA 
2 
Transcriptional regulation of 
white adipocyte 
differentiation(R) 
1.02E-05 TGFB1,CCND3,SREBF1,CEBPD,CREBBP,SREBF2 ,NCOR2 
2 Fatty acid, triacylglycerol, and ketone body metabolism(R) 1.02E-05 
LPIN1,MTF1,NPAS2,SREBF1,CPT1B,FADS1, 
CREBBP,SREBF2,NCOR2 
2 
RXR and RAR 
heterodimerization with other 
nuclear receptor(N) 
4.42E-04 THRA,TGFB1,SREBF1,NCOR2 
2 Base-Excision Repair, AP Site Formation(R) 5.56E-04 UNG,TDG,OGG1 
2 
Regulation of cholesterol 
biosynthesis by SREBP 
(SREBF)(R) 
4.48E-03 MTF1,SREBF1,CREBBP,SREBF2 
2 Signaling by TGF-beta Receptor Complex(R) 0.0101 TGFB1,RBL1,PPP1R15A,NCOR2 
2 Resolution of Abasic Sites (AP sites)(R) 0.0101 UNG,TDG,OGG1 
2 Generic Transcription Pathway(R) 0.0101 THRA,NR2F6,RBL1,CREBBP,NOTCH4,NCOR2 
2 TGF-beta signaling pathway(P) 0.0101 GDF1,TGFB1,JUND,CREBBP 
2 Base excision repair(K) 0.0101 UNG,TDG,OGG1 
2 Bladder cancer(K) 0.0174 DAPK2,DAPK3,FGFR3 
2 Notch-mediated HES/HEY network(N) 0.0226 TCF3,CREBBP,NCOR2 
2 Notch signaling pathway(K) 0.0226 CREBBP,NOTCH4,NCOR2 
2 Cell cycle(K) 0.0342 TGFB1,RBL1,CCND3,CREBBP 
2 Validated targets of C-MYC transcriptional repression(N) 0.0342 RBL1,CLU,CEBPD 
2 Circadian Clock(R) 0.0353 NPAS2,SREBF1,CREBBP 
2 Regulation of retinoblastoma protein(N) 0.036 CCND3,CEBPD,CREBBP 
2 map kinase inactivation of smrt corepressor(B) 0.0364 THRA,NCOR2 
2 mets affect on macrophage differentiation(B) 0.0364 RBL1,NCOR2 
2 cyclins and cell cycle regulation(B) 0.0373 RBL1,CCND3 
2 Signaling by NODAL(R) 0.0373 GDF1,DRAP1 
2 E2F transcription factor network(N) 0.038 RBL1,CCND3,CREBBP 
2 Regulation of nuclear SMAD2/3 signaling(N) 0.0492 TCF3,CREBBP,IRF7 
2 Endocytosis(K) 0.0492 LDLR,TGFB1,BIN1,FGFR3,SH3GLB2 
3 Meiotic synapsis(R) 5.93E-04 H2AFX,STAG2,LMNA,REC8 
3 
RNA Polymerase I, RNA 
Polymerase III, and 
Mitochondrial 
Transcription(R) 
7.40E-03 MTA1,CDK7,MBD3,PTRF 
3 Processing of Capped Intron-Containing Pre-mRNA(R) 7.40E-03 SNRPD2,PRPF8,PTBP1,CDC5L,CPSF1 
3 Acute myeloid leukemia(K) 0.0244 PML,CCNA1,TCF7 
4 Ubiquitin mediated proteolysis(K) 9.68E-04 FZR1,UBE3B,BTRC,CDC34,CUL5 
4 Prolactin receptor signaling(R) 0.025 BTRC,PRL 
4 APC/C-mediated degradation of cell cycle proteins(R) 0.025 FZR1,BTRC,PSMA1 
4 Hedgehog 'off' state(R) 0.025 BTRC,GLI2,PSMA1 
4 ErbB4 signaling events(N) 0.0362 PRL,WWOX 
4 Circadian rhythm(K) 0.0362 BTRC,PER1 
4 Signaling by ERBB4(R) 0.0362 BTRC,PRL,WWOX,PSMA1 
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5 Focal adhesion(K) 8.18E-12 ITGB4,ITGB5,ITGB8,PAK4,COL6A2,COL4A3, COL4A1,TNXB,ACTN1,FLNC,FLNA,VWF 
5 ECM-receptor interaction(K) 6.27E-11 DAG1,ITGB4,ITGB5,ITGB8,COL6A2,COL4A3, COL4A1,TNXB,VWF 
5 Extracellular matrix organization(R) 6.77E-10 
COL21A1,DAG1,ITGB4,ITGB5,ITGB8,DMD, 
COL6A2,COL4A3,COL4A1,ACTN1,NRXN1 
5 Integrin signalling pathway(P) 1.79E-07 ITGB4,ITGB5,ITGB8,COL6A2,COL4A3,COL4A1, ACTN1,FLNA 
5 
Arrhythmogenic right 
ventricular cardiomyopathy 
(ARVC)(K) 
9.77E-07 DAG1,ITGB4,ITGB5,ITGB8,DMD,ACTN1 
5 PI3K-Akt signaling pathway(K) 4.44E-05 
ITGB4,ITGB5,ITGB8,COL6A2,COL4A3,COL4A1, 
TNXB,VWF 
5 Hypertrophic cardiomyopathy (HCM)(K) 4.44E-05 DAG1,ITGB4,ITGB5,ITGB8,DMD 
5 Dilated cardiomyopathy(K) 5.53E-05 DAG1,ITGB4,ITGB5,ITGB8,DMD 
5 Regulation of actin cytoskeleton(K) 2.40E-04 ITGB4,ITGB5,ITGB8,PAK4,LIMK2,ACTN1 
5 Cell junction organization(R) 3.76E-04 ITGB4,ACTN1,FLNC,FLNA 
5 CDC42 signaling events(N) 3.76E-04 PAK4,MAP2K7,LIMK2,MAP3K11 
5 Reelin signaling pathway(N) 5.74E-04 MAP2K7,LRP8,MAP3K11 
5 Protein digestion and absorption(K) 9.00E-04 COL21A1,COL6A2,COL4A3,COL4A1 
5 agrin in postsynaptic differentiation(B) 2.22E-03 DAG1,DMD,PAK4 
5 GP1b-IX-V activation signalling(R) 2.65E-03 FLNA,VWF 
5 oxidative stress induced gene expression via nrf2(B) 4.92E-03 MAFG,MAFF 
5 Beta1 integrin cell surface interactions(N) 4.92E-03 COL6A2,COL4A3,COL4A1 
5 
Beta5 beta6 beta7 and beta8 
integrin cell surface 
interactions(N) 
6.62E-03 ITGB5,ITGB8 
5 Response to elevated platelet cytosolic Ca2+(R) 8.14E-03 ACTN1,FLNA,VWF 
5 Proteoglycans in cancer(K) 0.0114 COL21A1,ITGB5,FLNC,FLNA 
5 NCAM signaling for neurite out-growth(R) 0.0143 COL6A2,COL4A3,COL4A1,MAP3K11 
5 Amoebiasis(K) 0.0143 COL4A3,COL4A1,ACTN1 
5 Smooth Muscle Contraction(R) 0.0174 ITGB5,SORBS1 
5 MAPK signaling pathway(K) 0.0215 MAP2K7,FLNC,FLNA,MAP3K11 
5 Retinoid metabolism and transport(R) 0.0217 GPC5,LRP8 
5 Beta3 integrin cell surface interactions(N) 0.029 COL4A3,COL4A1 
5 Signaling by PDGF(R) 0.0311 COL6A2,COL4A3,COL4A1,MAP3K11 
5 RAC1 signaling pathway(N) 0.036 MAP2K7,MAP3K11 
5 Viral myocarditis(K) 0.0412 DAG1,DMD 
5 Signaling events mediated by focal adhesion kinase(N) 0.0454 ITGB5,ACTN1 
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